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ABSTRACT 
Immunoglobulin variable region diversity presents a unique challenge to the CD4 
T cell repertoire to discriminate between self and nonself.  Previous studies have 
suggested that deaggregated, monomeric IgG may be able to tolerize the CD4+ repertoire 
to its antigenic components, while aggregated species remain immunogenic even without 
adjuvant.  I hypothesized that monomeric IgG might induce T cells to adopt a regulatory 
phenotype, and I had unique reagents to examine the primary and memory response at the 
level of a specific T cell clone.  My data from in vivo studies utilizing the adoptive 
transfer of cells from a CD4+ T cell receptor (TCR) transgenic (Tg) line of mice show 
this distinction may be a function of aggregate stimulation of a T follicular helper (Tfh) 
response.  I challenged mice with monomeric Ig and two aggregate populations:  heat 
aggregated Ig and immune complexes.  Both aggregate populations induced an IgG 
humoral response to an antigenic peptide within the Ig, which never occurred in mice 
receiving monomeric Ig.  Aggregate populations induced an increased percentage of the 
TCR Tg cells to take on a Tfh phenotype.  The aggregates drove higher percentages of 
these cells to further proliferative divisions in the early proliferative response, compared 
to monomeric Ig, which drove cells to fewer divisions.  This was an intriguing indicator 
of the humoral immune response, and particularly intriguing given that the aggregates 
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were created from the monomeric Ig itself.  Monomeric Ig did not induce cells to 
differentiate to become CD25+FoxP3+ regulatory T cells when compared to aggregate 
populations.  I also tested these aggregate species capacity for driving TCR Tg cell 
division in mice depleted with anti-CD20 Ig.  In B cell depleted mice, the heat aggregated 
Ig lost its stimulatory capacity, while immune complexes did not.  This finding raised 
questions about the trafficking of antigenic species of the two aggregate populations.  As 
a whole, this data suggests that immune complexes generated in vivo during monoclonal 
antibody therapy may be a significant source of immunogenicity that could lead to 
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When Emil von Behring and Shibasaburo Kitasato first identified a component of 
serum that could transfer passive protection against tetanus or diphtheria toxin between 
immunized and naïve animals, they arrived at the simple, yet powerful, conclusion that 
this discovery would spark a revolution in therapeutics.   To say that their hunch augured 
well vastly understates the pharmaceutical-industrial complex that has emerged around 
the production of these antibodies, the name coined by Paul Ehrlich, for the use as 
therapy in an increasing number of disease states.  It has been projected that in 2014, the 
year that this thesis was written, monoclonal antibodies will account for 166 billion 
dollars in sales for pharmaceutical companies, which will be approximately one third of 
the total prescription drug market [1].   
Towards the end of their seminal publication, Kitasato and Behring sought to 
relay an optimistic message of therapeutic potential by quoting von Goethe’s Faust Part 
I, “Blood is a very special juice.”  In the spirit of Mephistopheles, the speaker goading 
Faust into signing a contract for his eternal soul, this benefit came with a price [2].  The 
early history of commercial antibody production, initiated by Behring himself, would 
also presage more complicated aspects of our current understanding of the 
immunoglobulin he co-discovered.  In a subsequent monograph, Behring stated a goal of 
mass production of antitoxin for the treatment of diphtheria in humans and set forth the 
experimental procedures by which he would ascertain an appropriate therapeutic protocol 
[3].  Starting in 1892, he worked with Farbwerke Hoechst to produce sheep anti-
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diphtheria toxin to be used in humans.  This antitoxin was a clinical success, but there 
was a proviso:  it was evident from the earliest usages that patients often developed skin 
rashes in response to multiple injections and that some patients developed systemic 
symptoms (fever, arthralgias) that Clemens von Pirquet and Bela Shick later described as 
“serum sickness” [4, 5].  Behring agreed with the hypothesis of Pirquet and Shick:  there 
was something foreign about transferring antitoxin from animals into humans that led to 
rejection.  Behring spent years devising purification techniques to rid the antitoxin of this 
consequence.  
While the modern techniques to produce therapeutic mAbs have sought to 
eliminate any traces of non-human structure, there are nevertheless immune responses to 
virtually all of these agents in some fraction of patients.  This is a therapeutic sequela of a 
paradox of Ig ontogeny that has long fascinated the immunological community:  if the 
immune system recognizes non-self, amino acid sequence diversity in pathogens and 
antibodies generate amino acid sequence diversity to bind pathogens, how does the 
immune system avoid responding to the antibodies mediating its own action?  To answer 
this question definitively in the context of every aspect of the immune system during a 
graduate thesis would border on megalomania.  Instead, the aims of this thesis will focus 
on the capacity for CD4+ T cells to perceive and respond to an antigenic sequence within 
an Ig by initiating a productive humoral immune response.  The ability, or lack thereof, 
for a CD4+ T cell to initiate this response has significant ramifications for the success of 
therapeutics in some fraction of the patient population for virtually every mAb, as well as 
implications for the more general biological question posed above:  how do we maintain 
antibody diversity without rejecting antibody diversity? 
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 Since the history of research surrounding Ig spans over one hundred years, it is 
unsurprising that there is a wealth of published experimental data that must be considered 
when addressing questions in this vein.  To confound the analysis further, much of this 
research falls into one of two diametrically opposed categories:  Ig as tolerogenic antigen 
or Ig as immunogenic antigen.  For the purposes of the introduction to this thesis, I hope 
to present a survey of the literature detailing these competing views.  This summary of an 
established division in the literature will be followed by a discussion of Ig 
immunogenicity and CD4+ T cell response with a particular emphasis on the CA30 Tg T 
cell model system that was used in the experiments detailed in the later chapters.  With 
this background established, I will present the hypotheses explored in the data chapters of 
the thesis and continue to the presentation of the body of the work. 
I.2 Immunoglobulin as tolerogenic antigen 
The 1940s to early 1960s was an era in which convergent lines of research laid a 
foundation for the study of immunological tolerance.  In the 1930s, researchers had come 
to the conclusion that young animals made poor immune responses when challenged with 
commonly studied antigens, which was considered to be a function of some deficiency in 
Ig production [6-12].   In the 1940s, this work was extended through the study of serum 
gamma globulin to assay for changes in protein character during animal development; it 
became obvious that young animals tended to have a delay between birth and the capacity 
to produce specific, high titer Ig responses upon challenge [12-18].  Around the same 
time, Ray Owen identified fetal “graft” tolerance through his studies of the circulations of 
fraternal twin calves; twin calves that gestated with a common placental circulation, but 
had divergent blood types, could contain red blood cells that displayed red cell antigens 
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that came from either of the twins.  Many of the twins assayed were adults, which 
implied a transfer of a regenerating progenitor cell that could continuously produce red 
blood cells in the recipient twin.  Owen commented on the potential for immunological 
implications of this finding [19].  Frank Macfarlane Burnet and Frank Fenner cited both 
of these phenomena, the variation in Ig production during youth and the fetal tolerance in 
fraternal twin calves, in the second edition of “The Production of Antibodies” [12]   
Burnet would eventually win the Nobel Prize for his analysis of Owen’s experiment, 
hypothesizing that the transfer of foreign cells into an embryo could yield indefinite 
immunological tolerance to the cells, which was later borne out in the lab of co-Prize 
winner Peter Medawar.  While it was not stated explicitly that these phenomena were the 
impetus for his conclusion, Burnet went on to state that it was likely that antibody 
production was affected by both the age of the animal as well as “the nature and 
frequency of the antigenic stimulus.”  Considering this conclusion with his hypothesis 
regarding fetal tolerance merely a chapter before, it is reasonable to consider Burnet to be 
an intellectual forefather of thought on how tolerance to serum proteins is achieved and 
maintained [12, 20, 21]. 
 A year before the reissue of “The Production of Antibodies”, Lloyd D. Felton 
delivered the presidential address to the American Association of Immunologists and 
spoke about a harmful manifestation of tolerance, “immune paralysis.”  By injecting 500 
µg of pneumococcus polysaccharide into mice, his group was able to eliminate the 
capacity for these mice to respond to an immunizing dose of polysaccharide [22].  During 
the 1950s, this “immune paralysis” intrigued a number of researchers who attempted to 
recapitulate these results by injecting large quantities of heterologous protein such as 
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albumin or gamma globulin, rather than polysaccharide, into rabbits or outbred mice.  
However, they could not repeat the paralysis until they followed the strategy implied by 
the work of Burnet and Medwar, by injecting the tolerizing dose of protein into neonatal 
animals.  This protein-specific tolerization persisted for extended periods of time after its 
induction and could be maintained even longer by administering booster immunizations 
of the experimental antigen [20, 21, 23-42].   
 When David Dresser began his experiments injecting bovine gamma globulin 
(BGG) into CBA mice, he was extending knowledge of this tolerization phenomenon in 
an inbred strain of mouse, using a published method to detect antigen-elimination, and 
investigating kinetic variables.  At first his results mirrored those of previous groups: the 
tolerization phenomenon occurred only in neonatal mice or, inconsistently, when BGG 
was injected intravenously.  However, while studying the role of lipids as adjuvants, he 
made a notable and divergent finding:  if he removed particulate matter by 
ultracentrifugation, the BGG tolerized adult animals via any route of administration.  This 
finding was subsequently recapitulated in guinea pigs.   While previous tolerance 
regimens had required large doses (hundreds of milligrams) of antigen and been 
inconsistent, ultracentrifuged BGG tolerized all adult mice at relatively low doses 
(hundreds of micrograms).  Dresser had identified heterologous, deaggregated gamma 
globulin as a potent tolerogen that could be used in studies ranging from the testing of 
adjuvants to understanding the kinetic of immunological tolerance [40, 42-52]. 
 William Weigle recognized the novelty of this tolerization by gamma globulin 
immediately and directed his research group to dissect the cellular mechanisms, a 
research question that he would follow throughout the rest of his career.  Within two 
6 
 
years of Dresser’s discovery of the unique function of BGG, Weigle’s group 
demonstrated that the same phenomenon occurred with human gamma globulin (HGG) 
and that the splenocytes of these mice remained tolerant even if adoptively transferred 
into an irradiated, secondary host.   This “adoptive tolerance” intrigued the researchers, as 
it could be mediated by either neonatally or adult tolerized splenocytes, and indicated to 
them that the mechanism of tolerance might be similar in both groups.  Continuing their 
studies with HGG, the group challenged the tolerization phenomenon with intricate time 
courses and injections of adjuvant in the context of different mouse strains, describing 
subtleties regarding the onset and abatement of tolerance that will be discussed in the data 
chapters of this thesis [53-66].  
 The original description of “adoptive tolerance” to HGG utilized splenocytes, a 
bulk population that contained both T and B cells.  In 1966, Henry Claman and his 
colleagues described the necessity for synergism between thymic- and bone marrow-
derived cells for Ig production [67].  Jacques Chiller, Gail Habicht, and Weigle made the 
logical leap and initiated experiments to test which cell population, the thymic or the 
bone marrow, was responsible for the tolerance to HGG.  The simple, surprising answer:  
both populations of cells were tolerized by the deaggregated HGG.  The kinetics of the 
phenomena were different, bone marrow cells were tolerized for about two months while 
the thymocytes were tolerized for over four months, but both populations of cells had to 
be functional to initiate an antibody response to immunogenic HGG and it was possible 
to show that tolerized cells from either location maintained tolerance in a transfer 
experiment [68-77].  This differentiation between tolerance in the B and T cell 
compartment was paradigm-creating; in the year before this thesis was written this work 
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was republished in the Journal of Immunology “Pillars of Immunology” series with a 
commentary about its historical significance to the field of self-tolerance [78].  From the 
perspective of Ig, it raised the questions:  how does heterologous Ig tolerizing the two 
types of cells, and was there a reason that Ig would induce this response rather than 
another serum protein such as albumin [54]? 
 To continue this progression of thought, it is valuable to consider a vein of Ig 
research that occurred in the years after Chiller, Habicht, and Weigle, but that ultimately 
drifted from the mainstream of immunology research.  Concurrent with the development 
of this suppression literature, other groups were building a compelling dataset to verify 
the Clonal Selection hypothesis, conceived in parts by Burnet, Talmage, and Jerne [79-
82].  As an important component of clonal selection involves the unique specificity of Ig 
receptors on lymphocytes, immunologists became intrigued by extensive diversity 
evident within the lymphocyte repertoire:  how many specificities could a mouse have?  
Could you transfer specificities from mouse to mouse?  What was the cellular basis of Ig 
allotype suppression [83-85]?  Researchers injected Ig from myelomas into mice and 
observed tolerance or, if aggregated, immunogenicity [86].  The immune system became 
an infinite hall of mirrors:  if antibodies could elicit antibodies against themselves and 
those antibodies could have antibodies against themselves as well, was this suppression 
in immune response to something like HGG just an extension of battling antibody 
specificities?  Although perhaps an inelegant description, this was the nexus of the 
“network theory of the immune system” of Jerne that became a significant topic of 
research from 1974 to roughly 1982 [84].  An important component of the theory as it 
developed was the existence of T cells that suppressed antibody responses due to 
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idiotypic-anti-idiotypic interactions, which was thought to explain the tolerized 
thymocytes of Chiller et al; these T cells were known as “suppressors” and contained a 
gene that mapped a region of the Major Histocompatibility Complex called “I-J”.  The 
existence of these suppressor T cells was debated within the literature with skeptics 
(including the chair of this thesis committee) and proponents based upon experimental 
data, until ultimately RNA hybridization revealed that the putative “I-J” gene did not 
exist at the site where others claimed to map it [83, 87-105].  To a great extent, network 
theory was relegated to the scrap heap of immunological thought.  However, this does not 
mean that every experimental finding from the period is completely irrelevant.  For 
example, regulatory T cells (Treg) function in some of the ways that the literature 
predicted as mechanisms for the suppressor T cell.  The capacity to suppress antibody 
responses with anti-idiotypic antibodies is still an intriguing finding and one must 
consider why this is, or is not, the norm in natural immune responses. 
 After the exodus from the realm of network theory, a few labs persisted in their 
efforts to define a mechanism for the tolerogenic effect of gamma globulin.  The HGG 
tolerization was robust and highly reproducible.  Many of the experimental observations 
were reminiscent of data that would be described in later, more controlled models testing 
central and peripheral tolerance, however, researchers struggled to find a definitive, 
unifying theories to explain the phenomenon.  Ideas ranged from antibody-dependent cell 
cytoxicity to a lack of appropriate costimulation in both the B and T cell compartments, a 
suppressive effect mediated by macrophages to an interaction with B cells that 
specifically targeted IL-4 secreting Th2 T cells [106-128].  The striking binary nature of 
the tolerance data compelled researchers forward:  tolerized T cell populations showed 
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virtually no proliferation or cytokine production in response to a secondary challenge in 
vitro.   
 In recent years, focus on the tolerogenic effect of Ig has often shifted to a 
consideration of issues related to therapeutics.  Multiple groups have identified the 
inclusion of peptides into the structure of IgG as a potential tolerogenic delivery 
mechanism that can decrease experimental immune responses or even temper pathology 
in a mouse model of autoimmune disease [129-148].  Findings such as these, in 
conjunction with computational methods of tolerogenic peptide analysis, have led to an 
intriguing new hypothesis: some IgG may contain naturally tolerogenic peptides that 
generate the production of Treg cells that can suppress ongoing response to other peptides 
within the structure [149-157].  Other hypotheses surrounding IgG suppression of the 
immune response derive from knowledge about the function of inhibitory receptors for 
the constant region of IgG (Fcγ) or sugar moieties (sialic acid) that are attached to the 
IgG during trafficking in the endoplasmic reticulum.  A notable example of the former is 
the work of Solveig Reitan and Kristian Hannestad, who examined the adjuvanticity of Ig 
containing an immunogenic idiotope but paired with differing isotypes.  They found that 
IgG and dimeric IgA were tolerogenic, while IgE, native, pentameric IgM, and F(ab’)2 
were immunogenic [158-160].  While they were unable to completely eliminate this 
dichotomy (tolerogenicity/immunogenicity) in various Fc receptor knockout mice, they 
concluded that it was likely that multiple Fc mediated mechanisms were involved in the 
process, including an inhibitory signal from the FcγRIIB on the surface of B cells and 
ADCC induced by stimulatory Fcγ on the surface of NK cells.  In the case of sugar 
moieties, the laboratory of Jeffery Ravetch has identified a receptor for sialic acid (SIGN-
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R1 in mice, DC-SIGN in humans) as the critical component for the suppression of 
immune function by high doses of intravenous administration of Ig (IVIg) [161-164].  As 
opposed to much of the tolerogenic phenomenology discussed thus far, IVIg mediates a 
generalized down regulation of immune function rather than a targeted tolerization, and 
has been used to alleviate acute episodes of autoimmune disease.  From their data, the 
group has surmised that SIGN-R1 is initiating this downregulation in function, however 
the direct mechanism of this systemic downmodulation is still in question.  Ravetch and 
his colleagues propose that engagement of SIGN-R1 is causing the secretion of a soluble 
factor that leads to upregulation of the inhibitory FcγRIIB on effector macrophage 
populations that suppress ongoing inflammatory responses.   
 To summarize this historical progression of work in regards to the tolerogenicity 
of Ig:  the administration of deaggregated gamma globulin, whether heterologous or 
isologous, does not yield a productive immune response as defined by the development of 
anti-gamma globulin antibody.  Furthermore, animals treated this way are tolerized in so 
far as they do not make a secondary or primary response upon challenge with an 
immunogenic form of the Ig and adoptive transfer of lymphocytes has demonstrated that 
they cannot participate in a productive response even when removed from the tolerizing 
environment.  There is mixed evidence for this tolerance being active (i.e. regulatory 
cells) vs. deletion of potential effectors, and both mechanisms may be able to play some 
role within both the B and T cell compartment.  More recent research has suggested roles 
for either cellular regulation or deletion, although much of the regulatory literature has 
either been predominantly putative or phenomenological at the level of suppression of 
autoimmune function.  One deficit in a great deal of this literature has been its reliance on 
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assumed behavior of bulk populations rather than on cells with identifiable or defined 
antigenic specificity, and as such, it has been difficult to dissect the potential for 
regulation versus deletion.  The physiological results obtained are of great interest, and 
their relevance should not be discounted, but one of the compelling reasons for the 
pursuit of this thesis is the capacity of our lab to track T cells of a defined specificity, as 
will be described in more detail. 
I.3 Immunoglobulin as immunogenic antigen 
In 1905, Pirquet and Schick described “Die Serumkrankheit” (The Serum 
Sickness), the systemic symptoms associated with an adaptive immune response to an 
administered heterologous horse serum in humans [5].  They recognized that the kinetics 
of the reaction, and the presence of a precipitin in some patients, indicated that the horse 
antibodies were acting as an antigen for ongoing production of an anti-horse Ig response.  
This recognition that a heterologous serum protein could induce a productive immune 
response was well established by the time that Dresser and others were injecting animals 
with various species of albumin or gamma globulin.  In fact, it was the work of Dresser 
with BGG that was unusual, if adult animals were injected with purposefully aggregated 
or not ultracentrifuged Ig, they made a productive humoral immune response that was in 
contrast to the tolerance that he observed.  These results complemented findings from 
groups investigating the capacity of antibody-antigen immune complexes to initiate 
cutaneous skin reactions, recapitulating the effect originally described by Nicolas Arthus 
in 1903 [165, 166].  In the case of the work of Dresser, a component of gamma globulin 
that could be eliminated through centrifugation (i.e. an aggregated species) was 
responsible for inducing the immune response in a dominant fashion when injected with 
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its tolerizing counterpart; in the Arthus recapitulations, immune complexes formed in 
moderately high antigen excess along the precipitation curve, a situation where the 
majority of the Ig could be expected to be in a complexed form, were highly efficient at 
inducing cutaneous inflammation or systemic anaphylactic response [167-180].  The 
discovery of the existence and function of the Fc receptors would give these observations 
a plausible mechanism [181, 182].  Futhermore, while B cells could utilize antigen-
specific, receptor-mediated intake to increase antigen presentation as a mechanism for 
increasing their capacity to stimulate T cells, Ig and Fc receptors presented an avenue 
through which other antigen presenting cells (APC) could bind antigen in a specific and 
receptor-mediated fashion (immune complexes) to augment presentation.  While these 
observations did not speak specifically to the nature of the antigenicity of Ig per se, in 
retrospect, they did demonstrate that immune complexes have a natural adjuvanticity that 
can increase the presentation of antigenic peptides from within the complex to T cells.  It 
is important to mention that FcγRIIB has been shown to deliver an inhibitory signal upon 
the binding of aggregated IgG, and that this inhibition is believed to regulate antibody 
production during an immune response [183].  While this caveat certainly must be taken 
into account when considering the totality of the effect of immune complexes on the 
progression of the immune response, the observations commented upon above suggests 
that this inhibition is not completely eliminating immune function when tested 
experimentally.  Furthermore, FcγRIIB deficient mice can be made tolerant in Ig 
tolerization experiments, and the receptor has always been cited as one component in a 
milieu of regulatory factors [120, 160]. 
13 
 
 An alternative method for evaluating the immunogenicity of Ig is to examine 
humoral responses against Ig-derived epitopes in either the constant or the variable 
region.  Rheumatoid factor (RF) is the classical example of an Ig that targets the Fc of 
IgG in the system.  It was discovered by two research groups independently in the years 
bookending World War II, the fog of war surrounding whether the original report was 
disseminated widely [184, 185].  In both cases, it was identified as a factor, found in the 
sera of some patients with rheumatoid arthritis (RA), which could agglutinate sheep red 
blood cells (SRBC) if an anti-SRBC antibody was also present in the reaction.  RF was 
most often described as being an IgM anti-Fcγ, although it has been shown that RF can 
be any isotype, not only IgM.  The validity of testing for RF as an assay for RA, and the 
role of RF in the pathophysiology of RA have both been questioned as knowledge about 
the disease has become more sophisticated [186].  However, for the purposes of 
evaluating the capacity for the Fcγ to act as an immunogenic antigen for a productive 
immune response, the existence of RF is confirmation.  Rheumatoid factor B cells are a 
common constituent of the natural repertoire and have been shown to expand during 
adaptive immune responses to unrelated protein antigens [187-194].  Recent work with 
transgenic mice expressing Ig chains from an RF has shown that RF B cells can exist 
quiescently within a normal mouse without becoming tolerized or deleted, but that these 
cells may secrete RF when bred to an autoimmune background [195, 196].    
 While RF targets the Fc component of the IgG, there is also ample experimental 
evidence to indicate that the variable regions of an Ig can also induce a productive 
humoral response [197-204].  This is particularly interesting given the knowledge that the 
variable region contains somatic diversity from several mechanisms that occur both 
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during development of the B cell receptor and the affinity maturation that occurs in the 
germinal center during a humoral response.  Isologous anti-idiotypic antibodies are a 
manifestation of the immunogenicity of this somatic antibody diversity.  Again, the 
literature supporting the network theory relied upon the generation of these anti-idiotypic 
antibodies to create the eponymous network, and results of associated studies must be 
considered despite the consensus movement away from the theory since the early 1980s.  
More recently, the work of Reitan and Hannestad examining anti-idiotype generation 
demonstrated that isotypes that are typically found in polymeric form in the body (IgM, 
IgA) could elicit anti-idiotypic responses in the absence of adjuvant [158-160]. 
 Amidst the years of controlled experimental investigation in animals, the clinical 
community has been carrying out a larger, less controlled, and higher stakes experiment 
into the immunogenicity of Ig:  the usage of monoclonal antibodies in patients.  Since the 
first published mAb treatment in a cancer patient in 1980, and particularly since the FDA 
approval of Muromanab-CD3 for allograft rejection in 1984, physicians, academic 
scientists, and pharmaceutical companies have sought ways to bring these mAb to the 
clinic [205, 206].  There are currently over 30 mAbs approved for therapy by the FDA 
and reports of over one hundred in ongoing clinical trials.  In 2009, the FDA published a 
guide suggesting to pharmaceutical companies that assaying for immunogenicity should 
be an important component of drug development with mAbs and other biologics [207].  
The scientific community had already sounded the alarm about immunogenicity of mAbs 
years earlier.  As of the early 1990s, researchers had observed that chimeric mouse 
antibodies used in therapy regularly generated an anti-Ig response, which they dubbed a 
HAMA (human anti-mouse antibody) or HACA (human anti-chimera antibody) and are 
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still a concern to this day [208-224].  They concluded that it was likely an immune 
response to murine components of the chimeric Ig, but some also conceded that it was 
likely that the humanization of therapeutic Igs, or even fully human Igs, would probably 
still lead to anti-idiotypic immune response (later to be called a HAHA – human anti-
human antibody) [207, 219, 221, 225].  While it was difficult to draw a direct correlation 
between the development or quantity of the HAMA and a specific clinical outcome, it 
was clear to these groups that this immune response had potential to end therapeutic 
efficacy and create pathology for patients.  Pharmaceutical companies responded by 
attempting to develop reagents that incorporated increasing amounts of human protein 
structure or, in recent years, were derived completely from human Ig genes.  Although it 
is rarely an emphasized point in papers about clinical trials, evidence of an immune 
response against a given mAb is generally a component of the adverse outcomes reported 
by researchers.  Sometimes they will report an anti-Ig response; sometimes they report 
outcomes associated with anti-Ig antibodies like infusion anaphylaxis or delayed-type 
hypersensitivity reactions at the injection site.  Most mAbs, if not all, generate evidence 
of an anti-Ig response whether they are chimeric or completely derived from human 
genes.  The rates of reaction or measured anti-Ig development range based upon the 
specific Ig, the disease being treated, and the schedule of administration; the anti-CD20 
antibody rituximab yielded an anti-Ig response in less than 10% of lymphoma patients, 
but in as high as 60% in one study of patients being treated for systemic lupus 
erythematosus [217, 218].  This knowledge has led physicians to design treatments with 
the co-administration of a mAb and chemotherapeutic agents such as methotrexate or 
azathioprine in the hopes that these agents will ablate any immune response [226].  
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However, the correlation between anti-Ig development and the success of treatment is 
still murky, at best, for most agents and the evidence for this co-administration of 
chemotherapeutic is generally anecdotal in part due to an insufficient study population.  
One notable exception to this paucity in data is in the usage of anti-TNF-α mAbs, 
particularly for rheumatoid arthritis.  In the last year, researchers have begun to make a 
quantitatively justified case that the development of anti-Ig responses has a significantly 
negative effect on hypersensitivity reactions, therapeutic response and soluble drug levels 
over time [227].  In concordance with the theoretical underpinnings, administration of a 
chemotherapeutic with the mAb could eliminate some of the negative outcomes 
associated with developing an anti-Ig response.  While more substantive data will be 
needed to make clinical judgments about treatment regimens, the fact remains that the 
therapeutic use of Ig has demonstrated that it can be immunogenic.  The rates of anti-Ig 
antibody development may vary based upon a number of factors, but some percentage of 
patients is able to make a productive immune response against virtually every mAb and 
ongoing data collection is finally beginning to justify the concern that has existed for over 
two decades. 
 The release of the guide on immunogenicity testing of biologics by the FDA in 
2009 hinted at another complicated aspect of this line of research:  immunologists and 
clinicians are no longer the only scientists hoping to dissect the capacity for mAbs to 
induce or evade the immune response.  Pharmaceutical scientists, those that examine the 
physicochemical attributes of manufactured pharmaceuticals, have begun to question 
what controllable aspects of the proteins they make can be modified to decrease rates of 
rejection.  The variables they test can range from modifying the glycosylation patterns of 
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the Fc to optimizing amino acids in the variable domains to decrease the immunogenicity 
[228-230].  The influence of antigen size on Ig immunogenicity has been a subject of 
investigation for some time; the original tolerance protocol of Dresser relied upon the 
ultracentrifugation of BGG to remove polymeric complexes, and larger accumulations of 
antigen such as heat aggregates and immune complexes have been shown to induce 
humoral and DTH responses. Pharmacologists recognize that aggregated Ig could be 
immunogenic and have begun to study Ig species that have been manipulated 
aggressively to simulate mishandling during production, storage, or administration [231-
233].  While there are definitely cultural differences between the immunologists and the 
pharmacologists in terms of their techniques and the extent to which data between the 
two realms can be compared, it is valuable to consider this type of experimentation into 
aggregate size as a complementary element of immunogenicity research.  
I.4 CD4+ T cells and the perception of immunoglobulin 
as antigen:  model systems 
While there is a substantial history of literature examining the extent to which Ig 
activates a productive immune response, the vast experimental data have a deficiency in 
regards to the role of individual CD4+ cells in tolerization or activation.  Certainly, there 
have been observations about CD4+ cells and indications about how they might perceive 
immunoglobulin.  A tolerized thymic compartment could not provide sufficient help to a 
naïve bone marrow compartment to yield a productive anti-HGG response [68, 69].  
HGG treatment seemed to decrease both IL-2 and IL-4 production in T cell populations 
leading to the interpretation that the tolerogenic Ig could suppress both Th1 and Th2 
CD4+ cells, with an increased emphasis on suppression of Th1 cells [116, 234].  
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Sequencing data have implied that the Fc may contain tolerogenic peptides that induce 
the proliferation of suppressive Treg cells [153-155, 157].  However, the production of 
high affinity IgG anti-mAb responses in patients against therapeutic Ig implies that there 
must be CD4+ cells participate in productive immune responses to the mAb.  Precursor 
percentages of some anti-mAb CD4+ cells have been defined in a naïve human repertoire 
[235, 236].   
 The biggest deficiency in all of this data is the reliance on experimental results 
that imply, rather than directly show, the effect of Ig on single T cells.  Prior to the era of 
transgenic mice, it was difficult, if not impossible, to track a monoclonal population of T 
cells that were activated by an Ig-derived peptide.  There are currently two mouse models 
with transgenic CD4+ T cells that recognize specific peptides generated via somatic 
mutation in isologous Ig V regions.  Both have been used to study central CD4+ 
tolerance to Ig-derived peptides as well as the consequences of failures of tolerance.  
Both will be described, in particular the CA30 – Vκ36-71 model which is the basis for the 
work in this thesis. 
 The first model derived from the observation that injections of an isologous IgA 
antibody derived from a myeloma could induce anti-idiotypic antibodies [201].  This 
anti-idiotypic response was T cell-dependent, and the antigenic light chain epitope was 
determined via antigen presentation with T cell clones derived from sensitized mice [200, 
237-245].  The researchers created two transgenic mice:  one expressing the lambda light 
chain with the antigenic somatically mutated residues (λ2315) and the other expressing an 
α/β T cell receptor which recognized the antigenic peptide in the context of the class II 
MHC I-Ed.  If the two mouse strains were crossed, there was a profound deletion in 
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CD4+/CD8+ thymocytes indicating that central tolerance mechanisms were influenced 
by the presence of the λ2315 light chain in the mouse [246].  Interestingly, large injections 
of IgG bearing the λ2315 could also delete the TCR-Tg cells in the T cell-only transgenic 
animal.  If a mother expressed the λ2315 and the TCR-Tg but the offspring expressed only 
the TCR-Tg, the transferred maternal IgG was insufficient to delete the TCR-Tg in the 
neonatal animal due to its low concentration.  This finding indicated that high 
concentrations of IgG could lead to Ig-derived antigen presentation to CD4+ cells, 
particularly in the thymus.  Further work with these mice focused more on the 
consequences of T cell/B cell cooperation and the illicit licensing of B cells expressing 
the λ2315 to secrete autoreactive antibodies due to CD4+ recognition of the light chain 
epitope [247-250]. 
 The second model, used in this thesis, was developed in our lab to investigate the 
development of tolerance to Ig-diversity.  The λ2315 system had begun as an investigation 
into the capacity for large amounts of isologous IgG to induce an anti-idiotypic response 
with the assumption that idiotypic antigen were probably immunogenic, just expressed at 
low enough levels within the system to evade tolerance induction.  In 1995, our lab asked 
a more fundamental question:  if T cells perceive peptides derived from Ig V regions can 
all Ig V regions induce CD4+ regulated humoral responses or is there a requirement for 
non-germline, somatic diversity in the Ig to direct a CD4+ mediated response [251]?  To 
investigate this question, it was important to inject a panel of Ig that utilized the same 
germline genes, but some of which utilized somatically mutated receptors that would 
hypothetically contain an antigenic peptide.  There was such a panel of Ig available that 
bound the hapten Ars (p-azophenylarsonate) and had been characterized extensively for 
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Ig genes and somatic mutation [252-254].  The experiment yielded T cell hybridomas that 
revealed the answer:  animals were tolerant to isologous germline Ig sequences, but could 
generate a fuseable CD4+ response to Ig with somatically generated diversity.  These 
results could be replicated by utilizing a different strain, C58 as opposed to A/J, that 
possessed the I-Ak MHC II, but did not possess the germline Ig V gene to which the A/J 
mouse had shown tolerance.  By generating and challenging C58 hybridomas, the lab 
could demonstrate that A/J APC were able to present peptides from the germline Ig, but 
unable to make a CD4+ T cell response against it and thus tolerant.  To study the 
mechanisms behind this tolerance, our lab generated two transgenic mice:  the Vκ36-71 
mouse, which expressed the somatically mutated κ light chain of the Ars-reactive mAb 
36-71, and the CA30 Tg, which expressed an αβ T cell receptor specific for an epitope in 
the Vκ36-71 framework-1 region [255].  Crossbreeding between the two transgenic strains 
led to deletion of the CA30 Tg T cells during development, while transfer of large 
numbers of CA30 Tg T cells into mice expressing only the Vκ36-71 caused development of 
a lupus-like autoimmune disease.  Both of these experiments relied upon interactions 
between large numbers of transgenic T cells and B cells, and so the lab shifted to model 
more physiological circumstances to investigate the role of tolerance in the system.  A 
series of bone marrow chimeras demonstrated multiple levels of CD4+ tolerance, both 
central and peripheral, that could serve as the regulatory mechanisms observed in the 
previous experiments [256].   Similarly, a dual transfer model in which Vκ36-71 B cells 
and CA30 T cells were transferred into a secondary animal to simulate the introduction of 
a novel B cell clone with a somatically mutated receptor containing antigenic peptides 
showed a mechanism of peripheral regulation, in which there was a disruption of memory 
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development by Tg B cells in an ongoing immune response and rapid differentiation of  
Tg B cells into short lived plasmablasts [257].  In both the bone marrow chimeras and 
dual transfer model, there were preliminary data indicating that the secretion of antigenic 
Ig may have played a role in some of the observed mechanisms of tolerance.  In 
particular, in the dual transfer model, there was early evidence that a transfer of sera from 
a Vκ36-71 Tg animal could induce CA30 T cell proliferation when both were injected into 
a κ-/- recipient.  However, sera was used rather than a monoclonal reagent, so it was 
possible that this result was a function of T cell stimulation by any isotype.  Regardless, 
this model presented an excellent opportunity for investigating the questions expressed 
over the course of this introduction, namely the extent to which Ig, and particularly IgG, 
could tolerize or activate CD4+ cells to make a productive humoral response to novel 
epitopes within the IgG itself. 
I.5 Conclusion and the scope of the thesis 
 
 There has been a debate within the immunological literature since at least 1961 as 
to the nature of perception of isologous Ig by the immune system.  Depending on 
preconceived bias, one can point to a long progression of papers to support a hypothesis 
either that Ig is intrinsically tolerogenic or immunogenic.  While the history of mAb 
therapeutics and the development of HAMA and HACA made an increasingly 
compelling argument for Ig being at least partially immunogenic, pharmaceutical 
scientists and their belief that aggregated, damaged species of Ig are responsible for 
inducing anti-Ig immune responses was sufficiently compelling to suspend disbelief at 
the outset of our work.  Given that our lab has a unique and powerful system to transfer 
and track transgenic, Ig-specific CD4+ cells, we started the project with a goal:  to 
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characterize the CD4+ response to an IgG1 containing an antigenic sequence within its 
light chain.  Our initial hypothesis was an extension of the landmark work by Chiller et 
al:  we believed that the CA30 T cells would not make a primary CD4+ response to a 
monomeric, deaggregated species of IgG1 containing an antigenic sequence.   
 In Chapter III, I will describe the production and purification of antibody, initial 
in vitro testing of presentation of antibody species, and a panel of tests to characterize 
particle concentration within the samples that would be used in in vivo transfer 
experiments.  I characterized my monoclonal reagent as a predominantly monomeric 
protein with very small populations of potentially immunogenic particles and little 
evidence of adjuvant activity in vivo or in vitro.  Conversely, I characterized heat 
aggregated Ig and immune complexes as reagents with large percentages of soluble and 
insoluble complexes that displayed early in vitro evidence of strong immunostimulatory 
capacity.  These data describe the first particle concentration analysis of immune 
complexes, which are naturally occurring structures. 
 In Chapter IV, I will describe a series of novel in vivo adoptive transfers that 
explored the primary response of a monoclonal CD4+ TCR Tg cell to species of 
immunoglobulin without adjuvant.  While others have reported the capacity for TCR Tg 
cells to proliferate after in vivo exposure to antigenic Ig, this is the first presentation of 
the full contraction and expansion of the primary response to monomeric Ig as well as 
two species hypothesized to be immunogenic:  heat aggregated Ig and immune 
complexes.  I demonstrated that both heat aggregated Ig and immune complexes, but not 
monomeric Ig, can prime mice to make a consistent secondary humoral response, and 
that this difference is not due to stimulation of regulatory T cells by monomeric Ig, but 
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instead appears to be a function of T follicular helper differentiation in response to heat 
aggregated Ig and immune complexes, which has never been reported.  Furthermore, I 
will describe a differential pattern of early proliferation in T cells exposed to monomeric 
Ig vs the immunogenic species that is a unique phenomenon in which T cells exposed to 
the immunogenic species have higher percentages of cells residing a later stages of 
division than those exposed to monomeric Ig, which has not been described without the 
use of adjuvant.  I identified an important role for the Fc in the early presentation of Ig-
derived peptides, in contrast to monomeric Ig, which was readily presented in vivo.  
Finally, I will present an early exploration of the role of B cells in the early presentation 
of Ig-derived peptides and will show evidence that exogenously administered heat 
aggregated Ig may be dependent on B cells for presentation in the spleen, whereas 
immune complexes are not, which has important ramifications for mAb therapy.      
 In Chapter V, I will describe experiments examining the dynamics of CA30 cells 
after a secondary challenge.   I will present data that suggests that monomeric Ig 
generates a poor memory population in comparison to peptide, and that this poor memory 
response is not augmented extensively by LPS or immune complexes.  Furthermore, I 
will show experiments suggesting that even with a strong adjuvant, the memory response 
to Ig is weaker than peptide and that monomeric Ig is a poor stimulator of secondary 






MATERIALS AND METHODS 
II.1 Production and Characterization of of Reagents 
II.1.1 T Cell medium (TCM) 
For in vitro and adoptive transfer experiments, cells were washed and cultured in 
T cell medium (TCM):  RPMI 1640 supplemented with 2-mercaptoethanol (50 µM), 
penicillin G (105 U/L), streptomycin sulfate (100 mg/L), sodium bicarbonate (2g/L) 
(Sigma Aldrich, St. Louis, MO), HEPES (7.5 mM) (Fisher Scientific, ), L-glutamine (2 
mM), 1x MEM essential amino acids, 1x non-essential amino acids, 1x sodium pyruvate 
(Gibco-BRL, Grand Island, NY), and 10% fetal calf serum. 
II.1.2 Hank’s Buffered Salt Solution (HBSS) 
For cell harvesting for flow cytometry, tissues were processed in Hank’s Buffered 
Salt Solution (HBSS):  0.137 M NaCl, 0.25 mM Na2HPO4, 4.2 mM NaHCO3, 5.4 mM 
KCl, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4, and 0.1 g glucose. (Sigma-
Aldrich, St. Louis, MO). 
II.1.3 Antibody production in mice 
C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J (Rag2-/-cγ-/-) mice were injected i.p. with 0.2 ml 
incomplete Freund’s adjuvant (IFA) (Sigma Aldrich, St. Louis, MO) 5 days before the 
i.p. injection of 5 x 106 hybridoma cells in phosphate buffered saline (PBS).  Ascitic fluid 
began to accumulate 5 to 7 days later and was collected via peritoneal lavage after mice 
were sacrificed in accordance with guidelines of the National Jewish Health Institutional 




II.1.4 Handling and dialysis of ascitic fluid for anion exchange chromatography 
Ascitic fluid was placed at 37°C for 20 minutes and then incubated on ice for 1 
hour.  After induction of clots, the fluid was centrifuged at 20,000 x g for 30 minutes at 
4°C, removed from the clot and visible lipid fraction with a Pasteur pipette, and passed 
through a 0.22 µm filter (Millipore, Billerica, MA) under standard sterile cell culture 
precautions.  Filtered ascites fluid was then immediately precipitated or stored at 4°C for 
less than 24 hours.  Ascitic fluid was precipitated while stirring on ice; saturated 
(NH4)2SO4 solution was added to the ascitic fluid at a rate of 1 ml/min until reaching 45% 
(v/v).  This solution was incubated on ice with stirring for 1 hour to maximize 
precipitation.  After precipitation, the solution was centrifuged for 1 hour at 20,000 x g at 
4°C and the supernatant removed and tested for residual antibody.  The precipitate was 
dissolved in a similar volume of phosphate buffered saline with 0.01% NaN3 (PBS-A) to 
the original precipitated solution volume, as this minimized protein precipitation during 
dialysis, and stored at 4°C or immediately dialyzed for anion exchange chromatography.  
For dialysis, the dissolved precipitate was placed in dialysis tubing with a molecular 
weight cutoff of 35,000 kilodaltons (kD) and dialyzed against ≥20 volumes of 10mM 
NaPO4 pH 7.9.  The protein was dialyzed over 48 hours which included 4 to 5 changes of 
10mM NaPO4 buffer, the first two changes typically containing 0.01% NaN3 to prevent 
bacterial growth and the final 2 to 3 changes eliminating its inclusion.  After dialysis, 
protein was immediately subjected to anion exchange chromatography and never stored 





II.1.5 Anion exchange chromatography 
Diethylaminoethyl (DEAE) anion exchange cellulose DE52 (Whatman, GE-
Healthcare, Pittsburgh, PA) was used in the purification of IgG1.  DE52 beads were 
swollen in distilled H2O for 1 hour.  The beads were then incubated with 5 equilibrations 
of 100 mM NaPO4 pH 7.9 buffer, followed by 10 equilibrations of 10 mM NaPO4 ph7.9.  
After this equilibration, the beads were loaded into a 50 mL syringe with a small plug of 
glass wool in the base, with a target volume 0.15 ml packed resin for every 1 mg of 
protein to be loaded onto the column.   After packing the column, the dialyzed protein in 
10mM NaPO4 pH 7.9 was passed through the column and loaded onto the anion 
exchange resin.  The column was washed 3 times, each wash containing 1 bed volume of 
the column of NaPO4 pH 7.9.  Protein was obtained by progressive column elutions in 
which the column was subjected to 2 times the bed volume washes with 10 mM NaPO4 
pH 7.9 with salt concentrations starting at 0.01 M NaCl and increasing 0.01 M with each 
subsequent wash.  The fraction obtained during each wash cycle was concentrated in an 
Amicon Ultra spin filter (Millipore, Billerica, MA) with a molecular weight cutoff of 50 
kD and then assayed for protein content using the absorbance at 280 nm measured by 
spectrophotometer.  Once the elution point had been defined for an antibody, in the case 
of this work typically 0.03 M NaCl, this concentration was used for subsequent anion 
exchange purifications.  
II.1.6 Low aggregation pharmaceutical buffer and Ig storage 
Protein was buffer exchanged from 10mM NaPO4 ph7.9 into a low aggregation 
pharmaceutical buffer that has been previously described (20 mM histidine, 222 mM 
trehalose dihydrate pH 5.5) using ≥4 spins in an Amicon Ultra spin filter, MW cutoff 
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50kD[233].  Ig concentration was brought to 4 mg/ml in the pharmaceutical buffer, and 
then the entire volume was passed through a 0.22 µm filter.  Polysorbate 80 (PS80) 
(Sigma Aldrich, St Louis, MO) was added to 0.02% (v/v).  Ig was then distributed into 2 
mg aliquots in sterile 1.5 ml microcentrifuge tubes and stored at -20°C.  Individual tubes 
of this Ig were subjected to a single freeze-thaw cycle prior to injection into animals. 
II.1.7 Arsanilation of mouse serum albumin 
Mouse serum albumin was dissolved in a solution of boric acid and sodium 
chloride (0.16 M H3BO3, 0.16 M NaCl) to a concentration of 10 mg/ml.  Two solutions 
were prepared and incubated on ice:  arsanilic acid was dissolved in 1 ml of 1 N HCl to 
create a 0.15 M arsanilic acid solution and NaNO2 was dissolved in cold water to create a 
0.2 M solution.  While stirring the arsanilic acid solution, the 0.2 M NaNO2 was titrated 
into the arsanilic acid in 50 µL drops to create a diazonium salt.  To assess this titration 
after the addition of each drop, 5 µl of the resultant solution was tested using starch 
iodide strips to assess for the presence of HNO2.  When the strip showed a blue hue 
immediately upon testing with the solution, the diazonium salt was prepared for coupling.  
This diazonium salt solution was titrated into the mouse serum albumin solution in 50 µL 
drops while stirring on ice.  The pH of the resulting solution was maintained between at 
pH 9.5 by adjusting with 0.5 N NaOH.  As the titration was occurring, the coupling of the 
hapten to the protein was assessed by diluting the solution 1/50 in 0.2 N NaOH and 
reading the absorbance at 477nm.  Coupling could be monitored by using the extinction 
coefficient of 8.85 x 103 to calculate the number of moles of Ars in the solution and then 
dividing by the moles of MSA in the reaction. Once a coupling of 12 – 15 Ars per MSA 
(Ars12-15-MSA) was achieved, the protein was diluted with 1 ml of 10x PBS, placed in 
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dialysis tubing with a MW cutoff of 35,000 kD, and against ≥20 volumes of PBS.  The 
protein was dialyzed over 48 hours which included 4 to 5 changes of PBS, the first two 
changes typically containing 0.01% NaN3 to prevent bacterial growth and the final 2 to 3 
changes eliminating its inclusion.  After dialysis, the protein concentration was calculated 
based upon the end dialysis volume, the protein was passed through a 0.22 µm filter and 
divided in small volumes into 1.5 ml microcentrifuge tubes and stored at -20°C.  
II.1.8 mAb 36-71 Fab and F(ab’)2 generation 
As mAb 36-71 is an IgG1, the sulfhydryl protease ficin could be used to generate 
both Fab and F(ab’)2 fragments.  For both procedures, mAb 36-71 was buffer exchanged 
from the low aggregation pharmaceutical buffer to a final concentration of 10mg/ml in a 
0.1 M citrate buffer pH6.0 using an Amicon Ultra spin column with MW cutoff of 50kD.  
Immobilized ficin (Thermo Fisher Scientific, Waltham, MA) was equilibrated with 10 
times resin slurry volume (2mL) of Fab digestion buffer (0.1M citrate, 5mM EDTA, 
25mM cysteine) or F(ab’)2 digestion buffer (0.1M citrate, 5mM EDTA, 4mM cysteine).  
Equilibrated ficin was incubated with 1 ml of mAb 36-71 in Fab or F(ab’)2 digestion 
buffer for 40 hours (F(ab’)2) or 5 hours (Fab) while being rotated in a 37°C incubator.  
The digested material was buffer exchanged into PBS-A and concentrated using an 
Amicon Ultra spin column with MW cutoff of 30kD.  Both species were size excluded 
independently via fast protein liquid chromatography (kindly completed by Fran 
Crawford in the Kappler/Marrack lab, NJH) and the fractions containing the two species 
pooled independently.  Both the Fab and F(ab’)2 were buffer exchanged into the low 
aggregation pharmaceutical buffer, passed through a 0.22 µm filter, and divided into 
sterile 1.5 ml microcentrifuge tubes and stored at -20°C. 
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II.1.9 Heat aggregation of Ig 
mAb 36-71 was buffer exchanged from low aggregation pharmaceutical buffer 
into PBS at a concentration of 7 mg/ml using an Amicon Ultra spin column with MW 
cutoff of 50 kD.  Individual 1 ml aliquots were incubated in a water bath at 63°C for 20 
minutes and then immediately placed on ice for 1 hour, by which time large insoluble 
aggregates were visible within the solution.  Insoluble aggregates were spun down by 
centrifuging at 1°,000 x g for 5 minutes, and the supernatant was measured for 
absorbance at 280nm using a spectrophotometer, allowing for an estimation of the mass 
of the insoluble fraction.  The soluble fraction was removed, pooled, and frozen at -20°C.  
The precipitated aggregates were washed 3 times with low aggregation pharmaceutical 
buffer and then divided into sterile 1.5 ml microcentrifuge tubes and stored at -20°C. 
II.1.10 Generation of Immune Complexes with Ars-MSA  
Due to the specificity of mAb 36-71, it was possible to generate immune 
complexes with the Ars-MSA reagent.  Due to some variability between batches of 
arsanilated albumin, it was necessary to determine an equivalence point for each batch 
prior to the generation of complexes for in vivo or in vitro experiments.  100 µg of mAb 
36-71 were mixed with varying amounts of Ars-MSA and diluted to 100 µl with PBS.  
These mixtures were incubated at 37°C with rotation for 3 hours and then centrifuged at 
13,000 x g for 5 minutes.  After centrifugation, the supernatants were measured for 
absorbance at 280 nm using a Nanodrop 1000 spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA)  to establish a precipitation curve.  Once an equivalence point 
had been established, experimental immune complexes were generated using similar 
conditions and either Ars-MSA at the equivalence point (referred to later as “large” 
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immune complexes due to the insoluble fraction) or at an amount of Ars-MSA 4 times 
larger than the mass at the equivalence point (referred to as immune complexes).  Similar 
amounts of Ars-MSA created in antigen excess were also incubated with Fab and F(ab’)2 
fragments, although the amounts of Fab (66 µg) and F(ab’)2 (73 µg) were varied to 
normalize the amount of antigenic 36-71 epitope in the sample.  Immune complexes were 
never frozen or stored prior to injection into animals or usage in in vitro culture and were 
used within 2 hours of generation. 
II.1.11 Ultracentrifugation of Ig 
To obtain monomeric Ig, multiples of 100 µg of mAb were diluted in sterile PBS 
to a concentration of 1 mg/ml and centrifuged at 165,000 x g in a fixed angle TLA-120.1 
rotor (Beckman Coulter, Brea, CA) for 3 hours.  The top 2/3 of the supernatant was 
removed for injection to avoid disturbing the pellet, and the sample was stored in a sterile 
1.5 ml microcentrifuge tube until used for experimentation within less than 6 hours.   
II.1.12 Size-exclusion chromatography 
Analytical size-exclusion chromatography was performed using an Agilent 1100 
chromatography system (Agilent Technologies, Santa Clara, CA) as has been described 
previously[233].  Prepared stocks of ultracentrifuged Ig, heat aggregated Ig, immune 
complexes, or diluent PBS was spun at 13,000 x g and the supernatant removed carefully 
to eliminate large insoluble particles.   Protein was loaded onto a Tosoh G3000 SWXL 
7.8 x 30 cm column (Tosoh Bioscience, Tokyo, Japan) and eluted with a mobile phase of 
PBS pH 7.4 at a flow rate of 1 mL/min.  The eluate was monitored at 280 nm and 215 nm 
to assess for protein recovery and percentages of monomer and dimer.  Triplicate samples 
were analyzed for each Ig preparation.  Monomer and dimer percentages were calculated 
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based upon areas under the respective peaks of absorbance at 215 nm.  Total protein 
recovery was calculated based upon the absorbance at 280 nm with the following 
equation:  (x*(y/60)) / (e*p) = total protein where x = total area integrated under the 
curve, y = flow rate, e = 1.4 cm2/mg, and p = path length (1 cm).   
II.1.13 Microflow imaging 
A Brightwell (Ottawa, ON, Canada) 4100 instrument was used for microflow 
imaging (MFI) to assess particle size and particle counts as has been described 
previously[233].  Prepared stocks of ultracentrifuged Ig, heat aggregated Ig, immune 
complexes, or diluent PBS were incubated at RT for 1 hour to allow settling of large 
insoluble particles.  550 µL of Ig sample was loaded onto the machine to allow total 
volume analysis of 500 µL; this was performed in triplicate for each Ig preparation.  The 
instrument was configured to allow for 1-50 µm particle detection by using “set point 3” 
mode and low magnification.   
II.1.14 Particle tracking analysis 
A NanoSight LM20 (NanoSight Ltd., Amesbury, UK) instrument with a 405 nm 
laser was used to perform particle tracking analysis (PTA) as has been described 
previously[258].  Prepared stocks of ultracentrifuged Ig, heat aggregated Ig, immune 
complexes, or diluent PBS were incubated at RT for 1 hour to allow settling of large 
insoluble particles.  500 µL of sample was loaded into the flow chamber before data 
acquisition.  Video was captured for 60 seconds using NTA 2.3 software at a setting 
recommended for low polydispersity samples, size detection limit automatically 
determined by the software (1 – 600 nm), and with manually defined shutter and gain 
settings.  Triplicate readings were obtained for each Ig preparation. 
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II.1.14 Estimate of Ig mass in protein particles 
Both MFI and PTA provided calculated concentrations of particles/mL for “bins” 
of particles defined by their circular diameter.  Given this concentration and the reported 
diameter, an estimate of protein mass for a given bin of particles could be calculated as 
reported previously[233].  This equation relied upon a number of assumptions:  first, the 
volume of a particle sphere could be calculated using the reported diameter.  This volume 
was assumed to be 75% protein and 25% water.  An average density of more than 30 
proteins was calculated to be 1.43 g/mL, and it was assumed that this value could be used 
to calculate the mass of protein as the mass of the particle would be bounded by that of 
protein (1.43 g/mL) and water (1.0 g/mL).  Thus an estimated mass could be calculated 
using the following equation: 0.75*v*1.43*n = estimated mass per bin, where v = 
calculated volume of particles in the bin based upon the diameter and n = number of 
particles in the bin, which could be calculated from the concentration of particles/mL and 
a known volume of solution. 
II.1.15 Limulus amebocyte lysate endotoxin quantification 
Bacterial endotoxin was quantified in Ig samples, Ars-MSA, and sterile PBS 
using a chromogenic microplate assay (Thermo Fisher Scientific, Waltham MA) based 
upon the classic Limulus polyphemus amebocyte lysate test.  Briefly, sample replicates 
were incubated with Limulus polyphemus amebocyte lysate at 37°C for 10 minutes.  A 
chromogenic substrate was added to the sample and incubated for 10 minutes, after which 
25% acetic acid was added to stop the potential conversion of the substrate by Limulus 
proteases.  Sample absorbance at 405 nm was detected in a Victor2 1420 multilabel 
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counter (Wallac, Turku, Finland) and compared to a standard curve to calculate 
concentration. 
II.2 In vitro and In vivo analysis of CD4+ T cell behavior 
II.2.1 Mice 
A/J, C57BL6 (B6), C;129S4-Rag2tm1.1Flv Il2rgtm1.1Flv/J (Rag2-/-cγ-/-), B6.Cg-
Thy1Tg(TcraTcrb)425Cbn/J (B6.OTII.pl), and B6xA/J F1 (B6AF1) mice were bred in-
house.  A/J CA30 Tg mice (CA30) have been described previously and were maintained 
on an A/J κ-/-  background in-house[255].  B6.PL-Thy1a/CyJ (B6.pl) and B6.SJL-Ptprca 
Pepcb/BoyJ (B6.SJL) mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME).  All mice were housed in the Biological Resource Center at National Jewish Health 
(Denver, CO).  CA30 mice were bred to B6.pl (CA30.Thy1.1) and B6.SJL 
(CA30.CD45.1) to create congenically-marked CA30 cells suitable to be transferred into 
B6AF1.  Mice used for experiments were generally 8-14 weeks old and included both 
sexes.  All mice were handled and bred with Institutional Animal Care and Use 
Committee (IACUC) approval in accordance with institutional guidelines. 
II.2.2 Tissue harvesting and cell preparation 
Mice were euthanized with CO2 in accordance with institutional guidelines, and 
spleen and peripheral lymph nodes (typically inguinal, brachial, axillary, and cervical) 
were extracted and stored in TCM (for adoptive transfer or in vitro experiments) or HBSS 
(for flow cytometric analysis).  Single cell suspensions were prepared by passing cells 
through a 40 µm cell strainer (BD Bioscience, New Bedford, MA) and 2 cycles of 
centrifugation at 300 x g for 5 minutes in a Multifuge 3 S-R centrifuge (Heraeus, 
Germany) and washed with TCM or HBSS.  Erythrocytes were depleted from samples of 
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splenocytes, but not lymph nodes, by incubating cells in lysis solution (8.3 g/L NH4Cl, 
10mM Tris-HCL pH 7.5) for 3 minutes followed by 2 washes.  Cells were enumerated 
with a Coulter AcT diff 2 Hematology Analyzer (Beckman Coulter, Brea, CA) and 
resuspended in TCM (in vitro experiments), HBSS (flow cytometric analysis) or sterile 
PBS (adoptive transfer). 
II.2.3 CFSE labeling  
For adoptive transfers and in vitro experiments to assess T cell proliferation, cells 
were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) using a 
protocol modified from the manufacturer’s recommendations (Thermo Fisher Scientific, 
Waltham, MA).  Briefly, lymph node cells were washed and resuspended in PBS, 0.1% 
BSA to a concentration of 1 - 3  x 107 cells/mL.  CFSE was added from a stock solution 
of 5 mM CFSE diluted in DMSO to the cells for a final working concentration of 10 µM 
CFSE.  Cells were incubated at 37°C for 5 minutes and then washed twice in TCM to 
sequester residual CFSE.  Cells were enumerated and resuspended in sterile PBS (for 
adoptive transfer) or TCM (for in vitro experiments).   
II.2.4 In vitro T cell activation assays 
CD4+ T cells were purified from the lymph nodes of transgenic animals (OTII or 
CA30.SJL F1) using the EasySep magnetic cell enrichment protocol (StemSep, 
Vancouver, BC, Canada) and enumerated with a Coulter AcT diff 2 Hematology analyzer 
and flow cytometric analysis.  In the case of CA30 activation assays, T cells were labeled 
with CFSE and enumerated.  For both assays, 2 x 105 purified T cells were cultured with 
2 x 105 irradiated (1100 rads) splenocytes from B6 (OTII) or B6AF1 (CA30) mice in 
TCM.  Antigens were added at varying concentrations to a total volume of 200 mL; 
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antigens included ultracentrifuged Ig, heat aggregated Ig, immune complexed Ig, the 
antigenic Vκ36-71 peptide (DIQMTQIPSSLSA), or the antigenic OVA323-339 peptide 
(ISQAVHAAHAEINEAGR).  Cultures were incubated at 37°C in 5% CO2 for 24 hours 
(OTII) or 5 – 6 days (CA30) and then analyzed for CD69 upregulation (OTII) or CFSE 
dilution (CA30). 
II.2.5 Adoptive transfers  
  After harvesting and initial enumeration, a fraction of lymph node cells was 
stained and assayed on a flow cytometer to identify transgenic T cell percentages of 
CA30 (CD4+Vβ8+) or OTII (CD4+Vα2+).  Based upon this percentage and the Coulter 
enumeration, T cells were diluted with sterile PBS to obtain a concentration of 5.0 x 105 
T cells/mL (all but proliferation experiments) or 5.0 x 105 – 2.5 x 107 T cells/mL (CFSE 
proliferation experiments).  Recipient mice received an i.v. transfer of 100µL of the 
specific cell suspension and allowed to rest for 24 hours prior to receiving a primary 
immunization.  The day of transfer was considered to be “day -1” in immunization 
protocols. 
II.2.6 Immunization protocols 
As many of the experiments in this thesis were based upon variations on base 
immunization protocols, exact protocols will be discussed in figure captions.  Mice 
received primary antigen injections 24 hours after the transfer of T cells on “day 0” of 
immunization protocols.  Primary injections were delivered i.p. unless otherwise 
specified.  In most cases, injections of antigen contained 100 µg of Ig species in 100 µl of 
sterile PBS without adjuvant or 10 µg – 300 µg of peptide.  In some cases, antigen was 
co-emulsified in complete Freund’s adjuvant (CFA) or precipitated in alum.  To 
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precipitate in alum, antigen was mixed 1:1 (v/v) with 0.2 AlKSO4 and precipitated with 
1M NaCO3, the precipitate was sedimented, washed 3x in sterile PBS, and resuspended in 
sterile PBS for injection.  All immunizations were staggered amongst multiple cages of 
animals.  Immunization protocols can generally be summarized in a few categories: 
 Early proliferation CFSE:  5 x 104 – 2.5 x 106 CFSE-labeled T cells were i.v. 
transferred on day -1, antigen was i.p. injected on d0, mice were sacrificed on d3 – d5.  
Splenocytes and, in some experiments, lymph node cells were collected, stained, and 
analyzed via flow cytometry.  Blood was collected to assay for the presence of 
transferred Ig species in the sera. 
 Primary response time course:  5 x 104 T cells were i.v. transferred on day -1, 
antigen was i.p. injected on d0, mice were sacrificed at multiple time points between d0 – 
d30.  Splenocytes were collected, stained, and analyzed via flow cytometry.  Blood was 
collected to assay for the presence of transferred Ig species in the sera and the 
development of an anti-Ig response by the recipient. 
 T follicular helper phenotyping:   5 x 104 T cells were i.v. transferred on day -1, 
antigen was i.p. injected on d0, mice were sacrificed on d14.  Splenocytes were collected, 
stained, and analyzed via flow cytometry.  Blood was collected to assay for the 
development of an anti-Ig response by the recipient. 
 Anti-Ig antibody development:  5 x104 T cells were i.v. transferred on day -1, 
antigen was i.p. injected on d0, and received booster injections of 100µg of an Ig species 
in sterile PBS on d21 and, in some cases, d42. Animals were bled prior to boost and 21 
days after boost to assess for anti-Ig antibody development. 
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 T cell boost expansion:  5 x 104 T cells were i.v. transferred on day -1, antigen 
was i.p. injected on d0, and mice received a booster injection of either 10µg of peptide 
and 10µg of bacterial LPS (Invivogen, San Diego, CA) or 100µg of an Ig species in 
sterile PBS on day 30 or day 21.  In all cases, mice were sacrificed 5 days after boost.  
Splenocytes were collected, stained, and analyzed via flow cytometry.  Blood was 
collected to assay for the development of an anti-Ig response by the recipient. 
 α-CD20 B cell depletion experiment:  Mice were injected i.p. with 500 µg of 
mIgG2a5D2, an α-mouse CD20 IgG2aκ reagent donated generously by Genentech (San 
Francisco, CA) or monoclonal IgG2aκ from the myeloma UPC 10 (Sigma-Aldrich, St. 
Louis, MO) in sterile low aggregation pharmaceutical buffer 24 hours prior to adoptive 
transfer (day -2).  24 hours later, 5 x 104 CFSE-labeled T cells were i.v. transferred, and 
antigen was injected 24 hours after cell transfer.  Mice received 100 µg monomeric mAb 
36-71, heat aggregated mAb 36-71, immune complexes, or negative control Ig.  Mice 
were sacrificed after 5 days and splenocytes were collected, stained, and analyzed via 
flow cytometry. 
II.2.7 Flow cytometry 
Reagents used for FACS were purchased from Biolegend (San Diego, CA), 
eBioscience (San Diego, CA), Thermo Fisher Scientific (St. Louis, MO), Tonbo 
Biosciences (San Diego, CA) or generated in house (Refer to Table 2.1 for list of 
reagents used for flow cytometry).  Cells were resuspended in staining buffer (PBS, 2% 
FCS, 0.1% NaN3).  Cells were surface stained with conjugated antibodies diluted in 
staining buffer on ice for 30 minutes in the presence of anti-CD16/32 (mAb 93) to block 
Fc receptors.  Following surface staining, cells were washed 2x with staining buffer and 
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then immediately analyzed with a flow cytometer, or fixed by incubating in 1.6% 
paraformaldehyde in staining buffer in the dark for 15 minutes at RT.  If cells were fixed 
and not immediately analyzed, they were stored in the dark at 4°C for less than 24 hours 
prior to analysis.  In some cases (FoxP3), cells were stained for intracellular antigen after 
surface phenotyping using a protocol from the Ebioscience FoxP3 transcription factor 
staining kit.  Briefly, cells were fixed and permeabilized, incubated with conjugated 
antibody diluted in permeabilization buffer for 1 hour on ice, and then washed 2x with 
permeabilization buffer and 2x with staining buffer before being analyzed immediately 
with a flow cytometer.  For experiments involving the identification of congenic CD4+ T 
cells, cells were gated for forward and side scatter and then gated on CD4+, MHC II-, 
CD19-, F4/80-, CD8α- cells.  At times, a data filter was implemented to exclude 99% of 
events falling outside of the CD4+, MHCII-, CD19-, F4/80-, CD8α- gate for the purposes 
of enriching for CD4+ event collection.   Flow cytometry data was acquired on a 
FACScan, LSRII, or CyAn ADP flow cytometer and analyzed using FlowJo 9.7.1 (Tree 
Star, Ashland, OR). 
II.2.8 Quantification of IgG α-Vκ36-71 antibody in sera 
Microlon ELISA plates (Greiner Bio-One, Monroe, NC) were coated with 2 
mg/ml IgM antibody ArsA11.1 in ascites fluid diluted in PBS O/N at 4° C and then 
incubated in a blocking buffer (2% BSA, 1% gelatin, 0.05% Tween 20 in PBS) for 2 
hours at 37°C.  Mouse serum was diluted between 1:100 and 1:25 in first well and titrated 
in serial 2-fold dilutions down the plate.  An α-Vκ36-71 IgG2b antibody that has been 
previously described  (mAb 17-63) was used as a standard starting at 200 ng/ml and 
serially diluted by half dilutions down the first two columns of the microlon plate. 
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Table 2.1 Reagents used for flow cytometry. 
Antibody clone Reactivity/description Source 
15A7 Fas (CD95) eBioscience 
53-6.7  CD8α eBioscience 
A20 CD45.1 
eBioscience or Tonbo 
Biosciences 
B20.1 Vα2 eBioscience 
BM8 F4/80 eBioscience 
Clone 90 CD38 Biolegend 
Clone 93 CD16/32 (Fc block) Biolegend or made in house 
eBio1D3 CD19 eBioscience 
FJK-16S FoxP3 eBioscience 
GK1.5 CD4 Biolegend 
H1.2F3 CD69 Biolegend 
IM7 CD44 Biolegend 
KJ16-133 Vβ8.1/Vβ8.2 eBioscience 
M5/114.15.2 MHC II (I-A/I-E) eBioscience 
OX7 CD90.1 (Thy1.1) Biolegend 
P3.6.2.8.1 Mouse IgG1 κ Isotype Control eBioscience 
PC61 CD25 Biolegend 
RA3-6B2 B220/CD45R Biolegend 
RMP1-30 PD-1 (CD279) Biolegend 
SPRCL5 CXCR5 eBioscience 
Streptavidin biotin conjugated antibodies Thermo Fisher Scientific 
 
Following a 3 hour incubation at 37°C, plates were washed 3 times with PBS and then 
incubated with 50 ng/well of a biotinylated polyclonal goat α-mouse IgG (Southern 
Biotech, Birmingham, AL) diluted in blocking buffer.  Plates were incubated for 1 hour 
at 37°C and then washed 3 times with PBS, at which point 10 ng/well of a DELFIA SA-
Europium reagent (Perkin Elmer, Waltham, MA) were added to the samples diluted in 
blocking buffer.  Following a 30-minute incubation at 4° C, plates were washed with PBS 
and were developed in europium enhancement solution (100 mM Sodium acetate, 1 mM 
TTA, 750 mM TOPO, pH 3.2) (made in house). Europium counts were read in a Wallac 
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Victor2 1420 multilabel counter at 590 nm for 1 second/well.  Regression analysis was 
performed using Prism graphing software (GraphPad Software, La Jolla, CA).   
II.2.9 Anti-Vκ36-71 ELISPOT 
Microlon ELISA plates were coated with 1 mg/ml of Vκ36-71 containing IgM 
ArsA11.1, which was stored in ascites fluid and coated on plates diluted in PBS overnight 
at 4°C.  Plates were incubated with RPMI 10% FCS for 2 hours at 37° C.  Splenocytes 
(5.0x105) were added to the first well of a row and titrated in serial 2-fold dilutions down 
the plate in TCM.  After 7 hours, plates were washed 3 times with PBS, 0.05% Triton X-
100.  Polyclonal goat α-mouse IgG was applied at 0.5 ng/ml in blocking buffer and 
allowed to incubate overnight at 4°C.  Plates were washed in PBS, and SA-AKP 
(Biolegend, San Diego, CA) was applied at 1:2000 in blocking buffer.  After washing, 
plates were developed in 100 mM Tris-HCl pH 9.5, 100 mM NaCl, 10 mM MgCl2 with 1 
mg/ml BCIP (Pierce, Rockford, IL) and developed for 2 hours at 37º.   Plates were 
scanned into TIFF images for blinded counting. 
II.3 Statistics 
Statistical analyses were performed using PRISM 5.0 (GraphPad, La Jolla, CA).  
Pairwise statistical analyses were made between samples using the Student’s t-Test as 





CHARACTERIZATION OF THE AGGREGATE CONCENTRATION, 
ADJUVANTICITY, AND IN VITRO STIMULATORY CAPACITY OF 
MONOCLONAL ANTIBODY 36-71 
III.1 Introduction 
As the primary aim of this dissertation was to ascertain the tolerogenicity or 
immunogenicity of a peptide delivered in an Ig for a specific CD4+ T cell, and the Ig 
species were produced in house, it was important to examine quantifiable differences 
between the reagents that would be used in in vivo experiments.   In some capacity, this 
characterization served to build a framework to assess the literature of tolerogenicity, 
which was often based upon functional capacity of a reagent rather than specific and 
quantifiable physical attributes, in the context of advanced techniques that are being used 
by pharmaceutical researchers in the assessment of therapeutic proteins used in the clinic.   
 When Dresser first discovered the tolerogenic capacity of bovine gamma globulin 
in adult CBA mice, the innovation was that he ultracentrifuged his preps of BGG at 
20,000 – 30,000 x g for 30 minutes [43].  He described this step as important for the 
removal of particulate matter and later commented that the pellets of this 
ultracentrifugation had been examined with an electron microscope and had shown no 
signs of bacterial contamination.  The inflammatory nature of immune complexes had 
already been identified in the context of studies of the Arthus phenomenon, so it logically 
followed that aggregated forms of Ig might exhibit similar behavior due to complement 
fixation.  William Weigle had studied this immune complex phenomenon and had also 
published on immunogenicity of a different heterologous serum protein, BSA, in rabbits 
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[167-170, 173-175, 259].  He had found that native BSA was immunogenic in most, but 
not all, rabbits, but that heat aggregated BSA was highly immunogenic.  As his lab 
replicated Dresser’s phenomenon with HGG, they began to use heat aggregated HGG as 
a positive control for immunogenicity and as the boosting antigen to assess for a 
secondary response [61, 62].    The parallels between an aggregated, particulate protein 
and the pellet of the ultracentrifuged B/HGG were obviously apparent as well; in 1969, 
Golub, a member of the group, showed that the immunogenic portion of native HGG 
could be removed by injecting it into a mouse in large quantities and then taking the 
serum from that mouse and injecting it into a secondary mouse [66].  This “biological 
filter” likely utilized the phagocytic apparatus responsible for inducing an immune 
response to remove the particulate matter that would have been removed by 
ultracentrifugation.  It was even able to tolerize a strain that was previously untolerizable 
with ultracentrifuged Ig:  the Balb/c, quite the immunological parlor trick.  However, the 
researchers at the time were satisfied with the concept that aggregated Ig could induce an 
immune response and were much more interested in the cellular mechanisms of the 
tolerance that they had witnessed with the ultracentrifuged Ig, and so the functional, 
rather than physical, characteristics of their aggregates took precedence.   
 In the modern realm of therapeutics, the antigenicity of manufactured protein is a 
critical conundrum in a billion dollar business that is increasingly coming under the 
scrutiny of regulatory infrastructure.  These scientists would concur with the observations 
of the earlier HGG researchers that the aggregated protein created by the heat or in the 
visible pellet after ultracentrifugation could be immunogenic.  However, the 
sophistication of their perception of aggregate species and their concern over the creation 
43 
 
of these aggregates has increased asymptotically since the days of Dresser.  At almost 
every step of manufacturing, storage, and administration, there is the potential for protein 
aggregation, and the aggregates in question can range from dimerization to particles with 
diameters in micron range [231, 233, 258, 260, 261].  Size exclusion chromatography has 
been a useful technique to identify loss of mass in a therapeutic protein population, but 
the limit on the mass that can be detected (<1000 kDa) has disallowed the 
characterization of larger aggregate populations that do not fall beneath this mass limit.  
More recently, protein tracking analysis (PTA) and microflow imaging (MFI) have 
allowed the identification of subvisible particles with diameters in the nanometer and 
micron range.  Given that the FDA has recently expressed concern that particles in the 1-
10μm diameter range may be immunogenic, and studies have shown that even smaller 
particles may be phagocytosed readily by APC, these analytical tools will probably 
become de rigeur for analysis of therapeutic proteins during development, from 
manufactured lot to manufactured lot, and in further studies of drug immunogenicity in 
mouse and man [262]. 
 Another consideration in regards to immunogenicity of the Ig to be used is the 
content of soluble toll-like receptor (TLR) agonists such as lipopolysaccharide (LPS).   In 
1963, Henry Claman identified LPS as a nonspecific agent that could preclude tolerance 
by ultracentrifuged BGG if it was administered on the same day [263].  Subsequent 
characterization enlarged the window of nonspecific activity for LPS tolerance ablation 
to three days before or after the dose of ultracentrifuged BGG.  LPS is well known for its 
role in inducing inflammation and has been implicated in both B and T cell activation.  
For this reason, the FDA has set limits for the LPS content of pharmaceutical grade 
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reagents, which generally range from 500 pg/kg drug (5 endotoxin units (EU)) to 50 
pg/ml (0.5 EU/ml) to be considered sterile water.  The classic test for LPS is Limulus 
amebocyte lysate (LAL) assay, based upon the original observation that bacterial 
endotoxin causes clotting of the amebocytes of the horseshoe crab, Limulus polyphemus 
[264, 265].         
 The objective of the work in this first chapter was to investigate physical and 
chemical characteristics of Ig samples that would be used in in vivo experiments with the 
CA30 T cell.  This included production and purification of monoclonal mAb 36-71, the 
production and purification of a Fab and F(ab’)2 from 36-71, and aggregation of mAb 36-
71 through heat-induced unfolding/aggregation and the creation of immune complexes 
with hapten (p-azophenylarsonate) conjugated mouse serum albumin.  The monomeric Ig 
was compared to these aggregated species using techniques to quantify soluble 
aggregates and subvisible particles in the nanometer and micron range.  All species were 
subjected to endotoxin testing via the LAL assay, and based upon the results, monomeric 
Ig was subjected to an in vivo test of adjuvanticity.  Finally, the monomeric Ig and the 
aggregated species were tested in an in vitro presentation assay as an early assessment for 
how they might drive T cell proliferation in vivo. 
III.2 Results 
III.2.1 Production of mAb 36-71, 36-71 F(ab’)2 and Fab 
The CA30 Tg CD4+ T cell recognizes an antigenic peptide located in the 
framework 1 (FR1) region of the κ light chain of mAb 36-71, an IgG1 with somatic 
mutations increasing its affinity for the hapten p-azophenylarsonate by ~200 fold over the 
germline antecedent [255, 266].  To generate sufficient mAb 36-71 for experimentation, 
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the Ig was grown as an ascites in Rag2-/-cγ-/- mice and purified via DE52 anion exchange 
cellulose.  This is in contrast to some pharmaceutical techniques utilizing antibody 
production in culture supernatants and purification via isotypic determinants. Ascites was 
chosen for its efficiency in antibody production as well as theoretical considerations 
based upon previous literature indicating glycosylation variation using cell culture 
production methods [267-269].  Anion exchange was chosen as a technique to obtain 
monomeric mAb based upon historical precedent as well as concern that acidic elutions 
typically associated with isotypic purification might lead to protein aggregation during 
elution.  Fab and F(ab’)2 were created using ficin, a sulfhydryl protease from fig latex 
with increased efficiency in cleavage for IgG1.  After size exclusion, these reagents were 
stored in a low aggregation pharmaceutical buffer that has been described previously and 
aliquoted for storage at -20°C.  All Ig products used were subjected to a single freeze-
thaw cycle to limit aggregation.  To ensure monomeric protein and remove aggregates 
from Ig preps prior to injection, I diluted Ig species in PBS to 1 mg/ml and 
ultracentrifuged at 165,000 x g in a TLA-120.1 fixed angle rotor.  After 
ultracentrifugation, I removed the top 2/3 of the supernatant and used this product within 
two hours of production.  I will use the term “monomeric Ig” to refer to ultracentrifuged 
mAb 36-71, but Fab and F(ab’)2 species were also ultracentrifuged prior to injection. 
III.2.2 Creation of heat aggregates and immune complexes 
  Heat aggregates were created in a manner consistent with previous literature, 
centrifuged, and the supernatant removed and assayed at OD280 to estimate the amount of 
mass remaining in the insoluble fraction that would be used for experiments.  At the 
concentration, time, and temperature used, heat aggregation rendered roughly 66% of the 
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original mass into insoluble aggregates in all aliquots.  Washed and stored aggregates 
from these preps were used for most experiments.  A case where the aggregation 
percentage was higher (~100%) due to an increase in temperature (~65°C) will be 
discussed sporadically as “large heat aggregates” due to the increased incorporation of Ig. 
 Immune complexes were formed by incubating 100 µg of mAb 36-71 with 
varying amounts of Ars-MSA in 100 µl of total volume.   Complexing was measured by 
centrifuging preps and assaying at OD280 for evidence of protein loss to insoluble 
complexes.  Figure 3.1 demonstrates the pattern of precipitation seen with two different 
preps of Ars-MSA, with the equivalence point at approximately 8 µg (Ars14-MSA) and 
16 µg (Ars12-MSA).  The term “immune complex” will be used to refer to complexes 
made with quantities of Ars-MSA approximately 4 times that required to reach the 
equivalence point(s) demonstrated in Figure 3.1, a practice based upon historical 
precedent[176-179].  There was no discernible difference between mice treated with 
immune complexes created with either Ars-MSA prep.  In a few cases, “large immune 
complexes” will refer to complexes made at the equivalence point(s) due to the increased 
incorporation of Ig. 
III.2.3 Ultracentrifuged mAb 3671 is monomeric when compared to heat aggregates 
and immune complexes 
 Size exclusion chromatography was used to assess for monomeric protein and 
soluble aggregates in each of the various preps.  Samples were centrifuged at 13,000 x g 
and then loaded onto the column. When assessed at absorbance at 280 nm, the void 




Figure 3.1  Precipitation of mAb 36-71 with arsanilated mouse serum albumin 
Increasing amounts of Ars12-MSA (closed square) or Ars14-MSA (open triangle) antigen 
were added to 100 µg of mAb 36-71 in a total volume of 100 µl of PBS.  Samples were 
incubated for 3 hours while rotating at 37°C and then centrifuged at 13,000 x g for 5 
minutes.  Supernatants were measured for OD280.  Values were calculated for soluble 
mass remaining in supernatant based upon ratio of calculated mass from 
absorbance/expected mass.  Values reflect means of three samples complexed 
independently and error bars specify standard deviation. 
 
can be seen around 8.1 minutes and a peak of the buffers (PBS with diluted histidine-
trehalose) can be seen at 11.1 minutes (Figure 3.2A).  The monomeric sample provided 
only a monomeric protein peak and a buffer peak with an integrated mass indicating 82% 
recovery of the ideal injected mass (74 µg/90 µg).  The heat aggregated samples provided 
only a buffer peak, showing no monomeric protein or protein in the void volume.  The 
immune complexes provided a peak in the void volume, a monomeric peak, and a buffer 
peak; the recovery was 44% of the ideal injected mass for the void volume (65 µg/146 
µg) and 7.5% for the monomeric protein (11 µg/146 µg).  To assess for dimers, 
absorbance at 215 nm was also measured to increase the sensitivity of detection (Figure 





Figure 3.2  SEC chromatograms of experimental Ig species 
SEC chromatograms of injections measured at both (A) 280 nm and (B) 215 nm for 
soluble protein analysis of the monomeric Ig (top), heat aggregated Ig (middle), and 
immune complex (bottom).  The void volume appears at 5.8 minutes, the monomeric Ig 
peak occurs at 8.1 minutes, and the diluted buffer peak appearas at 11.1 minutes.  In (B), 
the gray box denotes region magnified in the inset, which demonstrates a dimer peak that 
appears at 7.1 minutes.  Chromatograms are representative of triplicate analyses. 
 
nm.  By examining the absorbance in the time between the monomeric peak and the void 
volume in the Figure 3.2B inlay, dimeric populations of the Ig become more readily 
apparent; while it was difficult to differentiate mass definitively between dimeric and 
trimeric species in the immune complex population, the monomeric sample showed a 




III.2.4 Immune complexes have an increased mass of particles with diameters in the 
nanometer range 
Particle tracking analysis was used to assess the concentration of particles with 
diameters in the nanometer range in each sample (Figure 3.3A).  Both buffer (PBS and 
diluted histidine-trehalose) and monomeric protein contained nanoparticles; the 
nanoparticle concentration in the monomeric sample peaked in the 60 – 80 nm range, 
ultimately reaching a concentration roughly 3 times that of the PBS particles, which 
peaked in the 50 – 70 nm range.  Similar to the size exclusion data, the heat aggregates 
contained low concentrations of nanoparticles, with the highest concentration falling in 
the 50 – 70 nm range.  Immune complexes showed the highest concentrations of 
nanoparticles, reaching concentrations 1.6 times the highest concentration of monomeric 
nanoparticles or 5 times that of the buffer, with the highest concentrations falling in the 
210 – 230 nm range. 
 These particle tracking data could be used to estimate total protein mass per mL 
of protein solution, which is shown as a function of increasing nanoparticle size (Figure 
3.3B).  There was a base level of 100 ng/ml of nanoparticles in the monomeric (100 
ng/ml) and 200 ng/ml in the heat aggregated samples.  With the increased concentration 
of nanoparticles, particularly those with a larger diameter, the immune complex 
contained by far the most mass with an estimate of 7 µg/ml, roughly 35 – 70 times that of 






Figure 3.3  Particle size distributions and integrated mass for nano-sized 
populations in experimental Ig species  
(A) Particle size distributions were collected for nano-sized populations via particle 
tracking analysis of PBS, monomeric Ig, heat aggregated Ig, and immune complex. 
Monomeric samples (black line) are provided for comparison on each graph with other 
species represented in gray. Size of bins of 1 nm were used for representation of 
concentrations and error bars shown are standard deviation of triplicate samples.  (B) 
Integrated mass for the monomeric Ig (black), heat aggregated Ig (red), and immune 
complex (blue) using an estimation of protein mass per size bin as discussed in the 









III.2.5 Heat aggregates and immune complexes have an increased mass of particles 
with diameters in the micron range 
It has been shown previously that freeze-thaw cycles significantly increase the 
number of 1 – 5 micron diameter subvisible particles, and also increase the total mass of 
aggregated protein, much of which occurs in particles larger than 5 micron[233].  
Microflow imaging (MFI) was used to assess the concentrations of particles with 
diameters in the micron range in each of the samples (Figure 3.4A).  Both buffer and 
monomeric Ig contained micron sized particles in the range of 1 – 5 microns, with 
concentrations roughly equivalent for all subvisible particles in this size range (2.4 x 103 
particles/ml).  The heat aggregate and immune complex samples contained significantly 
higher concentrations in the 1 – 5 micron range.  The heat aggregated Ig samples peaked 
at 1.33 x 105 particles/ml at a size of 3 microns, a concentration 53-fold higher than the 
largest concentration for the buffer or monomeric protein (occurring at 1 micron).  The 
immune complex samples peaked at 8.6 x 104 particles/ml in the 1 micron range, a 
concentration 34-fold higher than the buffer or monomeric protein at the same size. 
 Similar to the nanoparticle analysis, the particle counts from the MFI could be 
used to estimate the total mass of particles in the measured range, 1 – 50 micron, which is 
shown as a function of increasing subvisible particle size (Figure 3.4B). There was a base  
concentration 433 ng/ml in the monomeric samples, which was modest in comparison 
with the heat aggregate and the immune complex samples.  The heat aggregate and 
immune complex contained 215 µg/ml and 693 µg/ml respectively, which were over 500-





Figure 3.4 Particle size distributions, integrated mass and representative images of 




















Figure 3.4 Particle size distributions, integrated mass and representative images of 
micron-sized particles in experimental Ig species 
(A) Particle size distributions were collected for micron-sized populations via microflow 
imaging of PBS, monomeric Ig, heat aggregated Ig, and immune complex. Size of bins of 
0.25 micron were used for representation of concentrations and error bars shown are 
standard deviation of triplicate samples.  PBS (gray) and monomeric Ig (white) are shown 
in different graph than heat aggregated Ig (gray) and immune complex (white)due to 
large disparity in particle concentration.  (B) Integrated mass for the monomeric Ig 
(black), heat aggregated Ig (red), and immune complex (blue) using an estimation of 
protein mass per size bin as discussed in the methods.  Error bars shown are standard 
deviation of estimated mass of the triplicate samples.  (C) Representative images of 
subvisible particles from heat aggregated Ig (top) and immune complex (bottom) of 












 An interesting, albeit qualitative, observation from the MFI analysis was the 
difference in the appearance of aggregate species of the same approximate size diameter 
from heat aggregate and immune complex samples (Figure 3.4C).  The representative 
examples in the 10 – 15 micron, 15 – 25 micron, and 25 – 40 micron ranges demonstrate 
the typical differences between the two species.  The heat aggregate subvisible particles 
appeared as dense, dark deposits with compact, globular formation as compared to the 
immune complex particles which appeared less dense, longer, and translucent.  
 III.2.6 Summary of mass distribution of Ig species  
 Table 3.1 presents a summary of the mass distribution of the Ig species based 
upon the SEC, PTA, and MFI that compares the recovered mass of each species to the 
ideal mass and the total mass that was actually recovered.  Although there was some loss 
of ideal mass, the recovered mass for the monomeric Ig was virtually all monomer 
(98.49%) with a small fraction of dimer (1.44%).  Heat aggregated Ig was missing the 
predominance of the ideal mass (78.48%) with the remaining mass being almost 
completely comprised of micron particles (99.91%).  The immune complex had a wide 
distribution of mass, with the majority of the ideal and actual mass falling in the soluble 
complex (46.74%) and micron particle (44.83%) range. 
III.2.7 Mass distribution of the alternative “large” heat aggregates and “large”  
immune complexes 
 As mentioned previously, there were two species of heat aggregates and immune 
complexes that were created that incorporated more Ig into the aggregates or complexes 
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the equivalence point.  These species were also analyzed using SEC, PTA, and MFI with 
the data and summary presented in Figure 3.5.  SEC showed that the large heat 
aggregates (LHA) had both monomeric protein (7.9%) and soluble aggregates that were 
difficult to differentiate between dimer and void volume populations (2.5%), while large 
immune complexes (LIC) had no soluble protein (Figure 3.5A). PTA showed 
nanoparticles in both the LHA and LIC, with the LHA nanoparticles peaking in the 50 – 
70 nm size range and accounting for 300 ng/ml, and the LIC nanoparticles peaking in the 
135 – 170 nm size range and accounting for 7 µg/ml (Figure 3.5B).  MFI showed micron 
sized particles in both groups, with both the LHA and the LIC peaking in the 1 micron 
diameter range (2.8 x 105 and 1 x 105 particles/ml respectively), although the LHA also 
had a peak at 2.5 microns (2.46 x 105 particles/ml), similar to the previously analyzed 
heat aggregates.  These particles accounted for 944 µg/ml in the LHA and 23.9 µg/ml in 
the LIC (Figure 3.5C).  The qualitative appearance of the LHA and LIC micron sized 
particles followed a similar pattern to the previously analyzed heat aggregates and 
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immune complexes (Figure 3.5D).  Interestingly, each of the mass distributions was more 
similar to the opposite species in the previously analyzed aggregates and complexes 
(Table 3.2).  Analysis of the LHA actually overestimated the ideal mass, predominantly 
due to variability in the MFI readings; of the mass that was recovered, it was distributed 
amongst all groups with contributions from monomer (0.75%), soluble aggregate 
(0.24%), nanometer particles (0.03%), and a majority of micron sized particles (99%).  In 
contrast, very little of the LIC ideal mass could be accounted for with only nanometer 
particles (0.6%) and micron particles (2%).  Given that the antibody-antigen complexes 
were formed closer to the equivalence point and could be expected to be larger and more 
likely to precipitate, it may not be surprising that 97.4% of the ideal mass was 
unaccounted for in these analyses 
Table 3.2 Mass distribution of large heat aggregate Ig and large immune complex 




















































































Figure 3.5 SEC, PTA, and MFI analyses of the large heat aggregated Ig and large 












Figure 3.5  SEC, PTA, and MFI analyses of the large heat aggregated Ig and large 
immune complex samples 
(A) SEC chromatograms of injections measured 280 nm for soluble protein analysis of 
the large heat aggregated Ig (left) and large immune complex samples (right).  The void 
volume appears at 5.8 minutes, the monomeric Ig peak occurs at 8.1 minutes, and the 
diluted buffer peak appearas at 11.1 minutes.  All chromatograms are representative of 
triplicate samples (B) Particle size distributions (left) were collected for nano-sized 
populations via particle tracking analysis of large heat aggregated Ig (black line) and 
large immune complex (gray line).  Size of bins of 1 nm were used for representation of 
concentrations and error bars shown are standard deviation of triplicate samples.  
Integrated mass (right) was calculated for the samples using an estimation of proteinmass 
per size bin as discussed in the methods.  Error bars shown are standard deviation of 
estimated mass of the triplicate samples.  (C) Particle size distributions (top) were 
collected for micron-sized populations via microflow imaging of large heat aggregated Ig 
(gray stripes) and large immune complex (white).  Size of bins of 0.25 micron were used 
for representation of concentrations and error bars shown are standard deviation of 
triplicate samples.  Integrated mass (bottom) for the large heat aggregated Ig (black), and 
large immune complex (gray) using an estimation of protein mass per size bin as 
discussed in the methods.  Error bars shown are standard deviation of estimated mass of 
the triplicate samples.  (D) Representative images of subvisible particles from large heat 












III.2.8 Limulus amebocyte lysate assay does not rule out the possibility of LPS 
contamination 
 A commercially available colorimetric LAL assay was obtained to test for LPS in 
the reagents to be used in in vivo experiments.  Reagents were tested in PBS and at 
concentrations prepared for injection into mice.  Due to the recommendation of the 
protocol for the assay, the number of reagents tested, and the limited amebocyte lysate 
provided, data was collected as duplicate measurements at a single point and, as such, 
will not be shown graphically.  However, a curve based upon an LPS standard was 
generated with each test for quantitation purposes and to ensure functional reagents, and 
this curve displayed linearity and range commensurate with recommended tolerances.   
The LAL test was performed three times using independent kits:  the first assay was 
performed on monomeric Ig and a prep of heat aggregate, which indicated that the 
monomeric Ig prep (0.355 EU/ml)  would be considered sterile water (0.5 EU/ml) and the 
heat aggregate prep would not (0.592 EU/ml).  Subsequent assays were performed on 
monomeric Ig (same prep as first assay), heat aggregates (different prep, but made from 
same prep of monomeric Ig), immune complexes, and Ars-MSA approximately six 
months later.  The results from these second and third assays were perplexing, as they 
showed all reagents except the heat aggregate (monomeric Ig, immune complex, Ars-
MSA) had LPS concentrations well above sterile water (>1.0 EU/ml).  Conversely, the 
heat aggregate had LPS concentrations below the threshold for sterile water (0.139 
EU/ml).  Based upon these results, it was not possible to conclude that the Ig preps had 
LPS concentrations similar to that of sterile water.  However, the inconsistency in the 
results, such as heat aggregate made from aliquots of positive-testing monomeric Ig 
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testing as a very low negative, call this assay into question.  There are published reports 
of false activation of the LAL assay by sugar moeities both from Ig and products that are 
purified using cellulose resins, and both the Ig and the MSA used were purified using 
cellulose products [270-272].       
III.2.9 mAb 36-71 does not act as a non-specific adjuvant in an in vivo model 
 To assess the adjuvanticity of the monomeric mAb 36-71 in vivo, it was tested as 
a non-specific inflammatory mediator in a model CD4+ immune response to ovalbumin, 
similar to a previously published study.  The experiment is briefly outlined in Figure 
3.7A: in short, 5 x 104 transgenic CD4+ T cells (OT-II) that recognize a peptide from 
chicken ovalbumin (OVA323-339) were adoptively transferred into mice and the next day 
mice were injected i.p. with no antigen, 300 µg OVA323-339,  300 µg OVA323-339 
emulsified in CFA, or 300 µg OVA323-339 and 100 µg of monomeric mAb 36-71 (Figure 
3.6A).  Based upon the previous work, I expected the OT-II cells to expand and increase 
in number by day 3 and then contract some by day 5 unless there was adjuvant, in which 
case the numbers would continue to expand.  Mice were sacrificed on day 3 and day 5 
and the T cell populations identified using a gating strategy relying on the expression of 
the congenic marker Thy1.1 on the OT-II cells (Figure 3.6B).  When cells were 
enumerated based upon cell counts and cell percentages, only the peptide emulsified in 
CFA caused an increase in OT-II cell numbers between day 3 and day 5, while the 
OVA323-339 or the OVA323-339 and mAb 36-71 caused a cell expansion by day 3, but a 
decrease by day 5 (Figure 3.6C).  In fact, the OT-II numbers were decreased in mice that 
received mAb 36-71 compared to mice that received  OVA323-339 alone.  To further 
ensure that this apparent lack of adjuvanticity was not a function of some epitope within 
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mAb 36-71 activating or impeding the OT-II and competing with OVA323-339, an in vitro 
antigen presentation assay was set up to assess for CD69 upregulation on transgenic OT-
II cells in response to antigen.  OVA323-339 was able to induce CD69 upregulation in OT-
II cells alone, in the presence of mAb 36-71, and in the presence of the antigenic 36-71 
peptide; the mAb 36-71 and 36-71 peptide could not stimulate CD69 upregulation 
(Figure 3.6D).   In total, these experiments indicated that 100 µg of mAb 36-71, the 
amount that would be used for future experiments, did not have sufficient non-specific 
adjuvanticity to induce a productive transgenic T cell response to a well studied model 
antigen.  This lack of adjuvanticity was unlikely to be some specific cross-reaction 
between the mAb 36-71 antigens and the OT-II T cell itself, giving even more credence 
to the interpretation that the mAb 36-71 was not teeming with non-specific adjuvant 
activity.  
III.2.10 Heat aggregated mAb 36-71 is a more potent antigen for in vitro CA30 
stimulation than monomeric Ig 
 As a final experiment before beginning in vivo characterization of the CA30 
response to the Ig species, I used an in vitro antigen presentation assay to ensure that the 
monomeric Ig and heat aggregates I had produced could stimulate these transgenic cells.  
Purified CA30 cells were CFSE labeled and cultured with irradiated splenocytes and 
antigen for 6 days, at which time they were harvested and assessed for the percentage of 
CA30 cells that diluted the CFSE as evidence of proliferation.  The antigenic peptide of 
mAb 36-71 was used as a positive control, as this would not require processing for 






















Figure 3.6  mAb 36-71 does not act as a non-specific adjuvant in an in vivo model 
Mice were treated in an experimental protocol presented in (A).  Briefly, C57BL6 mice 
received adoptive transfer of 5 x 104 congenic OTII.Thy1.1 followed 1 day later by i.p. 
injection of antigen.  Mice were sacrificed at day 3 or day 5 and splenocytes were 
assayed for Thy1.1+ cells.  (B) Representative FACS plots expressing the percentages of 
Thy1.1+ cells in the CD4+, MHC II-, CD19-, CD8α-, F4/80- gate for each treatment 
group.  (C)  Scatter plot showing the percentage of Thy1.1+ of total CD4+ in the mice at 
day 3 (gray circle) and day 5 (black square) for each mouse in the treatment group (n=4 
per group per day).  (D)  Scatter plot representing an in vitro assay to assess for activation 
of OTII.Thy1.1 cells by the mAb 36-71 or Vκ36-71.  Briefly, 2.5 x 105 OT-II.Thy1.1+ 
purified T cells were cultured with 2.5 x 105 lightly irradiated (1100 rad) C57BL6 
splenocytes.  Cells were stimulated with 1 µM OVA323-339 peptide or 1 µM Vκ36-71 
peptide or 100 nM mAb 36-71 or combinations thereof.  Cells were incubated for 24 





cells.  Because of the possibility that mAb 36-71 might not induce proliferation at all, 
monomeric Ig with 1 µg/ml LPS was also included as an experimental sample.  The 6 day 
time course was dictated by observing cell proliferation in the monomeric Ig cultures, as 
the heat aggregated and 36-71 peptide samples proliferated rapidly, determined by the 
observation of visible proliferative foci in these wells.  This led to a stark difference in 
the CFSE profiles by day 6, with heat aggregated and peptide CD4+ cells having diluted 
the CFSE robustly and monomeric samples having a relatively small percentage of cells 
in the middle of a proliferative process (Figure 3.7A).  The heat aggregated Ig induced a 
higher percentage of cells to proliferate at a concentration over 1000-fold lower than that 
of monomeric Ig (Figure 3.7B).  Unexpectedly, the addition of the LPS to the monomeric 
Ig did not lead to increases in CA30 proliferation.  It has been previously documented 
that aggregated antigen is superior at inducing CD4+ cell proliferation in vitro, and this 
held true for the Ig species.  Most importantly, these results showed that my Ig was 
capable of inducing CA30 proliferation and, as such, in vivo experimentation would be 
feasible.  I have preliminary data indicating that mAb 36-71 immune complexes generate 
a unique phenotype in culture; they do induce some proliferation, but they do not induce 
the same proliferative foci seen in heat aggregated or peptide samples.  Instead, immune 
complexes induce large syncytial structures within the wells that resemble pieces of 
tissue (large, somewhat translucent, containing tens to hundreds of cells).  We are curious 
whether this may be related to a report of immune complexes inducing neutrophil 





Figure 3.7 Heat aggregated Ig is a more potent antigen than monomeric Ig for in 
vitro CA30 cell stimulation 
CA30.Thy1.1 cells were purified and CFSE labeled.  2.5 x 105 CA30 cells were cultured 
with 2.5 x 105 lightly irradiated (1100 rad) B6AF1 splenocytes.  Cells received titrated 
amounts of Vκ36-71 peptide, mAb 36-71, heat aggregated Ig, or mAb 36-71 with 0.2 µg 
LPS per well.  Cultures were allowed to proceed for 6 days, at which point cells were 
stained for CD4+, Thy1.1+, MHC II- events to assess for CFSE proliferation.  (A) CFSE 
profiles from representative samples for each treatment.  A negative control is presented 
in black and the experimental condition is notated with the checked gray line.  (B)  
Percentage of CFSE diluted cells a compared to negative control at different points in the 
titration of reagents.  Results are mean of triplicate samples with bars denoting standard 








 The primary objective of the work in this chapter was to manufacture and 
characterize the Ig reagents to be used in in vivo experiments with the CA30 T cell, and 
to do so utilizing modern methods of pharmaceutical investigation that could provide a 
quantitative basis upon which to explain potential differences in the phenomenology 
related to them.  Although ultracentrifuged, monomeric Ig and heat aggregated Ig are the 
operationally defined reagents of Dresser and Weigle, they can be further assessed in the 
context of a level of physical scrutiny that is unparalleled and the basis for a rapidly 
growing pharmaceutical literature.   
 The production of mAb 36-71 and its variants was relatively straightforward, with 
a few nuances.  The choice to produce mAb 36-71 in ascites in part for concern about 
glycosylation variation was not based upon specific evidence comparing the ascites with 
a culture supernatant, but instead on reports from the literature.  Recent work on 
glycosylation of antibodies and their function would indicate that changes in these post-
translational modifications can increase the inflammatory capacity, decrease binding to 
FcRs, or perhaps suppress immune function globally, meaning that this decision to use 
ascites could have significant consequences on my in vivo results.  Similarly, this 
potential difference in glycosylation could be a source of the confusion with my results in 
the LAL assay, although I think it is more likely that the DE52 cellulose purification is 
responsible for this finding.  One advantage of the DE52 should be that the majority of 
the LPS would stick to the anion exchange column and should elute in a later fraction 
than Ig due to its negative charge.  The result of the OT-II in vivo assay, as well as the 
fact that I did not see LPS induced proliferation in splenocytes that have not been 
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irradiated (data not shown) with any of my Ig products leads me to believe that the 
sources of sugar residues are more likely the cause of the elevated values seen in the 
Limulus assay.  If the Ig was contaminated with some TLR agonist, I believe that I would 
have seen a more substantial response in the in vivo assay, but in retrospect, I should have 
used LPS or another soluble TLR agonist instead of CFA as a positive control, as this 
would have made the experiment more tightly controlled.   
 Discussing the creation of the heat aggregate and the immune complexes may 
seem rote, however it raises two points that affect interpretations of in vivo experiments.  
The first is that due to the amount of protein and volume used to create the aggregates, it 
was impractical to create a titration curve varying concentrations, time, and heat.  Instead, 
I relied on an established protocol and read the OD280 of the resultant product [274].  The 
variant heat aggregate, aggregated at approximately 2 degrees °C aggregated a higher 
percentage of protein. Based upon a given batch of Ars-MSA, the formation of immune 
complexes followed an orderly and replicable pattern, as would be predicted by theory 
and techniques such as the Ouchterlony double immunodiffusion test.  Second, the assays 
used to generate and characterize the heat aggregate do not reveal anything about the 
state of the Fc, which complicates interpretations of in vivo data.  Immune complexes are 
assumed to have intact Fc given the lack of any treatment that would cause 
perturbation/misfolding in the protein structure itself.  While the previous literature 
would suggest that misfolding of the Fc does not occur until a higher temperature (71°C) 
than the variable region (61°C), the fact that the aggregation procedure relies upon 
misfolding of protein means that the actual forms of the aggregate that are formed may 
contain vastly different available Fc arrays for binding[275].  While heat aggregate may 
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be a good positive control based upon precedent in these immunogenicity assays, the 
immune complex would seem to be the more consistently replicable reagent using a 
specific monoclonal antibody and antigen system.  The qualitative observation that the 
two species cause differential effects in splenocyte proliferation and behavior in vitro 
implies that it may be worthwhile to characterize differences in the Fc functionality 
between the two species in the future. 
 In regards to the SEC, PTA, and MFI data, the first thing to observe is that these 
techniques produced an enormous amount of data that can be analyzed from multiple 
different perspectives.  The data were analyzed based upon previously published methods 
that placed emphasis on particles of specific groups of sizing (1 – 5 micron, for example) 
and accounting for mass of the sample.  The SEC data was the most straightforward, 
identifying the soluble monomer and soluble aggregate populations in each sample, while 
the PTA and MFI could be used to define mass distributions based upon any category 
within the particles that were measured.  This type of resolution may eventually be useful 
in terms of identifying particle populations that are particularly immunogenic or 
tolerogenic, but in the current study the most useful aspect was to identify global 
distribution of the Ig mass.  The ultracentrifuged, monomeric Ig was predominantly 
monomeric, with a small amount of dimeric Ig and even smaller amounts of nanometer 
and micron sized particles.  There was a noticeable loss of mass compared to the ideal 
protein yield, however this could be explained by machine error or evaporation in the 
ultracentrifuge; in the past I have identified the Ig concentration of samples post-
centrifugation and have found virtually no loss, however I did not evaluate the mass in 
the samples after ultracentrifugation due to time constraints with the pharmaceutical 
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analyses.  There was no visible precipitate in the sample or the ultracentrifugation tube, 
implying that little of the Ig was lost to an insoluble fraction.  The heat aggregate mass 
distribution was weighted to micron sized particles and an insoluble fraction that was not 
analyzed in the pharmaceutical assays, but clearly visible in these samples.  In contrast, 
the immune complexes had a wide distribution of the mass including all types of size 
species, with the majority falling in the micron and soluble aggregate categories.  
Interestingly, the “larger” species of heat aggregate and immune complex appeared to be 
similar to the opposite species (i.e. LHA to immune complex) in terms of mass 
distribution.  A prediction that arose from the mass distribution in the heat aggregate and 
immune complex samples was that these species would have different patterns of 
immunogenicity in vivo, with immune complexes perhaps having tempered 
immunogenicity due to an increased monomer population in the sample.   
 Finally, the preliminary in vitro assay was useful for hypothesis generation for the 
in vivo studies as well as confirmation that the monomeric Ig and heat aggregated Ig 
could both stimulate CA30 proliferation.  The fact that heat aggregate was over 1000-fold 
more potent in stimulating proliferation indicated that there was probably a facilitated 
uptake of these particles as compared with monomeric Ig which was probably taken up 
through macropinocytosis.  This finding was not surprising based upon previous work 
examining increased presentation of particulate, aggregated OVA as compared to 
deaggregated OVA protein in T cell stimulation assays, however I had predicted that 
monomeric Ig might be readily taken up through some Fcγ related mechanism and, as 
such, had believed that the disparity between the monomeric Ig and heat aggregate might 
be decreased.  From the perspective of the in vivo work, this result, along with the 
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historical literature, supported a hypothesis that monomeric Ig would not be 




CHAPTER IV  
IG AGGREGATION LEADS TO PRODUCTIVE, CD4-MEDIATED HUMORAL 
IMMUNITY WHILE MONOMERIC IG STIMULATES AN EXISTENT, BUT 
NON-PRODUCTIVE, CD4+ RESPONSE 
IV.1 Introduction 
The rejection of monoclonal antibody therapeutics is a clinical quandary that 
recalls a long debate over the immunogenicity of Ig.  Seminal work in this field implied 
that deaggregated Ig could tolerize both the bone marrow (B cell) and thymus (T cell) 
compartments, and the quest to discover the mechanism(s) through which this tolerance 
in T cells is mediated has spanned nearly half a century.  Three of the consistent 
deficiencies in this literature has been the usage of bulk population of T cells, inferred 
data from pathological phenomenology, or in silico hypothetical analysis, to explore 
these mechanisms.   
  Our lab possessed a unique reagent, the CA30 transgenic T cell, which recognizes 
an antigenic peptide found in the somatically generated κ-light chain of an antibody 
generated in a canonical response of A/J mice to the hapten p-azophenylarsonate[255].  
This Ig, mAb 36-71, was an IgG1 that could be readily produced and purified and could 
be heat aggregated or complexed with a haptenated protein[252, 253].  Using an adoptive 
transfer model, congenic CA30 T cells could be transferred into recipient mice that 
subsequently received different preparations of the mAb 36-71, and the responses of 
these specific T cells could be tracked with a resolution heretofore unreported in the 
literature.  These specific T cell responses could be compared to humoral responses to 
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mAb 36-71 determinants generated in a similar fashion to determine whether aspects of 
the CA30 activation correlated with productive anti-Ig responses.   
 Based upon the historical literature as well as experience with a pilot study in an 
in vitro model, I hypothesized that monomeric 36-71 would not be perceived by 
transferred CA30 cells and this lack of perception would prevent the rise of a productive 
humoral response.  If any response to the monomeric Ig existed, I predicted that it would 
elicit CA30 conversion to regulatory T cells (Treg).  Conversely, I hypothesized that heat 
aggregated and immune complexed mAb 36-71 would lead to robust CA30 activation 
and strong humoral responses.  I undertook adoptive transfers with these unique reagents 
to test these hypotheses.  My results support a more complicated, nuanced picture of the 
in vivo immune response to an antigenic Ig: that monomeric Ig can readily elicit a CD4+ 
response, but one that is abortive and non-productive in generating a humoral response, 
but does not lead to the production of conventional Treg.  Conversely, heat aggregated and 
immune complexed Ig without significant adjuvant elicit a CD4+ response that appears 
modest in terms of cell numbers, but induces a population of cells to differentiate into T 
follicular helper (Tfh) cells that facilitate a productive humoral response.  While both 
induce this humoral response, the mechanisms by which they initiate the response may 
require different cell populations, and B cells may be playing a more important role in 








IV.2.1 Identification of CA30 T cells by using congenic markers in the B6AF1 
system 
The CA30 T cell recognizes a Vκ36-71 FR-1 peptide in the context of the MHC II 
I-Ak, which is why the CA30 transgenes are maintained on an A/J genetic background.  A 
class II tetramer bearing the antigenic peptide that could label CA30 cells was previously 
constructed and described, however the low yield of production and a rapid rate of loss of 
function at 4°C led me to adopt a congenic marker for identifying transferred CA30 T 
cells.  The CA30 mouse was bred to B6 mice containing either the Thy1.1 or CD45.1 
congenic markers that were used to identify the T cells when transferred into mice of 
background Thy1.2 or CD45.2.  Initially, work was carried out using the Thy1.1 marker, 
but this strategy was altered when plans were laid to use the Thy1.1 marker to identify an 
alternate transgenic T cell (OT-II) in B6AF1 recipient mice while CD45.1 was used to 
identify CA30 T cells.  While the OT-II B6AF1 turned out to be a functional failure due 
to a superantigen-mediated deletion of Vβ5-expressing OT-II cells, the breeding of 
CA30.CD45.1 mice was already well underway, at which point this congenic marker was 
used for all future analyses. 
IV.2.2 Monomeric Ig induces primary CA30 T cell proliferation, but heat 
aggregated Ig generates a weak humoral immune response 
   At the outset of in vivo experiments, my hypothesis was that ultracentrifuged, 
monomeric mAb 36-71 would not be perceived by adoptively transferred CA30 T cells, 
while heat aggregates would lead to robust CA30 proliferation and activation.  To test 
this, I adoptively transferred 5 x 104 CA30 cells into B6AF1 recipients and injected these 
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animals i.p. 24 hours later with 100 µg of negative control monomeric IgG1 (mAb 36-65), 
monomeric mAb 36-71, mAb 36-71 precipitated in alum, or mAb 36-71 heat aggregates, 
and then sacrificed the mice and assayed splenocytes at time points during a 35 day 
primary response.  Representative FACS from different treatments and timepoints are 
presented in Figure 4.1A.  The results of this time course demonstrated a few notable 
characteristics (Figure 4.1B).  First, contrary to expectation, the CA30 cells readily 
perceived, expanded, and retracted in response to the monomeric mAb 36-71, making a 
primary response similar to other transgenic models, in particular models of peptide-
induced tolerogenicity with rapid expansion and contraction indicating a non-productive 
response[276, 277]. The alum precipitated mAb 36-71 generated a primary response that 
mirrored other transgenic models using adjuvant to induce a productive response; the 
population of CA30 T cells on day 7 was 53 fold higher than the population elicited by 
the monomeric Ig.  The response to the heat aggregates was also surprising and appeared 
counter to the initial hypothesis; there was no statistical difference between the CD45.1+ 
cell numbers or percentage CD45.1+ of total CD4 compared to the response to the 
monomeric Ig.  I had expected robust proliferation more similar to the large, plateaued 
response to the mAb 36-71 precipitated in alum.  In retrospect, I believe that this initial 
experiment may have been underpowered for the subtlety of the CA30 response to heat 
aggregates, as a subsequent analysis of cell numbers at day 14 in the primary response 
with more mice showed a statistically significant increase in CA30 cells between heat 
aggregated and monomeric Ig treated groups (Figure 4.1C).   
To assess whether these injections in the initial time course were leading to a 
humoral response, sera were obtained from mice at day 30 post-immunization and tested 
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for IgG reactivity to the Vκ36-71 light chain in a DELFIA assay utilizing a plate-bound 
IgM containing this light chain (ArsA11.1) as a target antigen.  The alum-precipitated 
mAb 36-71 elicited an IgG anti-Vκ36-71 response in all mice that were treated (8/8), the 
monomeric Ig did not elicit such a response in any of the mice treated (0/8), and the heat 
aggregate treatment elicited this response in 3/8 mice that received it as a primary antigen 
(Table 4.1).  The alum-generated response produced a mean IgG α-Vκ36-71 concentration 
of 13 µg/ml, while the three mice in the aggregate treated group that made antibody 
produced a mean concentration of 142 ng/ml, a concentration 92 fold lower than that 
elicited by the alum.  The fact that heat aggregated Ig elicited a small, detectable primary 
humoral response in a fraction of animals that received treatment contrasted with the 
monomeric Ig treatment, which never elicited a response. 
IV.2.3 Heat aggregated, but not monomeric, Ig primes for a memory humoral 
response 
From the previous experiment, it appeared that the heat aggregate was able to 
generate a weak humoral immune response to the somatically mutated Vκ36-71 light chain, 
but the unexpected expansion of the CA30 cells in mice treated with monomeric Ig was   
Table 4.1  Heat aggregated Ig generates a weak humoral response in some recipients 
of the CA30 T cell. 
Treatment 
Mice Producing  
α-Vκ36-71 at day 30  
Mean concentration  
α-Vκ36-71 
Negative Control 0/8 - 
Monomeric Ig 0/8 - 
Heat Aggregated Ig 3/8 0.142 µg/ml (SD 0.03) 






Figure 4.2A  Primary proliferative time course of the CA30 T cell in response to 
monomeric Ig and heat aggregated Ig   
(A) B6AF1 mice received adoptive transfer of 5 x 104 congenic CA30.45.1 followed 1 
day later (day 0) by i.p. injection of 100µg antigen in sterile PBS or alum.  Mice were 
sacrificed at different time points and splenocytes assayed for CD45.1+ cells.  Presented 
are representative FACS plots from mice of different primary treatments (top) and days 
(side) expressing the percentages of CD45.1+ cells in the CD4+, MHC II-, CD19-, 





Figure 4.1B  Primary proliferative time course of the CA30 T cell in response to 
monomeric Ig and heat aggregated Ig 
(B) Mean CD45.1+ numbers in splenocytes (top) or CD45.1+ percentage among total 
CD4+ (bottom) of 4 mice per group per day in primary proliferative response of CA30 T 
cell to Ig species.  Antigen injected i.p. on day 0 included 100µg of negative control IgG1 
(crosses, dotted), 100 µg of monomeric Ig (circles, solid), 100 µg of heat aggregated Ig 
(open circles, gray) or 100 µg of Ig precipitated in alum (squares, dashed).   After 
identifying CD45.1+ population by FACS as in (A), cell numbers were calculated by 
multiplying CD45.1+ percentage among CD4+ by CD4+ percentage among live cell gate 
by total number of cells in the spleen.  Bars denote standard deviation of values.  Results 






Figure 4.1C  Primary proliferative time course of the CA30 in response to 
monomeric Ig and heat aggregated Ig 
(C)  Representative FACS plots (left) and number of CD4+ CD45.1+ cells (right) in 
splenocytes of mice at day 14 after injection of Ig species.  B6AF1 mice received 
adoptive transfer as in (A) and (B) and i.p. injection of 100 µg of  monomeric Ig of heat 
aggregate in sterile PBS one day later (day 0).  Mice were sacrificed at day 14 and 
splenocytes were assessed by FACS.  To increase the yield of CD45.1+ cells, events were 
pre-gated to exclude 99% of events outside a CD4+, MHC II-, CD19-, CD8α-, F4/80- 
gate.  Symbols represent individual mice and mean of cell percentages is denoted by the 
bar in the scatter plot.  Statistics represent a pairwise comparison calculated by a two-
tailed Student’s t-test with p<0.05 (*).  Data are representative of three independent 
experiments containing 5 or more mice per group. 
 
curious.  While there was a significant increase in the number and percentage of CA30 
cells in mice that received heat aggregate compared to monomeric Ig, this increase was 
2.5 fold as compared to over 50 fold for mice that received alum-precipitated Ig.  Perhaps 
both the monomeric Ig and the heat aggregate were eliciting humoral immune responses, 
but the magnitude was sufficiently low that they were difficult to detect.  To address this 
question, I sought to amplify the humoral response in mice to the Vκ36-71 by boosting 
these mice with heat aggregated Ig and testing for an increase in α-light chain IgG.  I 
adoptively transferred CA30 cells and injected mice with 100 µg of monomeric Ig, heat 
aggregated Ig, or the negative control IgG1.  After 21 days, these mice were bled and 
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boosted and then allowed to rest for 21 days before being bled again (Figure 4.2A).  The 
negative control IgG1 was included to act as an indicator of primary response by 
surviving naïve CA30 cells at the time when the other mice were being boosted; based 
upon literature that indicated that monomeric Ig might be tolerogenic, it was possible that 
I could find evidence of this by detecting a primary anti-light chain response in the 
negative mice and no response to the boost in the monomeric Ig mice.  Conversely, the 
monomeric Ig mice might boost an undetectable primary humoral response, suggesting 
that CA30 proliferation was productive.  In this experiment, the mice given a primary 
injection of heat aggregated Ig were the only ones that made either a primary or 
secondary humoral response (Figure 4.2B, Table 4.2).  In the primary response, 2/5 mice 
made an IgG anti-Vκ36-71 response to the heat aggregate, and that number rose to 5/5 
mice in the secondary response.  In 4/5 mice, the amount of detectable α-Vκ36-71 antibody 
was increased over that of the primary response, as would be predicted.  Neither the 
monomeric Ig (0/5, 0/5) nor the negative IgG1 (0/5, 0/5) produced a primary or secondary 
IgG anti-Vκ36-71 response.  While this may have been the result that was expected for the 
monomeric Ig, there was an interesting point about the negative IgG1 and the boost:  in 
the original literature about the HGG tolerance, mice with cells that were not tolerized, 
but also not primed, made a primary response to the heat aggregated HGG in the time 
period when the tolerized mice were “not responding” [68]  The lack of a detectable IgG 
response in any of the negative mice at day 21 post-boost (primary for that group) was 
interesting insofar as it was a deviation from the historical precedent.    
  As an aside, the boost in anti-Vκ36-71 IgG in animals that were primed with heat 





Figure 4.2  Heat aggregated Ig, but not monomeric Ig, primes for a memory 
humoral response 
Mice received experimental vaccination as in (A).  Briefly, B6AF1 mice received 
adoptive transfer of 5 x 104 CA30.CD45.1 cells and 1 day later were bled and i.p. injected 
with either 100 µg of either negative control Ig (open circle, gray), monomeric Ig (square, 
black), or heat aggregated Ig (triangle, gray) in sterile PBS.  Mice were rested for 21 
days, bled, and then received a booster injection of 100 µg of heat aggregated Ig in sterile 
PBS.  Mice were bled at day 42.  (B)  IgG α-Vκ36-71 concentration was quantified in sera 
using a DELFIA assay and extrapolated based upon a standard curve generated by a 
previously reported IgG2b α-Vκ36-71 (mAb 17-63).  Individual mice are represented by 
continuous line connecting sera concentration at each time point.  Each group contained 5 





















Negative Control 0/5 - 0/5 - 
Monomeric Ig 0/5 - 0/5 - 
Heat Aggregated Ig 2/5 0.307 µg/ml 5/5 
4.17 µg/ml  
(SD 6.33) 
 
study that was not expanded (Figure 4.3A).  A batch of heat aggregates that had been 
created accidentally, rather than in a controlled manner, were able to stimulate a primary 
response by day 30 (4/4) and a secondary response at day 35 (4/4), 5 days after a boost 
with the aggregates, while mice that received monomeric Ig developed neither a primary 
(0/4) nor secondary response (Figure 4.3B).  Splenocytes of these mice were tested by 
ELISPOT analysis for α-Vκ36-71 plasmablast formation, which showed a mean of 52 
plasmablasts/106 splenocytes that received two treatments with heat aggregate and no 
detectable ASC in mice that received a monomeric primary and heat aggregated 
secondary (Figure 4.3C).  The mice that received two doses of heat aggregate also 
showed an increased total ASC response on a control plate for total Igκ-bearing cells, so 
these mice were tested for the formation of a rheumatoid factor (IgM anti-IgG), which 
was negative (data not shown).    
IV.2.4 Heat aggregated Ig drives CA30 T cells through more division cycles than 
monomeric Ig in the spleen 
Monomeric Ig was able to induce a primary proliferative response of the CA30, 






















Figure 4.3  Evidence of humoral memory response to a unique heat aggregated Ig 
species  
Mice received experimental vaccination as in (A).  Briefly, B6AF1 mice received 
adoptive transfer of 5 x 104 CA30.CD45.1 cells and 1 day later were bled and i.p. injected 
with either 100 µg of monomeric Ig (circle, black), or a uniquely generated heat 
aggregated Ig (square, gray) in sterile PBS.  Mice were rested for 28 days, bled, and then 
received a booster injection of 100 µg of the same heat aggregated Ig in sterile PBS.  
Mice were sacrificed at day 33 and blood and splenocytes were collected for DELFIA 
and ELISPOT analysis  (B)  IgG α-Vκ36-71 concentration was quantified in sera using a 
DELFIA assay and extrapolated based upon a standard curve generated by a previously 
reported IgG2b α-Vκ36-71 (mAb 17-63).  Individual mice are represented by continuous 
line connecting sera concentration at each time point.  (C) IgG α-Vκ36-71 ELISPOT data 
from day 5 post boost (day 33).  Images of ELISPOT (left) are representative of five mice 
per group.  Frequency of IgG α-Vκ36-71 splenic ASCs (right) was determined by 






aggregates induced primary and secondary humoral responses, but the difference in 
CA30 cell numbers and percentages was less than I had initially predicted.  In 
approximately the last decade, the kinetics of cell division in a CD4+ primary response 
have been studied in two different models that provide conflicting views.  The first was a 
study that contrasted CD4+ (OT-II) and CD8+ (OT-I) proliferation in response to 
infection with a Listeria monocytogenes strain that expressed OVA, which showed that 
CD4+ cells divided a limited number of times and most cells only divided a few times 
even if antigen dosage was increased, whereas CD8 cells expanded rapidly to any dose 
that activated the cells[278].  Conversely, experiments utilizing a doxycycline-induced 
MHC II-peptide Tg mouse showed that a CD4+ Tg cell would proliferate as long as 
antigen was being presented in a primary response, and that activating dendritic cells with 
α-CD40 could prolong this presentation and proliferation[279-281].  Although, it is 
important to note that the activation of dendritic cells and prolonged presentation was not 
seen when an Ig-coupled protein was used to load dendritic cells instead of the MHC II-
peptide transgene.  I favored the second model as an analog for my experiments as I 
believed that the inflammatory milieu induced by Listeria might influence CD4+ cells to 
behave differently than those in my system with little-to-no adjuvant.  I hypothesized that 
the α-Vκ36-71 Ig that I saw in response to the heat aggregated Ig was a consequence of an 
increase in CA30 cell divisions compared to those treated with monomeric Ig.  By 
examining a day 5 time point with an increased number of mice, I predicted that I would 
see an increase in CA30 cell cell divisions.  To assess the number of divisions that 
occurred, I wanted to label the CA30 cells with CFSE, a fluorescent dye that stains 
proteins and is diluted by cellular mitosis, thus allowing for tracking of number of 
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divisions.  I performed the experiment by adoptively transferring 5 x 104 CA30 cells and 
then injected mice with either the negative control Ig, the monomeric Ig, or the heat 
aggregated Ig.  The CFSE proliferation profiles between the two groups were notably 
different; the cells that were treated with the monomeric Ig seemed to have the majority 
of cells in the 3rd or 4th division (Figure 4.4A).  Conversely, the heat aggregated Ig treated 
cells seemed to have a higher percentage of cells that reached the 5th, 6th, and 7th division.  
I used the Flowjo cell proliferation algorithm to identify the pattern of division in each 
experiment and calculated the percentages of the CA30 cells that could be found at each 
stage of division; the mean CFSE divisions for various Ig species can be found in Table 
A1.  As I had predicted, the heat aggregated Ig had a significantly higher percentage of 
cells remaining in the 7th division (Figure 4.4B).  This agreed with my hypothesis, that a 
higher percentage of cells would be found that had divided more times in the heat 
aggregate group. 
 I thought that this increase in the percentage of cells found at a later division 
might lead to an increase in the total percentage of the CA30 cells in the spleen as 
compared to monomeric Ig, but this was also shown to be incorrect.  To ensure that there 
was not an abundance of CA30 cells in the lymph nodes of mice that I had missed, I 
extracted individual lymph nodes (right and left inguinal, both brachial, both axillary) at 
day 5 from these mice and pooled the individual lymph nodes from each mouse within a 
treatment group and assessed for CFSE proliferation and CA30 T cell percentage (Figure 
4.4D).  I suspected that I would find evidence of enrichment of heavily divided CA30 T 





Figure 4.4 A-C Heat aggregated Ig drives CA30 T cells through more division cycles 


















Figure 4.4 A-C Heat aggregated Ig drives CA30 T cells through more division cycles 
than monomeric Ig in the spleen, but not lymph nodes 
Mice received adoptive transfer of 5 x 104 CFSE labeled CA30.CD45.1 cells and 1 day 
later (day 0) received 100 µg of negative control Ig, monomeric Ig, or heat aggregated Ig.  
Mice were sacrificed at day 5 and splenocytes were analyzed via FACS.  (A) 
Representative FACS plots of CFSE and CD45.1 staining in the CD4+, MHC II-, CD19-. 
CD8α-, F4/80- gate (top) and histograms containing CFSE proliferation profile gates 
generated by FlowJo proliferation algorithm and applied to all samples (bottom).  
Histograms are gated on CD4+CD45.1+ cells.  (B)  Mean percentages of 
CD4+CD45.1+CFSE+ cells in the 7th division as calculated from the gates derived by the 
FlowJo proliferation algorithm.  (C)  Mean percentage of CD45.1+ cells among total 
CD4+ cells for mice depicted in other figures.  Symbols represent individual mice and 
mean of cell percentages is denoted by the bar in the scatter plot.  Statistics represent a 
pairwise comparison calculated by a two-tailed Student’s t-test with p<0.005 (**).  Data 















Figure 4.4 D-F Heat aggregated Ig drives CA30 T cells through more division cycles 
than monomeric Ig in the spleen, but not lymph nodes 
Mice received adoptive transfer of 5 x 104 CFSE labeled CA30.CD45.1 cells and 1 day 
later (day 0) received 100 µg of negative control Ig, monomeric Ig, or heat aggregated Ig.  
Mice were sacrificed at day 5 and pooled LN cells were analyzed via FACS.  (D) 
Representative histograms containing CFSE proliferation profile gates generated by 
FlowJo proliferation algorithm and applied to all samples.  Histograms are gated on 
CD4+CD45.1+ cells and depict pooled cells from axillary LN.  (E)  Mean percentage of 
CD45.1+ cells among total CD4+ cells for pooled axillary, brachial, right inguinal, and 
left inguinal lymph nodes.  (F) Mean percentages of CD4+CD45.1+CFSE+ cells that had 
not divided as calculated from the gates derived by the FlowJo proliferation algorithm.  
Symbols represent pooled axillary, brachial, left inguinal, or right inguinal lymph nodes 
from 4 mice and mean of cell percentages is denoted by the bar in the scatter plot.  
Statistics represent a pairwise comparison calculated by a two-tailed Student’s t-test with 






assumption was wrong; in fact, the percentages of CA30 cells among total CD4+ 
population were lower in the lymph nodes of the mice that received heat aggregates, and 
the CFSE profile of these lymph nodes showed an increased undivided population 
(Figure 4.4E,F).  The percentages of this undivided population were significantly larger 
in mice that received heat aggregated Ig than in mice that received monomeric Ig.  Based 
upon previous experience with a similar phenomenon in the spleen in CFSE experiments 
utilizing larger adoptive transfers, I suspect that this decreased proliferation is a function 
of either increased clearance of the heat aggregated Ig or sequestration by a splenic 
population such as the marginal zone B cell. 
IV.2.5 Heat aggregates induce an increase in CA30 T follicular helper (Tfh) cells by 
day 14 
The evidence thus far indicated that heat aggregates could lead to a small, but 
significant increase in CA30 cells at day 14 when compared to monomeric Ig, it induced 
IgG α- Vκ36-71 in some mice by day 21 and this response would expand to booster 
injection whereas animals that received monomeric Ig never produced antibody, 
and that there was a different proliferative pattern for heat aggregates that led to a larger 
percentage of the CD also undergoing more divisions (7) whereas monomeric Ig had 
most cells divide but a large percentage  This implied that there might be functional 
differences in CA30 T cells between mice receiving the different forms of Ig, which 
might affect the early proliferation (to day 5) and accumulation at the time of the 
germinal center (day 14),  ultimately leading to a humoral response in one case but not 
the other.  There were two phenotypes that we were curious to investigate:  regulatory T 
cells (Treg) and T follicular helper (Tfh) cells.  Based upon research into the “T-regitopes” 
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postulated to exist in the Fc of Ig as well as the historical precedent for long-lived 
tolerance in treated thymocytes, we thought that the lack of antibody production and 
accumulation of T cells at lower cell divisions might be a function of the CA30 cells in 
animals receiving monomeric Ig differentiating into Tregs[149, 151, 153-155, 157].  
Conversely, while it was possible that the IgG α-Vκ36-71 generated in response to heat 
aggregated Ig was due to a T-independent process, the fact that a secondary 
immunization could boost the response led me to think that a germinal center might be 
involved in the generation of antibody, and the different proliferative profile of the CA30 
let me to wonder whether these cells were differentiating into Tfh.  To test these 
hypotheses, I set up an adoptive transfer with 5 x 104 CA30 T cells and injections of 100 
µg of monomeric Ig and heat aggregated Ig and sacrificed the mice on day 7, 10, or 14 on 
the assumption that these days should fall in the early development or close to the peak of 
a potential germinal center response.  I injected some mice with 100 µg of mAb 36-71 
precipitated in alum to act as a positive control to aid in the identification of Tfh and 
germinal center development and other mice with the negative control IgG1 to assess for 
differences in the germinal center formation.  Germinal center B cells were identified by 
staining and assessing for a CD38loFashi population.  At day 14, this population was 
readily seen in mice that had received alum precipitated Ig, but no increase in this 
population was seen in mice receiving the monomeric Ig or the heat aggregated Ig 
(Figure 4.5A).  That the heat aggregated Ig did not induce a noticeable germinal center B 
cell population was surprising given that previous work had demonstrated an α-Vκ36-71 
boost in response to a secondary injection.  However, the relatively low amount of α-
Vκ36-71 that I had seen in response to a primary injection in most cases (hundreds of 
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nanograms/ml) made me suspicious that the precursor frequency of the B cell recognizing 
the heat aggregated Vκ36-71 epitope might be low and that the lack of adjuvant might be 
limiting the expansion of this response.  
While there was not a difference between the monomeric Ig and the heat 
aggregated Ig in terms of the percentage of germinal center B cells, this did not mean that 
the CA30 cells were not phenotypically different.  I stained cells with typical markers to 
identify Treg cells, the high affinity IL-2 receptor CD25 and the transcription factor 
forkhead box P3 (FoxP3), in the hopes that I might identify an expanded population in 
the mice that received monomeric Ig (Figure 4.5B).  Given that I was most interested in 
the phenotype of the CA30 cells, I focused on the cells co-staining with these two 
markers in the monomeric Ig and heat aggregated groups.  At day 7, day 10, and day 14, 
there was no statistical difference between the percentages of CA30 cells that were 
CD25+FoxP3+ in the two groups (Figure 4.5C).  There was a variation in the Treg 
percentage in both groups, where there seemed to be a decrease in the percentage from 
day 7 to day 10 and then an increase from day 10 to day 14, however the intergroup 
differences on all days were insignificant, and the difference in percentage ranged from 
roughly 2 – 5 percent.  A naïve CA30 spleen examined during one of these experiments 
showed a Treg percentage of about 5.  This was not the expansion of Treg cells that I had 
expected to see in the monomeric Ig population, so I wondered if the expansion in Treg 
cells might have occurred in the total CD4+ population rather than the CA30 population 
specifically.  If the mAb 36-71 possessed “T-regitopes” in the Fc, perhaps the regulation 
was occurring at the level of a non-CA30 T cell.  However, an examination of the Treg 
percentage of the full CD4+ repertoire of the mice receiving these treatments also showed 
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no difference between the two groups (Figure 4.5D).  This does not fundamentally rule 
out the possibility that meaningful Treg cells were being formed in this repertoire or even 
within the CA30 subset, however it does imply that there was not a substantial expansion 
of Treg cells in either population. 
In the hypothesis I posited, the counterbalance to the Treg cell would be the 
formation of the Tfh cells in response to the heat aggregated Ig.  The lack of a substantive 
germinal center B cell population in either of the groups, particularly the heat aggregated 
Ig, did not bode well for the appearance of this population, but I thought that the 
increased precursor population of CA30 cells might offer an opportunity to see the 
phenotype arise.  Tfh cells were identified by their expression of the C-X-C chemokine 
receptor type-5 (CXCR5) and the inhibitory receptor programmed cell death-1 (PD-1), 
which have been previously described as markers of these cells (CXCR5hiPD-1hi).  To 
alleviate the problem of noise generated by low CA30 counts, I increased the number of 
adoptive transfer mice analyzed, as well as focused on collecting and storing a majority 
CD4+ events (99% to 1% falling outside of the CD4+, MHC II-, CD19- CD8α-, F4/80-
gate), which allowed for manageable flow cytometry files as well as increased CA30 
cells to allow for cleaner analyses.  The result of expanding the population showed that 
there was a significant increase in the number of CA30 cells that were CXCR5hiPD-1hi in 
mice receiving treatment with heat aggregated Ig (Figure 4.5E). While the general 
germinal center B cell population had not increased, that was an analysis of polyclonal B 
cell response to an antigen without additional adjuvant, whereas the CA30 analysis 
focused on a monoclonal cell population and allowed for increased resolution of a 
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relatively modest immune response.  This CA30 result suggested that the lack of the 
primary or secondary response to monomeric Ig was not due to suppression or to  
 
 
Figure 4.5 A-D Heat aggregated Ig induces an increase in CA30 T follicular helper 



















Figure 4.5 A-D Heat aggregated Ig induces an increase in CA30 T follicular helper 
(Tfh) cells by day 14 
Mice received adoptive transfer of 5 x 104 CFSE labeled CA30.CD45.1 cells and 1 day 
later (day 0) received 100 µg of negative control Ig, monomeric Ig, heat aggregated Ig, or 
Ig in alum.  Mice were sacrificed at day 7, 10, and 14 and splenocytes were analyzed via 
FACS.  (A)  Representative flow plots of percentage of germinal center B cells in treated 
mice at day 14.  Cells were gated as CD4-B220+ and analyzed for CD38loFashi cell 
percentages.  Flow plots are representative of 4 mice per group  (B)  Representative flow 
plots of percentage of CD25+FoxP3+ Treg among CD45.1+ cells in treated mice at day 
14.  Cells were gated as CD45.1+ CD4+, MHC II-, CD19-, CD8α-, F4/80-.  A naïve 
CA30.CD45.1 was substituted for negative control due to low cell numbers 7-14 days 
after adoptive transfer.  Flow plots are representative of 4 mice per group, except for the 
naïve CA30 (C)  Mean percentages of CD25+FoxP3+ cells among CD45.1+ cells at day 
7, 10, and 14 in mice treated with monomeric Ig or heat aggregated Ig.  Symbols 
represent individual mice, bars represent the mean, and error bars represent standard 
deviation.  Statistics represent a pairwise comparison calculated by a two-tailed Student’s 
t-test with p<0.05 (*).  (D)  Representative flow plots of percentage of CD25+FoxP3+ 
Treg among CD45.1+ cells in treated mice at day 14. Cells were gated as CD4+, MHC II-, 











Figure 4.5 E Heat aggregated Ig induces an increase in CA30 T follicular helper 
(Tfh) cells by day 14 
Mice received adoptive transfer of 5 x 104 CFSE labeled CA30.CD45.1 cells and 1 day 
later (day 0) received 100 µg of monomeric Ig or heat aggregated Ig.  Mice were 
sacrificed at day 14 and splenocytes were analyzed via FACS.  To increase the yield of 
CD45.1+ cells, events were pre-gated to exclude 99% of events outside a CD4+,         
MHC II-, CD19-, CD8α-, F4/80- gate.  (A)  Representative flow plots of percentage of 
CXCR5hiPD-1hi cells among CA30.CD45.1 population.  Cells were gated on 
CD4+CD45.1+ events.  (B)  Number of CD4+ CD45.1+ CXCR5hiPD-1hi cells per mouse.  
Symbols represent individual mice, bar represents the mean, and error bars represent the 
standard error.  Statistics represent a pairwise comparison calculated by a two-tailed 
Student’s t-test with p<0.05 (*).  Data are representative of three independent 











significant increase in the percentage of Treg cells, but instead to some failure in germinal 
center response as compared to heat aggregated Ig as described by the rise of Tfh in that 
population. 
IV.2.6 Immune complexes generate a similar humoral immune response to heat 
aggregated Ig in the CA30 adoptive transfer model 
Thus far, I had compared the immune responses to monomeric versus heat 
aggregated Ig because heat aggregates had had been used historically in BGG and HGG 
suppression experiments as an immunogenic species.  They also acted as a model for 
errors in manufacturing and handling of therapeutic monoclonal Ig that have been 
postulated to be the source of α-Ig responses in patients.  In the experiments described to 
this point, heat aggregated Ig produced a modest, but at times significantly increased 
primary CA30 proliferation in comparison to the initially surprising proliferation in 
response to monomeric Ig.  The heat aggregates caused a small primary humoral response 
that could be boosted as a secondary response with subsequent injections of heat 
aggregates, while the monomeric Ig did not produce a primary response to monomeric Ig 
or secondary boost to heat aggregates.  The heat aggregates drove CA30 cells to divide 
more in the early proliferative response. Finally, heat aggregates induced an increase in 
Tfh formation by day 14 in the primary response as compared to monomeric Ig, which 
implied a germinal center response.  Now, I wanted to explore whether these phenomena 
could be replicated with a species of Ig aggregate that would be a common occurrence 
during systemic immune responses rather than an error of exogenous Ig handling:  an 
immune complex.  The immune complex might act quite differently than the heat 
aggregate due to its formation; heat aggregates are generated by causing the association 
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of hydrophobic regions of misfolded protein, immune complexes are native Ig molecules 
associated into structures via binding of antigen.  They would be expected to have intact 
and functional Fc regions, and the increase in avidity expected that comes from 
associating multiple Fc regions together is thought to promote Fc signaling in some cases.  
It must be said that there may be functional Fc available in the heat aggregate, as it has 
been shown that unfolding occurs at a higher temperature (71°C) than the temperature 
used for this aggregation (61°C) [275].  Regardless, I wanted to evaluate immune 
complexes using the experimental assays that I had used with the heat aggregated Ig.    
First, I wanted to assess whether the immune complexes generated a primary CA30 
expansion and retraction over a similar time course that was used to evaluate the heat 
aggregated Ig.  I adoptively transferred 5 x 104 CA30 cells and immunized with 100 µg of 
monomeric Ig or the equivalent of 100 µg on mAb 36-71 in premade immune complexes.   
I sacrificed animals on day 2, 5, 11, and 21 and stained splenocytes to identify 
congenically marked CA30 cells.  The kinetics of CA30 T cell expansion was not 
different from monomeric Ig and similar to what I had initially observed with the heat 
aggregates (Figure 4.6A).  A reevaluation at day 14 did yield a statistically significant 
difference between the number of CA30 T cells in immune complex treatment as 
opposed to monomeric Ig (Figure 4.6B).  Again, the relative modesty of the response was 
notable, but this was a reasonable result in light of the lack of adjuvant in the primary 
injection. 
This presence of statistical difference in cell numbers at day 14, and the general 
similarity in primary response to the monomeric Ig, made me believe that I would be able 
to generate a humoral response to the Vκ36-71 with the immune complex, as I had with the 
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heat aggregate.  To test this, I adoptively transferred 5 x 104 CA30 cells into mice and 
then gave a primary injection with 100 µg of monomeric Ig or the equivalent Ig in 
preformed immune complexes.  I bled these mice at day 21 and immediately boosted 
with 100 µg equivalent in preformed immune complexes, and then repeated this at day 
42, with a final bleed at day 63.  Sera were tested for IgG α-Vκ36-71 activity using the 
same DELFIA assay used to assess the heat aggregates (Figure 4.7C, Table 4.3).  At d21, 
neither the mice receiving the immune complexes nor the monomeric Ig made an IgG α-
Vκ36-71 response (0/5, 0/5).  After a boost at day 21, 4/5 mice with a primary injection of 
immune complex made an IgG response by day 42, which reached 5/5 by day 63 after a 
second boost.  In all cases, the concentration of α-Vκ36-71 increased post boost, albeit 
modestly in some cases.  Mice that received a primary monomeric Ig injection did not 
develop an IgG response at either day 42 (0/5) after 1 boost or day 63 (0/5) after 2 boosts.  
This result indicated that immune complexes were able to generate a memory response , 
although the levels of IgG in the primary response, if any, were beneath detection.  
Monomeric Ig continued to fail to develop a primary response or memory responses, 
even after 2 additional injections with immune complexes.  
If the immune complexes could lead to a humoral response, I wanted to know 
whether the CFSE proliferation profile generated by immune complexes would be 
different than that induced by monomeric Ig.  To test this, I did similar adoptive transfers 
to what I had used previously, with  5 x 104 CFSE-labeled CA30 cells.  These mice were 
injected with immune complexes or monomeric Ig and then sacrificed at day 5 and 
splenocytes were analyzed for proliferation.  As opposed to the heat aggregates, the 








































































































































Monomeric Ig 0/5 - 0/5 - 0/5 - 
Immune Complex 
0/5 - 4/5 
0.768 µg/ml  
(SD 0.69) 
5/5 
3.63 µg/ml  
(SD 3.92) 
 
proliferation were consistent between transfers with different cell numbers, while the 
total percentages of cells differed.  My hypothesis, based upon the difference in the 
humoral response was that the CFSE profile would indicate a larger population of cells 
that proliferated to further divisions (7) when comparing the immune complex to the 
monomeric Ig. The qualitative CFSE profiles showed a consistent pattern in which the 
monomeric led to large percentages of cells in the range of 3 – 4 divisions, while the 
immune complexes had an increased percentage of the number of cells that reached 
further (7) divisions (Figure 4.6D).  Using the Flowjo CFSE proliferation algorithm, I 
identified peaks of division and calculated percentages of CA30 cells that were currently 
at each stage of division (Table A2). In the mice that received immune complexes, the 
percentage of CD45.1+ cells in the 7th division were significantly increased in 
comparison to mice receiving monomeric Ig. Again, I was curious whether there might 
be a sequestration or proliferation of cells in the lymph nodes that I was not perceiving by 





Figure 4.6 A-C Immune complexes generate a similar primary expansion and 














Figure 4.6 A-C Figure 4.6 A-C Immune complexes generate a similar primary 
expansion and humoral response to heat aggregates 
B6AF1 mice received adoptive transfer of 5 x 104 congenic CA30.45.1 followed 1 day 
later (day 0) by i.p. injection of 100 µg of monomeric Ig or immune complexes in sterile 
PBS.  Mice were sacrificed at different time points and splenocytes assayed for CD45.1+ 
cells.  (A) Mean CD45.1+ percentage among total CD4+ of 4 mice per group per day in 
primary proliferative response of CA30 T cell.  (B) Representative FACS plots (left) and 
number of CD4+ CD45.1+ (right) in splenocytes of mice at day 14 after injection of Ig 
species. To increase the yield of CD45.1+ cells, events were pre-gated to exclude 99% of 
events outside a CD4+, MHC II-, CD19-, CD8α-, F4/80- gate.  Symbols represent 
individual mice and mean of cell percentages is denoted by the bar in the scatter plot.  
Statistics represent a pairwise comparison calculated by a two-tailed Student’s t-test with 
p<0.05 (*).  Data are representative of three independent experiments containing 5 mice 
per group.  (C) IgG α-Vκ36-71 concentration in mice injected with immune complexes or 
monomeric Ig.  B6AF1 mice received adoptive transfer of 5 x 104 CA30.CD45.1 cells 
and 1 day later were bled and i.p. injected with either 100 µg of either monomeric Ig 
(black), or immune complex (gray) in sterile PBS.  Mice were rested for 21 days, bled, 
and then received a booster injection of 100 µg of heat aggregated Ig in sterile PBS.  
Mice were bled at day 42 and received another booster injection.  IgG α-Vκ36-71 
concentration was quantified in sera using a DELFIA assay and extrapolated based upon 
a standard curve generated by a previously reported IgG2b α-Vκ36-71 (mAb 17-63).  
Individual mice are represented by continuous line connecting sera concentration at each 











Figure 4.6 D-E Immune complexes generate a similar primary expansion and 













Figure 4.6 D-E Immune complexes generate a similar primary expansion and 
humoral response to heat aggregates 
(D) Representative FACS plots of CFSE and CD45.1 staining in the CD4+, MHC II-, 
CD19-. CD8α-, F4/80- gate (top), histograms containing CFSE proliferation profile gates 
generated by FlowJo proliferation algorithm and applied to all samples (bottom), and 
mean percentages of CD4+CD45.1+CFSE+ cells in the 7th division as calculated from the 
gates derived by the FlowJo proliferation algorithm (right). B6AF1 mice received 
adoptive transfer of 5 x 104 CFSE labeled CA30.CD45.1 cells and 1 day later (day 0) 
received 100 µg of monomeric Ig, or immune complex.  Mice were sacrificed at day 5 
and splenocytes were analyzed via FACS. Histograms are gated on CD4+CD45.1+ cells.  
Symbols represent individual mice and mean of cell percentages is denoted by the bar in 
the scatter plot.  Statistics represent a pairwise comparison calculated by a two-tailed 
Student’s t-test with p<0.05 (*).  Data are representative of two independent experiments 
containing 4 mice per group.  (E) Representative FACS plots of percentage of 
CXCR5hiPD-1hi cells among CA30.CD45.1 population (left) and number of CD4+ 
CD45.1+ CXCR5hiPD-1hi cells (right).  Mice received adoptive transfer of 5 x 104 CFSE 
labeled CA30.CD45.1 cells and 1 day later (day 0) received 100 µg of monomeric Ig or 
immune complex Ig.  Mice were sacrificed at day 14 and splenocytes were analyzed via 
FACS.  To increase the yield of CD45.1+ cells, events were pre-gated to exclude 99% of 
events outside a CD4+, MHC II-, CD19-, CD8α-, F4/80- gate.  Symbols represent 
individual mice, bar represents the mean, and error bars represent the standard error.  
Statistics represent a pairwise comparison calculated by a two-tailed Student’s t-test with 










then injected them IP with immune complexes or monomeric Ig and examined the 
axillary, brachial, right and left inguinal lymph nodes at day 5. Unlike what had been 
seen in the mice receiving heat aggregated Ig, there was no defect in CA30 T cell 
proliferation in the lymph node, but also not an enrichment (data not shown).  The overall 
portrait of proliferation in the lymph node suggested that the immune complex was less 
susceptible to the mechanism that hampered heat aggregated Ig from being presented in 
these sites.            
Finally, the humoral immune response and the increased percentage of cells in the 
6th and 7th division suggested that the immune complexes might be generating a Tfh 
response.  To test this, I adoptively transferred 5 x 104 CA30 cells into recipients and then 
injected them i.p. with 100 µg of monomeric Ig or the equivalent of 100 µg of mAb 36-71 
in immune complexes.  Mice were sacrificed on day 14 and splenocytes were analyzed 
for evidence of cells with CXCR5hiPD-1hi Tfh phenotype.  The percentages of Tfh were 
significantly increased at day 14 in the spleens of the mice that received immune 
complexes as compared to those that received monomeric Ig (Figure 4.6E).  This 
suggested that, similar to the heat aggregates, the immune complexes were inducing Tfh 
development, which accorded with the data indicating a successful humoral response in 
animals with this treatment as compared to mice injected with monomeric Ig. 
IV.2.7 Alternative “large” heat aggregates and immune complexes induce divergent 
proliferative profiles at day 5 
In the course of experimentation, I generated two species of aggregated Ig that 
acted anomalously in regards to the generation of a humoral response.  The first was a 
batch of heat aggregates that was aggregated at a higher temperature (65°C compared to 
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62°C) and incorporated a higher percentage of the Ig mass(~100% vs 66%) than the 
typical heat aggregates used in my experiments.  The second was immune complexes 
generated at the equivalence point concentration of Ars-MSA rather than 4 times the 
concentration of the equivalence point, which was standard in the majority of my 
experiments.  These complexes incorporated a larger component of the total Ig mass into 
the insoluble fraction.  Neither of these species generated a primary response (0/5, 0/5) 
when injected into animals that had received 5 x 104 CA30 cells and both displayed poor 
secondary responses when mice injected with the large aggregate were later challenged 
with “immunogenic” heat aggregated Ig (0/5) or when mice injected with large immune 
complexes were challenged twice (0/5 and subsequently 1/5)with immune complexes 
generated at antigen excess (Table 4.4).  I was curious whether there was a short term test 
that I could have used to identify these species as unlikely to induce a response prior to 
using them in longer term experiments, and because CA30 proliferation in vitro to 
monomeric Ig was nil compared to what was observed in vivo.  The difference in the 
proliferative patterns between the normal aggregated species (heat aggregated, Ag-excess 
immune complex), in comparison to monomeric Ig, and the fact that these aggregated 
species led to a humoral response and the monomeric Ig did not, led me to wonder 
whether the CFSE assay I had used previously would be a useful screening assay to 
identify reagents that were anomalous.  To test this, I adoptively transferred 2.5 x 105 
CFSE-labeled CA30 cells into mice and then injected them with 100 µg of the large heat 
aggregate or the equivalent of Ig mass in large immune complexes or control populations 
(monomeric Ig, heat aggregates, immune complexes).  I sacrificed these mice at day 5 
and assayed their splenocytes for evidence of CFSE dilution in the CA30 cells.  The 
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patterns of proliferation were different between the large species of the 
aggregates/complexes and the version used for most experiments.  In the case of the large 
heat aggregates, there was an increased percentage of cells that did not divide at all and a 
decreased percentage of cells that reached the furthest measured division (7)  (Figure 
4.7A, Table A3).  The large immune complexes had a pattern of division that was quite 
different from the Ag-excess immune complexes, with an increased percentage of cells 
that did not divide, an increased percentage of cells at divisions 1- 4, and decreased 
percentages of cells that had undergone 5 – 7 divisions (Figure 4.7B).  The similarity 
between the cell percentages that were in the 5 – 7th division in the monomeric Ig 
samples and the large heat aggregate and large immune complex groups was intriguing, 
because neither form of Ig produced a primary or memory immune response.  This does 
not prove that the increased divisions are critical to the development of a humoral 
response, per se, merely that this type of analysis could be potentially useful for 
evaluating future batches of mAb 36-71 heat aggregates and immune complexes prior to 
the usage in larger experiments. 
Table 4.4 Large heat aggregates and large immune complexes do not prime for a 




































































































































Large Heat Aggregate 0/5 - 0/5 - 0/5 - 
Large Immune 
Complex 0/5 - 0/5 - 1/5 1.76 µg/ml  
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IV.2.8 The lack of a functional Fc diminishes presentation of a peptide in the Fab 
region 
The concept of using this CFSE proliferation assay to evaluate reagents intrigued 
me and I wanted to use this methodology to ask another question about presentation that 
had puzzled me since my initial observation that monomeric mAb 36-71 induced robust 
proliferation:  did this presentation somehow rely on the Fc portion of the Ig?  To test 
this, I generated F(ab’)2 and Fab fragments using the enzyme ficin and purified them by 
size-exclusion chromatography with the help of Fran Crawford in the Kappler/Marrack 
lab.  It was important to generate both species because of the capacity for the F(ab’)2 to 
crosslink the receptor on a B cell, which the literature had suggested could induce a 
humoral response when injected into mice without adjuvant.   This was attributed to a 
capacity to crosslink the B cell receptor without engaging the inhibitory FcγRIIB.  
Conversely, a Fab α-IgD reagent has been shown to tolerize B cells when transferred, 
rather than induce a productive humoral response.  I hypothesized that this capacity to 
crosslink the receptor of B cells would allow the F(ab’)2 to be presented to the CA30 T 
cell, while the Fab would not be efficiently presented.  I adoptively transferred 2.5 x 105 
CA30 cells into recipient mice and then injected the mice with 100 µg of the monomeric 
Ig, or the equivalent amount of antigenic Vκ36-71 epitope in the form of F(ab’)2 (73 µg) or 
the Fab (66 µg).  After 5 days, I sacrificed the mice and assessed the splenocytes for 
CFSE proliferation of the CA30 cell.  When I calculated the CA30 percentage in the total 
CD4+ population, I realized that my hypothesis was incorrect.  Neither the Fab nor the 




Figure 4.7A-B Large heat aggregates and large immune complexes drive fewer 
divisions than expected 
Mice received adoptive transfer of 5 x 104 CFSE labeled CA30.CD45.1 cells and 1 day 
later (day 0) received either heat aggregated Ig or large heat aggregated Ig (experiment in 
A) or immune complex or large immune complex (experiment in B).  Mice were 
sacrificed at day 5 and splenocytes were analyzed via FACS.  Representative histograms 
containing CFSE proliferation profile gates generated by FlowJo proliferation algorithm 
and applied to all samples.  Histograms are gated on CD4+CD45.1+ cells.  Histograms 






than the monomeric Ig and, in fact, equivalent to the cell populations in mice that 
received the negative IgG1 (Figure 4.8A).  When I used the Flowjo CFSE proliferation 
algorithm to identify division peaks, I discovered that both the Fab and the F(ab’)2 had 
increases in the cell percentages at 0 and 1 division and had decreased percentages of 
cells in later divisions (Figure 4.8B, Table A4).  On top of having a decreased percentage 
of CA30 cells overall in comparison to monomeric Ig treated mice, the cells that were 
remaining were had not divided much.  Out of curiosity, I had also included an additional 
group which recieved F(ab’)2 complexed with Ars-MSA.  As I had normalized the 
amount of Fab region (and antigenic peptide) that I was injecting into these mice, I 
decided to complex the 73 µg of F(ab’)2 with the same amount of excess antigen, Ars-
MSA, that I would use to complex the roughly equivalent amount of Fab in 100µg of mAb 
36-71.  The F(ab’)2 complexes rescued the CA30 percentage of total CD4+, returning it 
to statistically equivalent with the monomeric population and rising it back above the 
negative IgG1 control (Figure 4.8C).  When I examined the cell proliferation patterns 
qualitatively and quantitatively, I saw a pattern that reminded me of the heat aggregate or 
the immune complex.  There was a decrease in the percentage of cells that were in the 
middle stages of division (2 – 5) that were followed by an increase of the percentage that 
were in division 6 or 7 as compared to the monomeric Ig.  The rescue in total CA30 
percentage had associated with an increase in the population that was at division 6 or 7, 
which was very similar to what had been seen in both the heat aggregate and the immune 
complex.    
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IV.2.9 B cells are an important source of presentation for heat aggregated Ig antigen 
to CA30, but not critical for presentation of immune complex or monomeric Ig 
The observation that complexing of F(ab’)2 could rescue the proliferation of 
CA30 was interesting in that it implied that there was probably some aspect of increase in 
antigen size that could lead to increased presentation.  It was possible that the Ars-MSA 
contained a sufficient amount of LPS or other adjuvant that was responsible for the 
increase in antigen presentation, however the negative result with the large immune 
complexes, which only contained 4-fold less antigen than the F(ab’)2 immune complex 
made this seem unlikely.  Given that the antigen size argument was more intriguing, I 
was curious whether the presentation of the immune complex or the heat aggregates 
could be influenced by targeting the cell that I believed might benefit from an increase 
inavidity of the Vκ36-71 antigen, the B cell.  It has been shown that marginal zone B cells 
transport antigen to the follicles to help them to reach follicular dendritic cells[282-284].  
Recent work has shown that low affinity B cells are important for the transport of virus-
like particles into the follicle, which allows for higher affinity B cells to obtain antigen 
and interact with primed T cells at the T-B border [285].  To test this hypothesis, I 
contacted Genentech and obtained the antibody clone 5D2, an IgG2a that binds mouse 
CD20 and leads to B cell depletion, the mouse version of the human antibody Rituximab.  
A day before adoptively transferring CA30 T cells, I injected mice IP with 500 µg of this 
antibody, 5D2, or an isotype control IgG2a with a kappa light chain acquired from Sigma 
Aldrich.  The next day, I adoptively transferred 5 x 104 CFSE-labeled CA30 T cells, and 






Figure 4.8 The lack of a functional Fc diminishes presentation of a peptide in the 


















Figure 4.8 The lack of a functional Fc diminishes presentation of a peptide in the 
Fab region but an F(ab')2 complex can rescue presentation 
Mice received adoptive transfer of 5 x 104 CFSE labeled CA30.CD45.1 cells and 1 day 
later (day 0) received 100 µg of negative control Ig, monomeric Ig, 73 µg of F(abʼ)2 or 
F(abʼ)2 complex or 66 µg of Fab. Mice were sacrificed at day 5 and splenocytes were 
analyzed via FACS.  (A)  Mean percentage of CD45.1+ cells among total CD4+ cells for 
monomeric Ig, F(abʼ)2, Fab, and negative control Ig  (B) Representative histograms 
containing CFSE proliferation profile gates generated by FlowJo proliferation algorithm 
and applied to all samples for monomeric Ig, F(abʼ)2 and Fab,  (C)  Mean percentage of 
CD45.1+ cells among total CD4+ cells for monomeric Ig and F(abʼ)2 complex (left) 
and   Representative histograms containing CFSE proliferation profile gates generated by 
FlowJo proliferation algorithm and applied to all samples for F(abʼ)2 complex. 
(right)  Histograms are gated on CD4+CD45.1+ events.  Symbols represent individual 
mice and mean of cell percentages is denoted by the bar in the scatter plot.  Statistics 












aggregates, or the equivalent in the form of immune complexes.  I waited for five days 
and then sacrificed the mice and evaluated the CFSE proliferation of CA30 cells by 
assaying mouse splenocytes.  My expectation was that this α-CD20 Ig would 
significantly decrease the CA30 T cell proliferation in mice treated with both the heat 
aggregate and the immune complex, given that both antigens were probably large enough 
to necessitate B cell transport to reach the follicles and initiate antigen-specific B cell 
presentation to T cells. I thought might be the source of the additional proliferation based 
upon the F(ab’)2 phenomenon.  The actual result was somewhat more complicated.  
First, I assessed the B cell depletion in the mice that had received 5D2 and saw a 
3 fold reduction in CD19+ cells within the spleen compared to isotype control (Figure 
4.9A). Upon examining the CA30/CD4 ratios, there was no significant difference 
between the mice that had been injected with monomeric Ig and received the isotype 
control or 5D2 ; similarly, the mice injected with Ag-excess immune complexes that had 
received either isotype or 5D2 and immune complexes did not have significantly different 
percentages (Figure 4.9B).  However, the mice that received the α-CD20 and heat 
aggregates had a significantly decreased percentage of CA30 T cells compared to mice 
that had received the isotype control and heat aggregates, although this was still above 
mice injected with negative control IgG1.  In the isotype control group, there was no 
statistical difference in the CA30/CD4 ratios among the different antigens, but when α-
CD20 therapy was examined, the group that was exposed to monomeric Ig had 
significantly higher CA30/CD4 percentages (4.9C). Thus, I was observing two effects in 
the mice treated with α-CD20:  there was a significant decrease in the heat aggregate 
CA30 percentage as seen between the two heat aggregate groups, and a significant 
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increase in CA30 percentages compared to immune complexes and heat aggregated Ig in 
mice that received α-CD20 and monomeric Ig.  
To put these findings in context, I examined the CFSE proliferation of each group 
of the mice that had received the monomeric Ig and the isotype control.  Qualitatively, it 
appeared that α-CD20 led to more CA30 cell divisions in mice injected with monomeric 
Ig, approximated by a division profile shifted 2-3 divisions forward (4.9D).  The heat 
aggregate and α-CD20 treated mice appeared to have an increased percentage of CA30 
cells that had not divided and decreased percentages of cells in the later division cycles, 
in contrast to what I had seen previously with heat aggregates.  Both immune complex 
samples appeared to follow a similar pattern to what I had seen previously, with 
relatively low populations of cells that had not divided and an increase in the percentage 
of cells that were in further division stages.  When I used the Flowjo CFSE proliferation 
algorithm to assign division peaks, I found that these qualitative observations were fairly 
accurate (Table A5, Figure 4.9E).  The mice receiving monomeric IgG had a small 
percentage of cell reach the 7th division when treated with isotype control, but a high 
percentage of cells if treated with α-CD20.  The mice receiving heat aggregated Ig had a 
decreased number of cells reach the 7th division when treated with either the isotype 
control, where it was decreased from what I had seen in other experiments, or α-CD20, 
which eliminated most of the proliferation from this antigen.  Finally, the immune 
complex treated mice had CA30 T cells that maintained a roughly consistent amount of 
proliferation whether treated with isotype control or α-CD20.  This was markedly 






Figure 4.9A-C α-CD20 therapy diminishes proliferation of CA30 T cells in response 





























Figure 4.9A-C α-CD20 therapy diminishes proliferation of CA30 T cells in response 
to heat aggregated Ig 
Mice received i.p. injection of 500 µg of a-CD20 (mIgG2a5D2) or isotype control (UPC 
110).  The next day (day -1), mice received adoptive transfer of 5 x 104 CFSE labeled 
CA30.CD45.1, and 1 day later (day 0) received 100 µg of negative control Ig, monomeric 
Ig, heat aggregated Ig, or immune complex.  Mice were sacrificed at day 5 and 
splenocytes were analyzed via FACS.  (A)  Mean B220+ percentage of splenocytes of 
mice receiving isotype control or a-CD20.  Events were in B220+CD4- gate.  (B) 
Comparison of mean percentage of CD45.1+ cells among total CD4+ cells for groups 
receiving a similar antigenic Ig species but different B cell depletion 
treatment.  (C)  Comparison of mean percentage of CD45.1+ cells among total CD4 for 
groups receiving same B cell depletion treatment but different antigenic Ig 
species.  Symbols represent individual mice and mean of cell percentages is denoted by 
the bar in the scatter plot.  Statistics represent a pairwise comparison calculated by a two-
tailed Studentʼs t-test with p<0.05 (*), p<0.005 (**).  Data is representative of two 







Figure 4.9D-E α-CD20 therapy diminishes proliferation of CA30 T cells in response 



















Figure 4.9D-E α-CD20 therapy diminishes proliferation of CA30 T cells in response 
to heat aggregated Ig 
Mice received B cell depletion treatment and CFSE transfer as described in 4.9A. (D) 
Representative histograms containing CFSE proliferation profile gates generated by 
FlowJo proliferation algorithm and applied to all combinations of B cell depletion 
therapy (side) and Ig antigen (top).  Histograms are gated on CD4+CD45.1+ 
events.  (E)  Mean percentages of CD4+CD45.1+CFSE+ cells in the 7th division as 
calculated from the gates derived by the FlowJo proliferation algorithm.  Symbols 
represent individual mice and mean of cell percentages is denoted by the bar in the scatter 







 The initial objective of the work in this chapter was to test the hypothesis that 
monomeric Ig would not be perceived by CA30 cells in vivo and not generate a 
productive CA30 expansion and subsequent humoral immune response, while aggregated 
species would be perceived, generate expansion, and lead to a humoral response.  To test 
this hypothesis in vivo, I used an adoptive transfer model in which I typically transferred 
5 x 104 congenically-marked (Thy1.1a or CD45.1) CA30 cells into B6AF1 mice and 
injected 100 µg of whole mAb 36-71, or a Vκ36-71 epitope molar equivalent of Fab or 
F(ab’)2 in various physical states.   This was the first comprehensive analysis of the 
primary response kinetics and phenotype of an individual CD4+ clone, specific to antigen 
contained within an Ig, to monomeric Ig or variants of that Ig, to include heat aggregates, 
immune complexes, F(ab’)2, and Fab species.  
 At the outset of the experiments, I was surprised to find that ultracentrifuged, 
monomeric Ig was perceived rapidly and induced a primary proliferative response of the 
CA30 T cell in vivo and that the magnitude of this primary response mirrored closely by 
the injection of heat aggregated Ig or immune complex.  In contrast to Ig with the 
adjuvant alum, which induced massive expansion in the primary response, the heat 
aggregate and the immune complex induced expansions that were significantly but 
modestly different than from the response to monomeric Ig and never greater than about 
2 fold in terms of CA30 cell numbers or CA30 percentages.  The IgG response to Vκ36-71 
elicited by immune complex or heat aggregate was similarly existent but modest, 
generally requiring a secondary boost to be consistently measured and never reached a 
serum concentration of more than 10 µg/ml.  From a global perspective, I was examining 
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the response of an Ig-reactive CD4+ T cell in a primary response that was teetering on the 
edge of the line between immunity and non-immunity, and trying to discern whether this 
non-immunity was a function of tolerance or ignorance.  By using heat aggregate or 
immune complex that was not augmented with a large amount of adjuvant, I was 
attempting to model the usage of therapeutic Ig in the clinic in which the reagents are 
generally assumed to be made with good manufacturing practice.  The proviso to this 
statement is that, as was seen in the first chapter, my reagents contained an insoluble 
fraction that, particularly in the case of the heat aggregates, was a visibly particulate 
species that would ostensibly be captured by IV filters during infusion in the clinic.  All 
of this being said, the use of heat aggregated Ig as a positive control was well 
documented in the early investigation of the immunogenicity or tolerogenicity of Ig 
species. 
    Once it was established that the immune complexes and heat aggregates could 
generate a humoral response that was boosted in a secondary response, but the 
monomeric Ig did not, I needed to address a potential mechanism to explain this 
difference.  At first, I relied upon the published observation that increased presentation 
and CD4+ division was associated with an immunogenic response, although there is 
some thought to the contrary, and examined CA30 proliferation through the use of CFSE 
[280].  I found a pattern of CA30 division that was similar between heat aggregates and 
immune complexes and different than monomeric Ig; the species that generated the 
humoral response also tended to have increased percentages of cells in the furthest 
division (7) observed using the FlowJo algorithm for definining peaks of proliferation..  
This increased percentage of cells that were in a late stage of division was particularly 
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interesting in the context of the observation that there was an increased percentage of 
CXCR5hiPD-1hi  T follicular helper cells in the CA30 population at day 14 in mice that 
received either heat aggregated Ig or immune complexes.  Recent work has suggested 
that prolonged antigen presentation is required for the development of the Tfh and that 
this presentation may be initiated by dendritic cells (DC) and then require subsequent B 
cell presentation when antigen is limiting or further DC stimulation if antigen is not 
limiting [286-289].  I believe that this manifestation of Tfh is more likely related to the 
development of the humoral response and the lack thereof in the mice receiving the 
monomeric Ig rather than an active suppression generated by the cells treated with 
monomeric Ig, as I did not observe a significant increase in a CD25+FoxP3+ Treg 
population in these cells at day 7, 10, or 14.   
 The CFSE data involving the species that were anomalous aggregates (the “large” 
species), without an Fc (F(ab’)2 or Fab), and the mice treated with α-CD20 are also 
interesting in this regard.  The large immune complexes and large heat aggregates acted 
differently than the smaller species of each type, not generating a detectable secondary 
response to an immunogenic stimulus and displaying different patterns of CFSE 
proliferation.  In both cases, aggregates within the samples were assumed to have been 
created with a greater mass of immunoglobulin based upon their formation, and perhaps 
this is related to decreased uptake by the B cell compartment and decreased presentation 
to CA30 T cells.  The summary of the mass distribution of these samples in chapter III 
supports this hypothesis in the case of the large immune complex, which was 
predominantly insoluble and lacked much in the way of small particulate or soluble Ig.  
However, the distribution of mass in the large heat aggregate was similar to that of the 
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immunogenic immune complexes, so this simplistic analysis requires refinement.  The 
decrease in the presentation of the F(ab’)2 and the Fab as measured by CFSE dilution 
implies that the Fc is important in generating the efficient proliferation seen with 
monomeric Ig.  Although, it is important to note that this may also be an expression of 
the volume of distribution of these smaller species, which would be expanded, and the 
knowledge that an intact Fc has been shown to be important for its role in recycling and 
preventing the elimination of monomeric Ig from the blood.  The fact that presentation of 
the F(ab’)2 could be rescued by complexing it with Ars-MSA further supports the idea 
that increasing the size of antigen may be important in inducing some APC population to 
participate in its presentation.  Finally, the α-CD20 presentation data adds another view 
of the role of the B cell in this early presentation of the Ig to CD4+ T cells.  The two most 
important observations are the increase in percentage of cells reaching further divisions in 
the mice receiving monomeric Ig and the notable decrease in CA30 percentage in the 
total CD4+ population in the mice treated with heat aggregated Ig.  The latter finding 
suggests an important role for B cells in the promoting the presentation of the aggregates, 
which may be a function of direct presentation by Ag-specific B cells or the nonspecific 
transport of aggregates to other APC by B cells.  I would speculate that the important B 
cells in this context may be marginal zone B cells, as the heat aggregation of Ig might be 
expected to create structures of repetitive antigen that could stimulate these cells in a T-
independent 2 type manner which would be similar to other work involving rheumatoid 
factor immune complexes and B cell stimulation [195, 196, 290].  The pattern of 
proliferation also appeared to show decreased percentages of cells reaching further 
divisions in the mice that received isotype control and heat aggreagated Ig, although the 
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percentage of CA30 T cells in total CD4+ was not decreased.  This may also be a clue to 
the role of B cells in the presentation of heat aggregated Ig antigen, as the injection of 
large amounts of an isotype control Ig 2 days before the inclusion of heat aggregated Ig 
may have been sufficient to disrupt some of the presentation.  Although the α-CD20 was 
stored in low-aggregation pharmaceutical buffer, it was not ultracentrifuged prior to 
injection.  The increase in the percentage of CA30 cells reaching further divisions with 
treatment of monomeric Ig and α-CD20 is more perplexing.  It is possible that this was a 
function of the decrease in the B cell compartment and an increase in resources and 
“space” for proliferation of the CA30 cell, similar to homeostatic proliferation seen in 
lymphopenic environments.  Conversely, it could show a role for B cells in the 
suppression of CD4+ T cell response to an antigen with the potential to be tolerogenic.  
The monomeric Ig weakly bind and tolerize Ag-specific B cells in a manner similar to 
previous work with rabbit α-IgD Fab, and perhaps these B cells would negatively effect 
the proliferation of the CA30 T cell.  This would also similar to another model in our lab, 
in which anergic B cells suppressed humoral responses and are poor stimulators of T cells 
that are presented with hapten conjugates of protein-peptide antigen [291].  This 
suppression could also occur non-specifically due to uptake of monomeric Ig through Fc 
receptors, although the inhibitory FcγRIIB would be unlikely to bind very much 
monomeric Ig[183]. 
 In summary, the work in this chapter provided a unique view into the perception-
of by an antigen-specific CD4+ and subsequent humoral response-to monomeric Ig in 
comparison to aggregated species.  For the first time, it demonstrated the expansion and 
contraction of a specific CD4+ T cell in response to monomeric Ig without a subsequent 
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humoral response.  These cells did not become Treg at an increased percentage, as had 
been previously hypothesized.  Instead, both heat aggregates and immune complexes 
generated humoral responses against antigen within the Ig.  The difference in this 
response appeared to be in its increased percentages of CD4+ T cells that had reached 7 
divisions by day 5 and an increased percentage of Tfh at day 14.  The chapter also 
contains data suggesting that the Fc region is important for presentation of monomeric Ig 
and that the response to heat aggregated Ig may require B cells to aid in the early stages 
of antigen presentation.  
          






THE EFFECT OF IG FORM ON THE EXPANSION OF MEMORY 
CA30 T CELLS 
V.1 Introduction 
The hallmark finding of the literature base initiated by Dresser in 1961 and 
extended by Chiller, Habicht, and Weigle in the early 1970s was the lack of a humoral 
immune response to an immunogenic form of Ig, whether heat aggregated or emulsified 
in complete Freund’s adjuvant (CFA), when the animals in question had been treated 
previously with ultracentrifuged, monomeric Ig[43, 68, 69].  That the tolerance extended 
to the memory response was critical for the separation of the phenomenology into its 
constituent cellular components.  For Chiller, Habicht, and Weigle, this meant that 
tolerized thymocytes could be mixed with normal bone marrow, or tolerized bone 
marrow mixed with normal thymocytes, and injected into irradiated mice to create a 
“central lympoid organ chimera”, milieus with predominantly tolerized or normal B and 
T cell compartments.  At the dose of Ig that I typically used in my experiments, 100 µg, 
the monomeric HGG-tolerized thymocytes did not support the formation of antibody 
secreting cells (ASCs) from normal bone marrow upon two challenges with heat 
aggregated HGG, whereas HGG-tolerized bone marrow only instituted 9% of the 
tolerance in terms of ASC formation that could be achieved with a higher dose of 
tolerogen (2.5 mg) [69].  In this example, the thymocytes were tolerized in some way, 
although the exact mechanism, be it active suppression by a regulatory cell population, 
deletion, or anergy, was unidentified.  In the experiments described in the preceding 
chapter, I observed that the adoptively transferred CA30 T cells expanded and contracted 
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in vivo in response to the injection of ultracentrifuged, monomeric mAb 36-71 and that 
this general pattern of expansion and contraction was mirrored closely, with significant 
differences, by CA30 cells exposed to heat aggregate or immune complex.  However, the 
monomeric Ig did not yield an IgG primary response nor an IgG secondary boost to heat 
aggregates, or secondary and tertiary reponses to immune complexes, as assessed using 
antigenic Vκ36-71 light chain as an antigen. In contrast, both the immune complex and 
heat aggregate did induce a humoral response that was particularly notable after a boost 
with the same antigen.  This lack of a memory humoral response by the monomeric Ig led 
me to wonder whether I had generated tolerized T cells. If so any CA30 cells remaining 
in these mice after the primary response should not respond to secondary injection of 
antigen.   
To test this, I adoptively transferred 5 x 104 congenic CA30 cells into B6AF1 
mice, primed them with various Ig antigen, and then injected them with a secondary 
stimulus 30 days after the primary injection.  Five days after the secondary injection, I 
sacrificed mice and assayed for congenic CA30 cells in the spleen, comparing their 
frequencies to those of mice that had received a primary treatment but had not received 
the secondary injection.  Due to the long period of time required for mice to incubate 
with these treatments, the number of mice required for boost/non-boost comparisons, my 
own time constraints, and the complexity of the data, these experiments were carried out 
at the beginning and the end of my studies with a long pause in the middle, meaning that 
the data that I present in this chapter raises more questions than it provides answers.  
However, I believe that the results are interesting in light of the data presented in other 
chapters, and I believe that the presentation of these novel data is important.  The result 
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of the work provides the first demonstration that an individual CD4+ T cell clone could 
be exposed in vivo to a monomeric Ig and subsequently expanded in response to a 
secondary boost of a corresponding antigenic peptide.   However, the magnitude of this 
expansion varied based upon both the primary and the secondary stimulus, which may 
have important implications for future experiments considering the primary and 
secondary presentation of Ig antigen to the T cell compartment. 
V.2 Results 
V.2.1 CA30 T cells exposed to monomeric Ig can expand in a memory response, but 
this expansion is similar to that of CD4+ T cells exposed to a tolerogen 
The first publication involving adoptively transfer of transgenic CD4+ T cells into 
mice also documented the observation that the injection of soluble, antigenic peptide 
without adjuvant led to rapid expansion, contraction, and a minor recall upon secondary 
stimulation [276].  In comparison to the response to peptide delivered with an adjuvant, 
this response was deemed to be tolerogenic, as the adjuvant treated mice maintained a 
larger residual population of T cells during the phase of gradual contraction, and these 
cells were more responsive to a secondary stimulus.  Given that CA30 T cells expanded 
and contracted in a primary response, I was curious whether their response to a secondary 
stimulus would be more similar to the expansion seen in mice that received a primary 
tolerogenic stimulus than in mice that received adjuvant with the initial injectiom.  To 
test this, I adoptively transferred 5 x 104 congenically marked CA30 T cells into B6AF1 
mice and IP injected these mice with either 10 µg of Vκ36-71 peptide in PBS, 100 µg of 
ultracentrifuged, deaggregated mAb 36-71 in PBS, 10 µg of Vκ36-71 peptide plus 10 µg of 
bacterial LPS in PBS, or 100 µg of ultracentrifuged, deaggregated mAb 36-71 plus 10 µg 
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of bacterial LPS in PBS (Figure 5.1A).  After 30 days, I boosted all groups with 10 µg of 
Vκ36-71 peptide plus 10 µg of bacterial LPS in PBS or PBS alone, sacrificed the animals 5 
days later and assayed for CA30 T cells in spleens by flow cytometric analyses (Figure 
5.1B).  The adjuvant LPS was used in the secondary stimulus on the recommendation of 
Dr. Megan Macleod, a member of the Kappler/Marrack lab at the time, who advocated 
for the usage of LPS to increase the expansion of cells in the memory response.   
At day 5 post-boost, the group primed with Vκ36-71 peptide plus LPS appeared to give the 
greatest recall response (Figure 5.1C, D).  The CA30 cell percentage of the total CD4+ 
population was relatively constant among all of the groups that did not receive a booster 
injection.  In mice primed with Vκ36-71 peptide plus LPS there was a significantly 
increased CA30 cell percentage of the total CD4+ cells after the boost relative to that of 
any other group, and no substantial differences among the other groups.  Mean 
percentages of CA30 cells in the total CD4+ population were compared between 
unboosted and boosted mice in each treatment group to provide an estimate of fold 
change in percentages as a measure of expansion in response to the secondary injection 
(Table 5.1).  The group initially injected with monomeric mAb 36-71 produced a fold 
change in CA30 cell percentages similar to that of the group receiving Vκ36-71 peptide 
alone, the treatment predicted to be tolerogenic.  Moreover, addition of LPS to the mAb 
36-71 increased the fold change in percentage relative to that of the group that was 
initially injected with monomeric Ig alone.  However fold change in CA30 number for 
the group initially injected with the Vκ36-71 peptide plus LPS primary was the greatest of 






Figure 5.1  CA30 T cells exposed to monomeric Ig expand in a memory response, 























Figure 5.1  CA30 T cells exposed to monomeric Ig expand in a memory response, 
but this expansion is similar to that of CD4+ T cells exposed to a tolerogen  
Mice received experimental injections as in (A).  Mice received adoptive transfer of 5 x 
104 CA30.Thy1.1 cells and 1 day later (day 0) received injection with 100 µg of 
monomeric Ig with or without 10 µg of LPS or 10 µg of Vκ36-71 peptide with or without 
10 µg of LPS.  30 days later, they received a booster injection of 10 µg Vκ36-71 peptide 
plus 10 µg LPS.  Mice were sacrificed at day 5 post-booster (day 35) and splenocytes 
were analyzed via FACS.  (B) Representative FACS plots from mice of different primary 
treatments (top) and boost status (side) expressing the percentages of Thy1.1+ cells in the 
CD4+, MHC II-, CD19-, CD8α-, F4/80- gate.  (C)  Mean percentage of Thy1.1+ cells 
among total CD4+ cells  in mice that were not boosted.  (D)  Mean percentage of 
Thy1.1+ cells among total CD4+ cells in mice that were boosted with Vκ36-71 















Table 5.1  CA30 T cells exposed to monomeric Ig expand in a memory response, but 
this expansion is similar to that of CD4+ T cells exposed to a tolerogen  
Treatment 
Mean Thy1.1% of Total CD4 
day 35 (Unboosted) 
Mean Thy1.1% of Total CD4 
day 35 
(10 µg α-Vκ36-71  peptide + 10 
µg  LPS ) 
Fold 
Change 
Peptide 0.0389 SD 0.03467 
0.2383 
SD 0.2780 6.1 
Peptide + LPS 0.1032 SD 0.1342 
1.702 





SD 0.0630 4 




SD 0.1500 4.3 
 
primary injection of mAb 36-71 plus LPS was somewhat surprising, as I had expected the 
inclusion of LPS with the mAb 36-71 to drive a more robust secondary expansion. 
V.2.2 The primary expansion of residual CA30 T cells in negative control mice is 
larger than that of mice treated with various mAb 36-71 species 
The result from this initial memory experiment was intriguing, but I wanted to 
screen multiple conditions to set the stage for future experimentation.  I had expected a 
more substantial CA30 T cell expansion in mice that had received mAb 36-71 and LPS, 
and was curious whether this expansion could be augmented by using an alternative form 
of the Ig.  The original paper characterizing the primary response of adoptive transgenic 
CD4+ T cells had used CFA as an adjuvant to induce a productive immune response with 
peptide, and I wanted to know whether I could replicate these results with the Vκ36-71 
peptide or the mAb 36-71[276].  I had also recently made Ars-MSA (mouse serum 
albumin) and wanted to see if immune complexes between this and mAb 36-71 behaved 
similarly to the monomeric Ig alone.  Finally, I wanted to include a test of the primary 
response of a residual population of CA30 T cells at day 30 in mice that received no 
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primary injection of mAb 36-71 or corresponding peptide, as expansion of such cells 
could confound my interpretations. 
To these ends, I adoptively transferred 5 x 104 congenic CA30 cells into B6AF1 
mice and then i.p. injected them with 100 µg of ultracentrifuged, monomeric mAb 36-71, 
100 µg of mAb 36-71 emulsified in CFA, 10 µg of Vκ36-71 peptide emulsified in CFA, 
100 µg of immune complexed mAb 36-71, or 100µg of the negative control IgG1 (Figure 
5.2A).  After 30 days, I boosted these mice with 10 µg of Vκ36-71 peptide plus 10 µg of 
bacterial LPS or with PBS.  5 days after the boost, I sacrificed these animals and assayed 
their splenocytes by flow cytometry for congenic CA30 T cells (Figure 5.2B).  At day 5 
post-boost, the mice that had received the negative control IgG1 appeared to give the 
most substantial proliferative response (Figure 5.2C,D).  In the unboosted mice, the 
percentage of CA30 of the total CD4+ population was highest in the mice that had 
received the mAb 36-71 emulsified in CFA.  This was unexpected, as I had predicted that 
mice primed with the Vκ36-71 peptide emulsified in CFA would have an equivalent or 
greater percentage of residual CA30 T cells.  Similar to that of the peptide plus LPS 
group in the preceding experiment, the residual population in the peptide CFA group was 
indistinguishable from that of the monomeric Ig group.  Also, the residual CA30 
percentage in the mice receiving the immune complexes was also indistinguishable from 
that of mice receiving the monomeric 36-71. The unboosted mice that received the 
negative control IgG1 had very low percentages of cells remaining.  After the mice were 
boosted, those receiving primary injections of Ig plus CFA or peptide plus CFA 
developed the highest percentages of CA30 T cells in the CD4+ population, while the 
negative control IgG1, monomeric mAb 36-71, and immune complexes appeared to 
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achieve similar levels.  Mean percentages of CA30 cells among total CD4+ cells were 
compared between unboosted and boosted mice in each treatment group to provide an 
estimate of fold change in percentages of cells (Table 5.2). 
The results were somewhat surprising; even though the mice treated with mAb 
36-71 and CFA had the highest residual and boosted CA30 population by percentage, the 
fold change post-boost was less than half of the fold change for the mice receiving the 
Vκ36-71 peptide and CFA Also, it was less than a third of the primary expansion of the 
CA30 cell seen in the negative control IgG1-receiving mice, although this can be largely 
explained by the few residual cells present in this group prior to the secondary injection 
and greater clonal expansion reported in primary versus secondary responses.  The mice 
receiving the monomeric mAb 36-71 and the immune complexes both had fold changes 
in CA30 percentages that were similar to what had been seen in the previous experiment 
for the tolerogenic peptide and the mAb 36-71.  Although the mAb 36-71 group showed a 
slightly decreased fold expansion in this specific experiment and was only half of that 
induced by the immune complexes, both were low compared to those of other groups 
V.2.3 Monomeric Ig is a poor inducer of memory expansion of CA30 T cells 
Results from the previous two experiments were interpreted in the shadow of a 
recall stimulus of the Vκ36-71 peptide plus LPS.  In a scenario weighted towards 
inducing a secondary boost, I had induced one, but was this the correct model for an 
example of therapeutic Ig, where the secondary stimulus is another infusion of the 
monomeric Ig without any exogenous adjuvant.  When I performed the time course 
comparing monomeric, heat aggregated, and alum precipitated Ig presented in Chapter 





Figure 5.2 The primary expansion of residual CA30 T cells in negative control mice 



















Figure 5.2 The primary expansion of residual CA30 T cells in negative control mice 
is larger than that of mice treated with various mAB 36-71 species 
Mice received experimental injections as in (A).  Mice received adoptive transfer of 5 x 
104 CA30.Thy1.1 cells and 1 day later (day 0) received injection with 100 µg of negative 
control Ig, monomeric Ig, immune complexes, Ig emulsified in CFA, or 10 µg of Vκ36-71 
peptide emulsified in CFA.  30 days later, they received a booster injection of 10 µg  
Vκ36-71 peptide plus 10 µg LPS.  Mice were sacrificed at day 5 post-booster (day 35) and 
splenocytes were analyzed via FACS.  (B) Representative FACS plots from mice of 
different primary treatments (top) and boost status (side) expressing the percentages of 
Thy1.1+ cells in the CD4+, MHC II-, CD19-, CD8α-, F4/80- gate.  (C)  Mean percentage 
of Thy1.1+ cells among total CD4+ cells  in mice that were not boosted.  (D)  Mean 
percentage of Thy1.1+ cells among total CD4+ cells in mice that were boosted with Vκ36-















Table 5.2 The primary expansion of residual CA30 T cells in negative control mice 
is larger than that of mice treated with various mAb 36-71 species 
Treatment 
Mean Thy1.1% of Total 
CD4 day 35 (Unboosted) 
Mean Thy1.1% of Total CD4 day 35 








SD 0.0681 34.1 










SD 0.5084 1.3 









SD 0.0350 3.4 
 
I had transferred 5 x 104 congenic CA30 cells into mice and injected them i.p. 
with 100 µg of negative control monomeric IgG1 (mAb 36-65), monomeric mAb 36-71, 
mAb 36-71 precipitated in alum, or mAb 36-71 heat aggregates.  30 days later, I boosted 
some mice with 100 µg of  monomeric mAb 36-71 in PBS (as opposed to Vκ36-71 peptide 
plus LPS) and other mice I did not boost (as they were a component of the time course) 
(Figure 5.3A).  5 days later, I sacrificed the mice and assayed their splenocytes via flow 
cytometry for congenic CA30 cells (Figure 5.3B).  At day 5 post-boost, all groups had 
poor recall proliferative responses (Figure 5.3C,D).  In the unboosted mice, the mice that 
had received mAb 36-71 precipitated in alum had the highest percentage of CA30 T cells 
in the CD4+ population.  The unboosted groups that received monomeric Ig, the negative 
control, or the heat aggregated Ig all possessed low percentages of CA30 T cells.  After 
the boost, CA30 cell populations increased in all groups the cell populations increased in 
all groups, but only slightly.  As before, mean percentage of CA30 cells among total 
CD4+ cells were compared between unboosted and boosted groups to provide an estimate 
of fold change (Table 5.3).  This appearance of a weak secondary manifested itself in two 
notable observations.  First, the mAb 36-71 precipitated in alum primary injection gave 
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the weakest proliferative response after the secondary mAb 36-71 stimulus, which 
seemed incongruous with the use of adjuvant in the primary.  Second, the mice that 
received negative control Ig, and as such were making a primary response after the 
booster injection, had a fold change in the CA30/CD4 ratio equivalent to the mice that 
had initially received an injection of monomeric Ig.  In comparison to the previous 
experiment, in which the primary responders boosted with peptide and LPS made the 
largest expansion compared to the residual population of cells, the expansion in response 
to a secondary injection of mAb 36-71 was essentially equivalent to what had been 
observed in mice tolerized with peptide or monomeric Ig.  
V.2.4 Memory expansion of CA30 T cells primed with aggregated Ig species does 
not appear to be dependent upon rechallenge with the same antigen 
While examining the humoral response to mice with adoptively transferred CA30 
T cells and immune complexes, I made a perplexing observation (Table 5.4).  In an 
experiment based upon the adoptive transfer of 5 x 104 CA30 T cells into B6AF1 mice, 
priming with monomeric Ig or immune complex, and then two boosts with immune 
complex (day 21, day 42), I had included a pilot group of mice that received a primary 
injection of 100µg of heat aggregated Ig followed by the two boosts with immune 
complex.  While the mice receiving a primary injection of monomeric Ig never made a 
response to the booster injections, and 4/5 of the mice receiving immune complexes made 
a response after the secondary injection, the mice receiving a primary injection of heat 
aggregated Ig made a poor response after the secondary injection with immune complex 




























Figure 5.3  Monomeric Ig is a poor inducer of memory expansion of CA30 T cells 
Mice received experimental injections as in (A).  Mice received adoptive transfer of 5 x 
104 CA30.CD45.1 cells and 1 day later (day 0) received injection with 100 µg of negative 
control Ig, monomeric Ig, heat aggregated Ig, or Ig precipitated in alum.  30 days later, 
they received a booster injection of 100 µg of monomeric Ig.  Mice were sacrificed at day 
5 post-booster (day 35) and splenocytes were analyzed via FACS.  (B) Representative 
FACS plots from mice of different primary treatments (top) and boost status (side) 
expressing the percentages of CD45.1+ cells in the CD4+, MHC II-, CD19-, CD8α-, 
F4/80- gate.  (C)  Mean percentage of CD45.1+ cells among total CD4+ cells  in mice 
that were not boosted.  (D)  Mean percentage of CD45.1+ cells among total CD4+ cells 




Table 5.3 Monomeric Ig is a poor inducer of memory expansion of CA30 T cells 
Treatment 
Mean CD45.1% of 
Total CD4 day 35 
(Unboosted) 
Mean CD45.1% of Total 
CD4 day 35 








SD 0.0030 3.4 
Monomeric Ig 0.0115 SD 0.0085 
0.0404 
SD 0.0469 3.5 
Ig in Alum 0.3359 SD 0.2246 
0.4488 






SD 0.0155 3.6 
 
These data stood in contrast to those of a similar experiment that I had done in 
which both primary and secondary injections were with aggregated Ig, which induced all 
mice to produce an IgG humoral response after just one booster injection.  This was 
interesting to me based upon recent reports of a requirement of B cells for successful 
CD4+ T cell memory response in several models.  The exact mechanism of this need for 
B cell involvement in the memory recall is still speculative, and there is some 
disagreement over the need for various functions, such as antigen presentation to mediate 
this effect with different pathogens[292-294].  I was curious if this need for B cells to 
facilitate the expansion of memory CA30 cells might play a role in the inconsistent 
humoral response by the mice in the group that received a heat aggregated Ig primary 
injection and booster injections with immune complex boosts.  To test this, I adoptively 
transferred 5 x 104 congenic CA30 T cells into B6AF1 mice and injected them with either 
100 µg of heat aggregated Ig or the equivalent Ig in immune complexes.  I allowed the 
mice to rest for 30 days, at which point I provided a booster injection of heat aggregated 
Ig, immune complex, or a negative control boost with PBS (Figure 5.4A).  5 days later, I 
sacrificed the mice and assayed their splenocytes via flow cytometry for congenic CA30 
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cells (Figure 5.4B).   At day 5 post-boost, all groups had responded poorly (Figure 5.4C).  
Unboosted CA30 cells that had been exposed to heat aggregated Ig in the primary had a 
slightly larger residual CA30 cell percentage of total CD4+ than those that had been 
exposed to immune complexes.  Although the proliferative responses were weak, in both 
cases they seemed stronger in mice boosted with immune complex.  Mean percentages of 
CA30 cells among total CD4+ T cells cells were compared between unboosted and 
boosted mice in each treatment group to provide an estimate of fold change (Table 5.4).  I 
had expected that a secondary antigen that matched the primary antigen (heat 
aggregated/heat aggregated) would be superior to a mismatched primary and secondary 
(heat aggregated/immune complex).  However, this experiment showed that the immune 
complex was superior to the heat aggregated Ig as an antigen at eliciting a secondary 
expansion in the case of either type of priming antigen.  It is important to note that the 
expansion was similar in all cases to what had been seen previously in regards to 
monomeric Ig or tolerogenic peptide, but the fold changes in this experiment suggested 
that the heat aggregated Ig was not as good in eliciting a memory CA30 T cell expansion. 
V.3 Discussion 
 
 Although the experiments described in this chapter should be viewed as 
preliminary due to the high variability in the data as evidenced by the standard deviations 
of the cell percentages and the fact that the experiments were only performed once, 
several of the observations are worthy of consideration in the context of future plans.  
This work provided the first demonstration that an individual CD4+ T cell clone could be 
exposed in vivo to an antigenic monomeric Ig and then subsequently recalled for 





Figure 5.4 Memory expansion of CA30 T cells primed with aggregated species does 
not appear to be dependent upon rechallenge with the same antigen 
Mice received experimental injections as in (A).  Mice received adoptive transfer of 5 x 
104 CA30.CD45.1 cells and 1 day later (day 0) received injection with 100 µg of heat 
aggregated Ig or immune complex in sterile PBS.  30 days later, they received a either 
received a booster injection of 100 µg of heat aggregated Ig or 100 µg of immune 
complex or PBS.  Mice were sacrificed at day 5 post-booster (day 35) and splenocytes 
were analyzed via FACS.  (B) Representative FACS plots from mice of different primary 
treatments (top) and boost status (side) expressing the percentages of CD45.1+ cells in 
the CD4+, MHC II-, CD19-, CD8α-, F4/80- gate.  (C)  Mean percentage of CD45.1+ 
cells among total CD4+ cells.  Top label describes primary injection, bottom label 





Table 5.4 Memory expansion of CA30 T cells primed with aggregated species does 
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However, the expansion of CA30 T cells exposed to monomeric Ig in the primary 
response and then recalled with antigenic peptide plus LPS was not detectably different 
than that of cells from mice given a primary injection of Vκ36-71 peptide alone, a 
classically tolerogenic stimulus.  CD4+ T cell expansion and contraction to a tolerogenic 
stimulus, and subsequent failure to expand robustly or produce IL-2, has been repeatedly 
demonstrated since the initial adoptive transfer of transgenic CD4+ cells[277]. 
While the OVA peptide was used as the tolerogen in this initial set of experiments, 
induction of tolerance in CD4+ T cells by soluble OVA has been demonstrated as well, 
and as such it is reasonable to postulate that the failure of the CA30 T cell exposed to 
monomeric Ig to expand in a secondary recall could be related to its status as a soluble 
protein rather than an unique effect of a structural component of Ig.  
 The increased fold change seen in CA30 cells in mice receiving primary 
injections with Vκ36-71 peptide, compared to mAb 36-71 when both are delivered with 
adjuvant is more intriguing.  I would have expected that the Ig in adjuvant would have 
been as effective, if not more effective, in inducing a memory CD4+ population due to 
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the probably generation of a germinal center. The mice exposed to mAb 36-71 with 
adjuvant during the primary have differential retention of cells.  The group that received 
the Ig emulsified in CFA had an increased percentage of CA30 among total CD4+ cells 
in the unboosted group at day 35, while the mice that received the Ig with soluble LPS 
have  residual percentages of CA30 similar to that of mice treated with monomeric Ig.  
The difference could be easily explained by a depot effect due to the CFA. However, 
even if this is the case, why is the memory expansion of the cells exposed to mAb 36-71 
in CFA only half as much as that the cells in mice that received Vκ36-71 in CFA as a 
primary?  One hypothesis that would be suggested by some recent publications, and is 
related to the work in Chapter IV, is that compared to peptide the mAb 36-71 may 
present more of an opportunity for the development of a T follicular helper subset in the 
CA30 cells because of its increased capacity to crosslink antigen receptors and activate B 
cells [295-297].  B cell activation and germinal center formation have been shown to be 
important for the formation of Tfh, and I have shown that the CA30 cell can adopt a Tfh 
phenotype in response to species of mAb 36-71[287, 289, 298].  There is increasing 
evidence for the formation of memory cells derived from the Tfh component of a CD4+ 
response, however these cells may be less responsive in terms of proliferation in 
comparison to more classical central memory T cells (Tcm).  Perhaps this observed 
differential between the fold expansions of CA30 T cells initially exposed to a peptide 
plus adjuvant versus whole Ig plus adjuvant was actually a manifestation of Tfh 
development in the context of humoral immunity induced by whole Ig.  While the mAb 
36-71 in LPS did not generate a primary IgG humoral response, all mice receiving mAb 
36-71 emulsified in CFA did have measurable IgG anti-Vκ36-71.  There was no detectable 
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anti-Vκ36-71response for the animals that received the peptide with adjuvant, although the 
assay used to assess for the response utilized an IgM containing the peptide in the κ-light 
chain rather than an assay against the peptide itself. 
 The poor proliferation in all groups upon secondary injection with monomeric Ig, 
heat aggregated Ig, or the immune complex, all without adjuvant, was both vaguely 
surprising and affirming.  It has been shown that a toll-like receptor stimulus is not 
necessary for activation of CD4+ memory cells, although such a stimulus does increase 
the response [299]. That the monomeric Ig was unable to stimulate a greater fold change 
in the mice that had been treated with mAb 36-71 adsorbed to alum suggests that it was 
not teeming with TLR ligands.   
An intriguing question emerged from the poor response elicited by a late post 
transfer injection of monomeric Ig:  if monomeric Ig is proficient at inducing CA30 cell 
proliferation in spleen as demonstrated in mice injected with it shortly after adoptive 
transfer, why was there such a weak fold change at day 5 in the CA30 cells that had been 
incubated in the mouse for 30 days prior to Ig injection.  In an earlier experiment, Vκ36-71 
peptide plus LPS had been quite proficient as a secondary stimulus to induce a robust 
fold change/primary response in these cells.  This raises questions regarding the 
localization of monomeric Ig or its processed peptides in the spleen and the trafficking of 
the CA30 T cells as a function of time after adoptive transfer.  The localization of 
immune complexes in the lymph nodes has been demonstrated using intravital 
microscopy, and the role of complement association with immune complexes, 
complement receptor 3 on the surface of subcapsular sinus macrophages, and 
complement receptor 2 on naïve B cells have been detailed in the transport of antigen to 
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follicular dendritic cells[284, 300-305].  However, we still do not know which cell is 
presenting mAb 36-71 peptides in vivo, and how this cell is acquiring the Ig.  The B cell 
depletion experiments in Chapter IV would suggest that it is not a B cell dependent 
process, at least for monomeric Ig.   Both monocytes and macrophages express the 
activating FcγRIII and inhibitory FcγRIIB, which can bind IgG1, however they are not 
high affinity and are generally thought bind immune complexes rather than monomeric Ig 
[306].  Numerous additional hypotheses can be expressed to predict the source of this 
uptake, including some mechanism for aggregation after transfer into the animal with 
subsequent complement deposition or lectin binding of glycosylated residues.  






VI.1 Context and Discussion of the Findings 
 
 The primary objective of this thesis was to explore the behavior of a CD4+ T cell 
that perceives an immunoglobulin-derived peptide in the context of MHC II when 
adoptively transferred cells were challenged with an antigenic IgG1 in vivo. Based upon a 
review of the literature, the initial hypothesis was that this cell would not perceive the 
IgG1 if it was initially introduced in a monomeric form, but that it would perceive and 
respond with a robust primary response if the IgG1 was introduced in an aggregated form, 
even in the absence of adjuvant.  To investigate this hypothesis, I sought to produce and 
characterize various forms of Ig, test the primary response of the CA30 T cell to these 
species in an adoptive transfer model, and perform initial experiments examining the 
capacity to recall the CA30 T cell in a memory response after primary exposure to some 
of these reagents in the adoptive transfer model.  The immunogenicity or tolerogenicity 
of Ig for CD4+ T cells has vast implications for the future of monoclonal antibody 
therapy, and this work presents novel data generated in vivo that increases our 
understanding of the how these therapeutics may initiate immune responses. 
VI.1.1 Chapter III: Are particle mass and LPS contamination as important as 
immune complexes with regard to immunogenicity? 
In Chapter III, I discussed the production and characterization of the aggregation 
status and adjuvanticity of the Ig species analyzed in the thesis, with an emphasis on 
monomeric Ig.  This analysis was primarily descriptive, but sought to bridge a chasm 
between historical immunological literature about the immunogenicity of Ig and the 
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modern high-resolution techniques of pharmaceutical analyses for assessing structural 
characteristics of protein solutions, which are on the path to becoming adopted as part of 
the regulatory apparatus surrounding these therapeutics.  Studies using animal models 
have indicated that aggregation enhances the immunogenicity of specific proteins used in 
human therapies, and these data have been extrapolated to postulate that defects in 
manufacturing or handling contribute to the immunogenicity of protein therapeutics, 
including Ig [231, 258, 261, 307, 308].  Similarly, there is great concern surrounding the 
contamination of these reagents with toll-like receptor agonists such as LPS, which is 
typically assayed using some derivative of the Limulus amebocyte lysate test.  The 
earliest literature about tolerance induced by BGG and HGG was produced at a time 
when assessing particle size was limited to ultracentrifugation, size exclusion 
chromatography and mass conservation analyses.  At that time, investigators did not 
assess their protein for LPS content, and yet they were able to achieve tolerance or 
immunogenicity with relatively small amounts of injected Ig.  This is not to say that there 
is not a substantial immunological literature investigating the role of protein aggregation, 
immune complexes, LPS contamination, and other size and structural characteristics of 
antigen in its immunogenicity; in fact, the literature base for this type of assessment is 
broad to the point of being overwhelming.  The global point is that pharmaceutical 
scientists are developing increasingly high resolution techniques to study structural 
abnormalities for which they want to predict immunogenicity and immunologists are 
developing increasingly high resolution techniques to study the immune response for 
which they need sophisticated antigen. The confluence of these aims is in its infancy.  
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The findings of my pharmaceutical analyses painted an interesting profile for 
monomeric Ig, heat aggregated Ig, and immune complexes.  The ultracentrifuged Ig was 
indeed predominantly monomeric (82% of the ideal mass, 98.5% of the recovered mass) 
with very small fractions of dimer and particles with radii in either the nanometer or 
micron range that may have been a consequence of the sterile PBS used to dilute these 
samples.  The heat aggregated Ig showed a vastly different pattern, with nearly all of the 
detectable mass contained in particles with micron scale radii (21.5% of the ideal mass, 
99% of the recovered mass) and an undetectable 78.5% of ideal mass presumably 
sequestered in dense insoluble complexes.  The immune complexes demonstrated a third 
pattern, with a more equitable distribution of mass amongst many particle types including 
soluble aggregates (39.7% of the ideal mass, 44% of the recovered mass), micron-sized 
particles (42.2% of the ideal mass, 47% of the recovered mass), and an assumed insoluble 
fraction (10.5% of the ideal mass).  This disparity between the mass distribution in the 
heat aggregated Ig and the immune complex was also manifested qualitatively by distinct 
appearances of the two species due to differences in the micron sized particles.  In the 
context of the results discussed in Chapter IV, the assumptions going into the thesis about 
the role of monomeric Ig in tolerance development and the capacity for aggregated 
species to behave in an immunogenic fashion, may have been correct in spirit but 
complicated in their mechanics.  The monomeric Ig, which would eventually lead to a 
proliferative primary response of the T cells but little evidence of humoral immunity, was 
mostly comprised of monomeric protein rather than detectable particulate species, 
making the ready presentation in the in vivo model ever more intriguing.  The heat 
aggregated Ig and the immune complex both led to productive humoral responses, 
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mirrored by increased percentages of CA30 cells converting to Tfh, even though these 
species look decidedly different when compared using these modern techniques for 
structural evaluation.  This divide is further interesting in regards to other differences in 
the biological effects of these species that will be discussed further in the context of of 
Chapter IV data, which suggest that the mechanisms of perception of these antigens by 
the immune system are quite different.  The inclusion of the analysis of the “large” heat 
aggregated Ig and “large” immune complex species, neither of which were effective in 
inducing a humoral response, raises the question of what extent these analytical 
techniques are identifying an immunogenic population as opposed to identifying 
structural abonormalities without functional consequence.  The mass profile of the 
“large” heat aggregated Ig was more similar to that of my Ag-excess (small) immune 
complex, while the “large” immune complex mass profile more closely mirrored the 
smaller, immunogenic heat aggregated Ig.  While not without flaws, this initial 
characterization raises an important question for the future of research into the 
immunogenicity of monoclonal antibody therapeutics:  are the pharmaceutical scientists 
inordinately focused on the immunogenicity of a rare species obtained as a manufacturing 
or handling defect and ignoring highly immunogenic immune complexes, which are a 
natural consequence of their action in vivo.  With another therapeutic protein, for 
example recombinant growth hormone, the capacity for the pre-administration handling 
of the protein to cause aggregation and activate some the adaptive immune system may 
be entirely relevant as these species do not naturally directly interact with effector 
components of the immune system, unlike with an Fc component that binds to receptors 
on immune cells.   
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 Analyses of the adjuvanticity of monomeric Ig, and to an extent the heat 
aggregate and immune complex, were complicated by the method of purification, which 
used a cellulose resin and could be the cause of the positive Limulus amebocyte assay 
result for the some of the reagents.  This will be discussed again in the consideration of 
limitations of this thesis.  However, the results of these assays should be considered in the 
context of the in vivo data.  In the LAL assay, monomeric Ig and heat aggregated Ig gave 
different results using three kits.  The monomeric Ig tested as being the equivalent of 
sterile water once and then tested as having greater than 1.0 EU/ml twice.  The heat 
aggregated Ig tested as having slightly more endotoxin than sterile water once (0.592 
EU/ml) and then twice tested as containing less endotoxin (~0.14 EU/ml) than the sterile 
water threshold (0.5 EU/ml). The immune complexes and Ars-MSA used to complex the 
Ig were tested only with the second and third kits, and tested as having greater than 1.0 
EU/ml.  The monomeric Ig was used to test for adjuvant activity in an in vivo assay to see 
if it could increase OT-II proliferation in response to OVA peptide, which it did not.  The 
positive control in this assay was emulsified in CFA, which may have been an unduly 
strong positive control for potential LPS in the monomeric Ig, but there was no increase 
in cell proliferation between the mice receiving the OVA peptide alone or the OVA 
peptide and monomeric Ig.  While it will be important in the future to consider alternative 
methods of purification or alternative assays to assess LPS and other TLR agonists within 
Ig samples, the disparity between the LAL test results for the monomeric Ig and heat 
aggregated Ig implies to me that differences in endotoxin contamination between the 
monomeric Ig and the heat aggregated, and probably the immune complex, are not likely 
to be the cause of the differential results observed in the in vivo assays.  Heat aggregated 
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Ig that tested very low in the LAL led to a humoral response in mice with transferred 
CA30 T cells, and monomeric Ig that tested as high in the LAL elicited primary 
proliferation, but not humoral responses to secondary or even tertiary boosts.  In either 
case, these results are interesting:  monomeric Ig, with a modicum of endotoxin and in an 
environment with an high precursor frequency of potential helper T cells, was unable to 
elicit a humoral immune response, while heat aggregated Ig and immune complexes were 
able to do so, even though the heat aggregate contained lower measured levels of 
endotoxin and the immune complex is made with the monomeric Ig.  Perhaps endotoxin 
is less important as an adjuvant than something about the size or some other physical 
characteristics of the aggregate populations.  It seems unlikely that the aggregate 
populations are specifically enriched for LPS compared to monomeric Ig.  In fact, the 
immunostimulatory capacity of soluble immune complexes has been established 
previously, although in the context of adjuvanticity for the targeted antigen rather than for 
the Ig itself [309-311].  It would be interesting to repeat the humoral response 
experiments including a group with monomeric Ig plus LPS as a primary stimulus and 
then inject these animals with booster vaccinations of either immune complex or heat 
aggregate to see if this adjuvant would be sufficient to induce a break in tolerance.    
VI.1.2 Chapter IV:  Monomeric Ig versus immune complexes: differential inducers 
of Th1 and Th2 development, or tolerogenic versus immunogenic stimuli? 
In Chapter IV, I described an in vivo characterization of the primary response of 
the CA30 T cell to the various Ig species and the capacity to generate a memory humoral 
response, as assessed by production of detectable anti-Vκ36-71 Ig.  These analyses were a 
novel extension of a canon of work dating from the early 1960s investigating the capacity 
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for ultracentrifuged HGG or BGG to induce tolerance against subsequent injections of the 
gamma globulin with adjuvant or in an aggregated form.  My work also was aimed at 
improving our understanding of the behavior of T cells reactive to Ig-derived peptides in 
secreted immunoglobulin as much prior work focused on the response of these cells to 
auto-presented BCR-derived peptides by B cells in adoptive transfer models, bone 
marrow chimaeras, or intact transgenic mice [246, 248, 255-257, 312-317].  My 
hypothesis at the outset was that the monomeric Ig would not be perceived by the CA30 
T cell in vivo and as such not lead to a humoral response, while I believed that the heat 
aggregated Ig and the immune complexes would induce proliferation and a productive 
humoral response. 
 I quickly discovered that my hypothesis was only partly correct in that the 
monomeric Ig stimulated no humoral Ig response but virtually the same primary 
proliferation, in terms of CA30 T cell percentages and cell numbers, as the heat 
aggregated Ig, while the heat aggregated Ig induced both a primary Ig response with 
memory and a stronger CA30 recall proliferative response.  Immune complexes induced 
a primary expansion and contraction of CA30 T cells that was similar to that induced by 
monomeric Ig and heat aggregated Ig, and also induced a detectable anti-Vκ36-71 IgG 
secondary response but not a primary response.  The heat aggregated Ig and immune 
complexes were perhaps less immunogenic than I had expected, which was exhibited by 
relatively low concentrations of anti-Vκ36-71 in the sera of mice, even after a booster 
injection.  This also manifested itself in the observation that mice that received adoptively 
transferred CA30 cells and then received heat aggregated Ig 22 days later did not make a 
detectable IgG anti-Vκ36-71 response 21 days after injection of the Ig.   Experiments in the 
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early literature involving heat aggregated Ig assayed for an anti-gamma globulin 
response, by elimination of injected radioactive iodinated-gamma globulin or the 
formation of gamma-globulin specific ASC[43-45, 49, 61, 62, 66, 68-70].   In both cases, 
it is possible that these methods were primarily detecting an IgM response.  However, 
indirect ASC (plaque) assays also showed positivity in some cases, indicating that IgG 
contributed to these immune responses.  It is important to recognize that the BGG and 
HGG used in these early experiments were polyclonal fractions of gamma globulin and 
would contain a large number of potential antigenic epitopes because they are foreign in 
mice and because of idiotypic diversity.  When assessing the immune response to mAb 
36-71, I measured the response to the Vκ36-71 rather than the full idiotype of the 
monomeric Ig.  It is not unreasonable to suspect that the number of precursor B cells 
within the mouse that would respond to the full idiotype of a single Ig, let alone the light 
chain alone, would be much smaller than the number of precursor B cells for 
heterologous Ig. 
 To investigate potential explanations of why heat aggregates and immune 
complexes elicited humoral Ig responses where monomeric Ig did not, despite only a 
modest, but significant increase in cell numbers during expansion/contraction of the 
primary responses, I used an in vivo CFSE assay to explore the proliferative pattern of the 
cells.  The following trends emerged:  a high percentage of the CA30 cells that were 
exposed to monomeric Ig in vivo divided at least once by day 5, with the highest 
percentage of cells found at the 2nd – 4th division before dropping to a lower percentage 
of cells in the 6th – 7th division and complete dilution of the CFSE.  CA30 cells exposed 
to heat aggregated Ig divided more extensively than cells responding to monomeric Ig.  
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Many reached the 7th division or lost detectable CFSE.  However, the CA30 T cells in the 
lymph nodes tended to show less proliferation and reached lower numbers of division in 
response to this species, which may indicate that an i.p. injection of heat aggregated Ig is 
being sequestered in the peritoneum, the spleen, or eliminated.  Immune complexes 
produced the highest percentages of cells in the 6th – 7th division and beyond the range of 
CFSE detection.  Therefore, there were two major division profiles the cells exposed to 
monomeric Ig tended to have large percentages of the CA30 cells in the 2nd – 4th division, 
while the heat aggregated Ig and the immune complex tended to have larger percentages 
of cells in the 6th and 7th division or having diluted their CFSE entirely.  The simplest 
interpretation of this data is that the monomeric Ig is being presented by a tolerogenic 
APC population, such as immature dendritic cells, which have been shown to temper 
CD4+ responses and induce the production of CD25+Foxp+ Treg as well as FoxP3- 
regulatory populations such as the T regulatory-1[318, 319].  The fact that I did not 
identify high conversion of CA30 T cells into FoxP3+ on day 7, 10, or 14 would seem to 
preclude these cells from being the regulatory aspect of this initial CFSE proliferation.  I 
did not assay for IL-10 production by the CA30, so it is not possible for me to assess 
whether this may be a factor in the limited CFSE proliferation, but it may be worthwhile 
to consider in the future.   
An alternative view based on the increased divisions of the cells in mice 
stimulated by immune complexes or heat aggregated Ig and the limited divisions in mice 
receiving monomeric Ig may be related to two patterns are similar to the two models of 
CD4+ proliferation discussed in the literature.  The proliferation of CA30 cells that were 
exposed to monomeric Ig looked similar to the proliferation of OT-II cells in response to 
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in vivo infection with a recombinant Listeria monocytogenes expressing a truncated 
OVA[278].  When this paper was published, the authors sought to demonstrate that CD8 
cells divided rapidly and robustly to antigen, while CD4+ cells went through a limited 
number of divisions.  A Listeria infection should induce a strongly Th1 inflammatory 
environment which is unlikely to be generated by a monomeric Ig injected without 
adjuvant, however an exploration of the characteristics of the CD4+ cells activated by 
this Listeria infection may be insightful in understanding the limited divisions in response 
to the monomeric protein, given that it probably did not initiate a Th2 profile response. 
Conversely, the heat aggregated Ig and the immune complexes tended to induce a 
division profile more similar to that reported for Tg CD4+ cells activated in a 
doxycycline-induced model of persistent antigen presentation by dendritic cells.  
Increased division of the Tg CD4+ cells was seen either by prolonged, pharmaceutically-
enforced antigen presentation by resting DC or by brief antigen-presentation by CD40-
activated DC [279-281].  If activated DCs are responsible for the presentation of the 
Vκ36-71 epitope to the CA30 T cell in the case of the immune complex or the heat 
aggregated Ig, this could provide insight into the eventual humoral response.  Based upon 
the results of my α-CD20 analysis, this DC mediated presentation may be more 
important for immune complexes than heat aggregates, which may rely on B cells for 
antigen presentation, or simply transport of heat aggregates to additional APCs.  It has 
been shown that dendritic cells that have been activated with LPS for a prolonged period 
of time and become “exhausted” are more likely to induce CD4+ cells to take on Th2 or 
undifferentiated Th0 phenotypes upon antigen presentation [320].   This model in which 
soluble Ig drives Th1 polarization while immune complexes and heat aggregated Ig, drive 
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a Th2 response is in agreement with results of two other models involving suppresssion of 
autoimmune disease.  The research group of Habib Zaghouani has published several 
studies involving an Ig-delivery system of T cell epitopes to either induce tolerance, or 
ameliorate manifestations of model autoimmune diseases [129, 130, 140, 141].   This Ig-
delivery system incorporates peptides perceived by T cells in complementarity 
determining region 3 (CDR3) of an IgG2b/k antibody.  They used adoptive transfers of 
CD4+ Tg T cells and subsequent injections of Ig-peptide constructs to describe the effect 
of these Ig on the progression of model autoimmune diseases.  Using an EAE model of 
multiple sclerosis, they found that injections of an aggregated Ig containing the myelin 
oligodendrocyte glycoprotein (MOG) could suppress the induction or progression of 
disease.  When they examined the cytokine profile induced in CD4+ Tg cells specific for 
MOG peptide by this aggregated Ig, they found that the cells preferentially secreted the 
Th2 cytokines IL-4 and IL-5 as opposed to the Th1 cytokine IFNγ, which was more likely 
to be secreted if these T cells were exposed to a soluble form of the Ig-MOG and a TLR 
agonist (CpG).  In a model of type I diabetes (TID), they used an alternative Ig-epitope 
construct, this time incorporating a peptide from glutamic acid decarboxylase 2 (GAD2) 
into IgG2b/κ.  If this antibody was injected in a soluble form, it could delay the onset of 
fulminant TID once mice have reached the stage of insulitis and it could restore 
normoglycemia to hyperglycemic mice.  Based upon subsequent experiments, they 
attributed the tolerogenic effect in this model to Ig-GAD2 induction of the Th1 cytokine 
IFNγ, which in turn downregulated the production of the proinflammatory cytokine IL-17 
by Th17 CD4+ cells.  It is interesting that these two models using the injection of Ig-
peptide constructs for tolerization regimens report mechanisms that are related to two 
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models of antigen presentation that have similarities to my CFSE findings.  It is 
important to note two differences about the Ig in the Zaghouani model:  first, the handling 
of the soluble Ig is not described prior to IP injection and there is no specification of 
ultracentrifugation or any other methodology to ensure monomeric Ig as opposed to 
potential aggregated species. Their use of the term “soluble” implies that they are either 
not perceiving or deliberately removing any insoluble component of the Ig, although this 
is not described explicitly.  Second, the inclusion of the T cell epitopes in the CDR3 
region ablates binding of the IgG2b,κ to the hapten p-azophenylarsonate, so they were 
unable to incorporate immune complexes into their EAE study.  In addition, the 
aggregates they used were generated by precipitation with ammonium sulfate rather than 
by heat.  This aggregated Ig is neither effective in inducing presentation in Fcγr-/- APC in 
vitro, nor in inducing tolerance in the EAE model in vivo in Fcγr-/- mice, so it is assumed 
that the predominant APC uptake occurs through Fc receptors.   However differences 
between the physical structures and consequent biological activity of my immune 
complexes and these ammonium sulfate precipitated Ig are yet undetermined. 
 If this thread of logic is valid, it is not surprising that my CA30 cells differentiated 
into Tfh cells in higher numbers in mice exposed to immune complexes and heat 
aggregates as opposed to monomeric Ig.  The presence of a humoral response matched 
with a CFSE profile that is more similar to a Th2 response is consistent with Tfh 
development in mice that received immune complexes or Ig aggregates.  It has been 
shown that activated DCs initiate differentiation towards a Tfh phenotype in CD4+ cells 
and have the capacity to progress and maintain this differentiation in some models.[287, 
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289, 298]  An alternative model is that this initiation by DCs is followed by required 
cognate interactions between nascent Tfh and B cells to progress and maintain this status.  
If the most important differentiation between my work and the early work on 
tolerization by monomeric Ig is that others were observing tolerance and immunogenicity 
of a large, heterologous, polyclonal population of antigen as opposed to my monoclonal 
cells, the second most important differentiation is that the Chiller, Habicht, and Weigle 
observation of tolerance induction was differentiated using centrally derived cells, i.e. 
from the bone marrow and thymus, rather than peripherally derived cells.  It is not 
unexpected that multivalent immune complexes and heat aggregates made with foreign Ig 
should induce a B cell response, but to what extent should we expect tolerization of the B 
cell compartment by the monomeric Ig?  The previous work by the lab of David Parker 
would suggest that tolerance induction in B cells is more likely to occur with a 
monovalent antigen, such as a Fab, rather than with a divalent antigen of monomeric Ig 
[321].  However, poor crosslinking of the B cell receptor by a divalent antigen and 
without a danger signal such as a TLR agonist might also lead to impaired presentation of 
antigen to T cells with insufficient co-stimulation.  I think it is unlikely that all Vk36-71 
specific peripheral B cells are deleted due to monomeric Ig, although I have not shown 
this.  In the Chiller, Habicht, and Weigle work, they demonstrated that the tolerization 
through the injection of similar amounts of immunoglobulin to my experiment only 
tolerized the bone marrow compartment by 10% [69].  Of course, it is always important 
to point out that the expected precursor frequency for their foreign, diverse antigen is 
quite different than my monoclonal reagent.  Perhaps the difference in Tfh development 
between the mice injected with multivalent forms of Ig as opposed to monomeric Ig is the 
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reflection of a stoichiometric threshold, in which the multivalent species are more likely 
to activate more B cells to cross a threshold level of B cell Ag-presentation required to 
maintain the Tfh phenotype.  Based upon a previous study in our lab that showed a 
propensity for CA30 cells to adopt Tfh-like characteristics in an adoptive transfer system 
designed to investigate regulation between the CA30 cell and B cells expressing Vκ36-71 
in the germinal center, we knew that the CA30 T cell had the capacity, and perhaps the 
propensity to differentiate into Tfh [257].   There will be a lengthier discussion of CD4+ 
Tg T cell behavior in a further exploration of the limitations of this study, but a recent 
paper has suggested that individual CD4+ Tg cells tend to adopt patterns of 
differentiation when stimulated in vivo, and this was not the case in regards to the Tfh 
phenotype in my model when I injected monomeric Ig, despite previous evidence that the 
CA30 cell may be likely to enter this differentiation pathway [322]. 
 In the latter part of Chapter IV, I wanted to investigate the bounds of my 
phenomena in the CFSE proliferation to assay for the importance of Fc in presentation 
and the role of B cells in early CD4+ proliferation.  These analyses paint divergent 
pictures of the presentation of immune complexes and the heat aggregated Ig.   
Eliminating the Fc region of the mAb 36-71 led to decreased CA30 CFSE proliferation, 
which is consistent with a potential Fc mediated presentation of monomeric Ig.  The fact 
that complexing the F(ab’)2 with antigen restored the proliferation profile seen in 
treatments with immune complexes was not as easily interpreted.  It could indicate that 
these structures can be bound by lectin receptors for sugars in the hinge region in the 
F(ab’)2, that the increased valence of the idiotypic epitope enhanced binding to Ag-
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specific B cells or in a less interesting scenario, that the Ars-MSA used to complex the 
F(ab’)2 contained a TLR agonist.    
Eliminating B cells with the anti-CD20 therapy led to a decrease in overall CA30 
proliferation to heat aggregated Ig, although this may have also been affected when the 
mice were treated with a large amount of isotype control.  The decrease in the CA30/CD4 
ratio between the mice treated with heat aggregated Ig and α-CD20 was significant 
compared to those treated with the isotype control, but the CA30 proliferation profile was 
also shifted to the right in mice receiving the isotype control.  The proliferation of the 
cells in mice receiving the immune complexes stayed the same and the proliferation 
increased in mice receiving monomeric Ig, although this may have been a function of the 
induced lymphopenic environment in the spleen.   If the effective presentation of heat 
aggregated Ig relies on the activation of a population such as B cells in the marginal zone, 
it is possible that the infusion of a polyclonal control IgG2a 2 days prior to injection of 
heat aggregated Ig could have sequestered these cells with potential to react to 
aggregates, thus diminishing the difference between control and experimental groups.  
This idea also raises comparisons to a recent model examining mice expressing the 
AM14 rheumatoid factor transgene, in which B cells expressing the receptor can be 
recruited into extrafollicular clusters if they are exposed to immune complexes generated 
by an IgG2a anti-chromatin antibody [195, 196].  It has been shown that the B cells in 
these extrafollicular clusters do not require CD4+ T cells to class switch and secrete 
antibodies, but that the secretion of antibody by these cells can be augmented by CD4+ T 
cell help.  A critical component of this model is the TLR agonist activity of the chromatin 
in the immune complex that costimulates B cells to secrete antibody in the absence of a 
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traditional interaction with a T cell.  If my heat aggregated Ig is contaminated with a TLR 
agonist, it could be possible that the eventual secretion anti-Vκ36-71 antibody and the 
enhanced presentation for the CA30 cells is reliant on a similar mechanism. 
VI.1.3 Chapter V:  Evidence of Tfh memory or a critique of my experimental 
protocol?	  
The results presented in Chapter V are preliminary in their findings, but two 
observations particularly intrigued me.  The first is that mice that received a primary 
injection of monomeric Ig emulsified in CFA had a poorer fold increase in CA30 cells 
after a challenge with Vκ36-71 plus LPS at day 30 than mice that received a primary 
injection of Vκ36-71 peptide emulsified in CFA.  This was despite the presence of a much 
larger residual population of CA30 cells at day 35 in Ig-CFA injected mice that were not 
boosted.  Similarly, in mice injected with monomeric Ig plus LPS the increase in CA30 T 
cells upon a secondary challenge was less than that of mice primed with peptide and LPS.  
In this case, both residual CA30 cell populations were similar at day 35 in mice that were 
not boosted.  A potential caveat is that the dose of peptide was roughly 10 nanomoles of 
peptide versus 1.3 nanomoles of peptide in 100 µg of monomeric Ig.  However, in the 
mice receiving peptide, CA30 T cells contracted back to a level well below that of mice 
that received Ig-CFA and in line with the level seen in the group that received Ig-LPS.  
There are two explanations that I have considered for this increased expansion of the 
CA30 cells in mice injected with peptide as opposed to monomeric Ig.  The first 
explanation is based upon reports that CD4+ T cells in early stages of proliferation due to 
suboptimal antigen stimulation are the most likely to differentiate into memory cells 
[323, 324].  It is possible that 10 nanomoles of peptide are cleared rapidly in the mice 
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receiving the soluble peptide and LPS, or dispersed sporadically to the systemic 
circulation when emulsified in a CFA depot.  On the other hand, it is tempting to consider 
that the difference is instead related to recent reports that Tfh memory cells undergo less 
robust memory expansion in comparison to classical Tcm cells [296].  The monomeric Ig 
should present a superior epitope for B cell recognition in comparison to the peptide, and 
B cells may play a critical role in maintenance and expansion of Tfh cells.  The use of the 
adjuvant CFA or LPS could explain the difference between the fold changes in these 
populations receiving emulsified Ig and populations receiving monomeric Ig without 
additional adjuvant.  While the observations are not proof of this phenomenon, the Tfh 
data from Chapter IV does make it seem like an interesting alternative explanation for the 
phenomenon. 
 The other observation from Chapter V that I find interesting is the poor CA30 
response to a secondary injection of monomeric Ig regardless of the first injection, and 
particularly a failure in expansion of CA30 cells that were exposed to a negative control 
IgG1 as a primary antigen.  When similarly primed mice were boosted with peptide and 
LPS in the secondary response, there was the largest fold increase in CA30 cells of all 
treatment groups.  The presence of two variables (Ig/peptide, no LPS/LPS) makes it 
difficult to interpret whether the difference between the peptide and the monomeric Ig 
was truly responsible for this phenomenon.  However, it does raise a question that 
concerns me when considering this model from a physiological perspective.  Most of my 
experimental protocols involved the adoptive transfer of congenic CA30 cells on day -1 
and injection of the antigen on day 0, 24 hours later, to allow the cells to enter lymphoid 
organs prior to stimulation.  I did not undertake time courses to see whether the primary 
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proliferation of cells that I could measure would diminish at a rate faster than the actual 
loss of cells.  It is possible that this failure to respond to a booster injection indicates a 
tier of regulation that involves differential trafficking of memory CD4+ T cells and Ig. 
Perhaps my adoptive transfer model is weighted towards generating a primary CA30 
response due to a confluence of the trafficking of cells and antigen that is artificially 
concocted by the specific time course used.  From the perspective of generating future 
models of CD4+ perception of exogenously transferred or newly-generated Ig epitopes, 
this type of antigen availability question may be important. 
VI.2 Limitations 
 
	   To this point, I have discussed some limitations within the work in the chapters at 
varying points when analyzing the results of the experiments.  I would describe many of 
these limitations as primarily technical rather than thematic.  Examples of these are 
particularly evident in Chapter III include:  the potential for crossreaction of cellulose-
derived glucans in the Limulus amebocyte lysate assay misleading me to believe that 
some of my Ig preps had endotoxin, and an inability to separate the Ig samples into 
individual mass category components to test them individually for immunogenicity.  In 
Chapter IV, the fact that the CA30 Tg is present on an A/J genetic background and 
requires the MHC II I-Ak for recognition of the antigenic peptide makes it prohibitively 
difficult to breed any genetic deficiency onto recipients or donors. There are two 
limitations to this work that I want to highlight as concerns for future experiments 
addressing questions deriving from the results in this thesis:  the use of I-Ak-restricted 





VI.2.1 The use of the CA30 CD4+ TCR Tg T cell 
In the last year, the Journal of Immunology reprinted the original study examining 
the primary response of a CD4+ TCR Tg T cell in an adoptive transfer model in their 
Pillars of Immunology series, and this status as a venerable paper in the history of 
immunology is well deserved[276, 325, 326].  The ability to know the specificity of an 
individual CD4+ cell and the capacity to track that cell using congenic markers or 
tetramer staining or any of a number of labeling techniques are powerful tools that have 
been used in a vast number of adoptive transfer studies since the first report.  The 
adoptive transfer aspect of these studies is an important point, as this original paper, and 
many others after it, have argued that the number of Tg cells present in any given study 
may have significant effects on the progression and characteristics of the immune 
response.  I generally transferred 5 x 104 CA30 cells into mice, which if one assumes a 
10% seeding rate for cells, could lead to anywhere from 10 – 500 fold more cells reactive 
with the Vκ36-71 epitope than would be found in the natural wildtype repertoire based 
upon studies of other CD4+ epitopes [327].  For the purpose of improving resolution, 
these CA30 T cell numbers were detectable by staining for congenic markers in the 
spleen and lymph nodes of adoptive recipients.   By consistently transferring the same 
number of CA30 cells and injecting the same amount of Ig, I could compare experiments 
for consistency of responses, which was generally quite good.   That same reproducibility 
may be a major caveat to this work.  A recent publication from the lab of Marc Jenkins, 
the same lab that produced the first adoptive transfer of CD4+ Tg T cells, has suggested 
that CD4+ Tg T cells follow specific and reproducible effector differentiation patterns 
when stimulated with antigen [322].  Using single cell adoptive transfers, the group 
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stimulated T cells and examined patterns of differentiation into Th1, Tfh, and GC-Tfh 
phenotypes.  Unlike naïve, wildtype CD4+ cells from a polyclonal repertoire, the CD4+ 
TCR Tgs produced predictable distributions of differentiation, which the group argues 
were dictated by the TCR transgene.  The initial intent of the work in this dissertation 
was to examine the effect of antigenic, soluble Ig at the level of a single CD4+ cell, and 
this was to be accomplished using the resolution provided by the CA30 TCR Tg cell.   
The CA30 TCR transgene was cloned from a T cell hybridoma fused from mice injected 
with the mAb 36-71 in adjuvant that elicited an immunogenic response.  The CA30 T cell 
has been shown previously to take on a Tfh like phenotype in a co-adoptive transfer 
model with Vκ36-71 Tg B cells.  In a way, it would have been surprising if antigenic Ig, i.e 
the heat aggregated Ig or immune complexes, had not generated an increased Tfh 
phenotype.  It was unlikely that the activated CA30 cell would have differentiated in any 
way other than what had been previously observed with this cell, and the fact that the 
original TCR was cloned from a hybridoma fused after an immunogenic response to the 
mAb 36-71 made it similarly unlikely that this cell would ever have adopted a regulatory 
phenotype in vivo.  While I suppose this is not impossible, I believe that our use of the 
CA30 Tg T cell had weighted us towards a specific phenotypic result, and that future 
considerations of such questions should be targeted towards a more physiological, but 
still definable, polyclonal T cell repertoire.   
VI.2.2 The use of a single isotype 
The work in this dissertation relies upon a single antigenic Ig, the mAb 36-71, 
which has an IgG1 isotype.   I believe that this is both a strength and a limitation of my 
approach.   In terms of strength, a single isotype is that I believe that this work has 
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suggested that there are physical characteristics of monomeric Ig, heat aggregated Ig, and 
immune complexes that may mitigate the perception of antigen by CD4+ T cells in vivo, 
whether the Ag is derived from the Ig itself or another protein within the complex.  Early 
in the project, there had been plans to compare responses to IgM carrying the Vκ36-71 
peptide with those elicited by mAb 36-71.  If this work had followed the pattern of a 
previous study of the immunogenicity of IgM and IgG, it is possible that I would have 
seen activation of the CA30 cell by IgM that looked similar to what I eventually saw 
when I used IgG1 immune complexes.  This result would have been interesting, and will 
continue to be a question worth pursuing, but I think that it would have taken me, and 
perhaps specifically me, down the wrong path.  Ultimately, this thesis addresses antigen 
size, antigen valency, Fc availability, in CD4+ cell activation and differentiation.  If had 
initially compared IgG to IgM instead of complexes and heat aggregates, I doubt that I 
would have addressed the influence of physically-oriented characteristics that I 
eventually landed upon, or whether I would have been seduced by the difference in the Fc 
alone between the two isotypes.  I do believe that it is a limitation of this work that I only 
looked at IgG1, as it binds to a specific set of FcγRs, it is less inflammatory and 
opsonogenic than IgG2 species, it has a lower valence than IgM and IgA; there are any 
number of reasons to consider looking at alternative isotypes, not the least of which is 
that the majority of monoclonal antibody therapeutics for humans would actually equate 
to a mouse IgG2a/c isotype.  However, I would caution future researchers to think 
carefully about the fundamental physical questions such as how a specific isotype will 




VI.3 Recommendation for future work 
VI.3.1 Building and transitioning to the B6.3kλ Tg mouse as a source of Ig	  
Two of the limitations mentioned previously were the difficulty in breeding 
genetic deficiencies onto the donors or recipients in the CA30 Tg TCR CD4+ model and 
the potential for skewing of the phenotypic repertoire by utilizing a monoclonal TCR Tg 
population.  During the time of this dissertation, I initiated work on constructing a novel 
immunoglobulin light chain containing a CD4+ epitope that could be used to create a new 
transgenic mouse strain to overcome both of these limitations.  The three criteria that I 
considered were that I wanted the peptide of choice to be immunogenic for a polyclonal 
T cell repertoire in the context of the MHC II I-Ab, found in the C57BL6 strain, to allow 
for ease of breeding genetic deficiencies, I wanted the peptide of choice to have a 
documented I-Ab-peptide tetramer construct that had been verified and produced in a 
consistent way, and I wanted the immunoglobulin light chain to be able to pair with a 
heavy chain in the B6 repertoire to produce an antibody with a known specificity.   These 
criteria were fulfilled by the peptide-3K model of the Kappler/Marrack lab, which has 
been used to study TCR/MHCII binding and memory cells from a polyclonal T cell 
repertoire in C57BL6 mice, and the B1-8 immunoglobulin model derived from the 
injection of the hapten (4-hydroxy-3-nitrophenyl)acetyl (NP) protein conjugates into 
C57BL6 mice [328, 329].  I developed a plan to insert the 3K peptide onto the carboxy-
terminal end of the Igλ constant region 1, the constant region used in the Vλ1Jλ1Cλ1 
light chain paired with the heavy chain B1-8 for NP-specificity.  I did some initial in vitro 
testing indicating that a light chain construct containing the 3K peptide could pair with a 
B1-8 heavy chain and bind NP (data not shown), after which point my mentor, Larry 
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Wysocki, designed a genomic construct with a GFP reporter that will eventually be used 
for the generation of a transgenic mouse that can either be bred to B1-8 knock-in mice to 
create NP-specific B cells, or injected with NP-protein conjugates to fuse hybridomas and 
obtain a panel of 3K-containing, NP-specific antibodies for future experiments. 
 These 3K-containing, NP-specific antibodies could be utilized to investigate 
questions about the acquisition and presentation of antigen from Ig as well as the 
activation and differentiation of the Ig-specific T cells themselves using genetic 
deficiencies, genetic reporter mice, or other mice expressing genetic constructs for the 
depletion of specific cells in a rapid and systematic fashion.  The possibilities are myriad:  
FcR knockouts of multiple types, CD11c-DTR mice for the elimination of dendritic cells, 
FoxP3 reporter mice to assay for 3K-specific, Treg development, or µMT mice for the 
elimination of B cells.  As the Ig produced by these hybridomas should be NP-specific, 
these mice could be injected with monomeric Ig, immune complexes, or heat aggregates 
in a manner similar to which I have already done.  One of my favorite speculative 
questions is whether any strains of autoimmune mice on the C57BL6 background, for 
example the B6.Sle1Sle2Sle3 mouse, may have increased sensitivity to Ig 
immunogenicity in the T cell compartment, which could be a source of the generation of 
rheumatoid factor antibodies, although the current AM14 rheumatoid factor model would 
suggest that this is TLR agonist dependent rather than Ig dependent per se.  If and when 
this transgenic mouse is finally produced, the potential for rapidly feasible, intriguing 





VI.3.2 The immunogenicity of immune complexes in monoclonal antibody therapy 
Prior to the completion of the B6.3Kλ Tg mouse, I think that the current CA30 
TCR Tg system is amenable to several types of experiments.  From a clinical perspective, 
I think that one of the most important observations to come from this work is that the 
pharmaceutical researchers investigating the possibility for production or handling errors 
to lead to immunogenic, aggregated mAb are probably correct that this could be a source 
of some immunogenicity, but that immune complexes may be just as, if not more, 
concerning for the development of anti-mAb antibodies.  There are quick experiments 
that could help establish this idea further.  First, I think we need to assess the isotype of 
the anti-Vκ36-71 Ig being made in the B6AF1 mice with transferred CA30 cells.  I am 
curious whether the mice that received heat aggregated Ig may be making more of a T-
independent response as compared to the mice that received immune complexes.  Then, I 
think we need to establish whether B6AF1 mice will make anti-Vκ36-71   IgG in response 
to heat aggregated Ig or immune complexes without the transfer of CA30 T cells.  The 
question remains whether the increase in T cell precursor frequency was necessary to 
induce the memory production of anti-Vκ36-71 IgG.  If we can show that the response to 
heat aggregated Ig is different than the response to immune complexes, which I think the 
anti-CD20 experiments already suggest, this would be an interesting development and 
suggest that the rejection of monoclonal antibody may develop due to mishandling in 
some cases and much more commonly to immune complexes in others.  Assuming that 
this is true, I think that we should repeat CFSE experiments with the creation of immune 
complexes in vivo rather than prior to injection, but injecting in antibody and Ars-MSA 
independently.  If we see a similar CFSE profile in response to this in vivo generation of 
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complexes, I think it makes the case against in vivo complexes during therapy to be even 
more compelling.  Based upon the original tolerization experiments with monomeric Ig, 
we have always wondered whether we might be able to use an Ig product to tolerize the T 
cell repertoire in a potential patient prior to the injection of the mAb.  Based upon my 
data with the Fab and F(ab’)2, my CFSE data surrounding the monomeric Ig, and the type 
1 diabetes data of Zaghouani’s group, I would be very interested to test an Fc-Fab fusion 
protein as a potential tolerizing agent for CA30 cells in vivo.  Based upon my humoral 
response data as well as my CFSE data, I think that monomeric Ig is tolerizing in so far 
as it is not immunizing, but that it cannot be used to tolerize patients about to receive the 
same mAb, because they will make immune complexes with the intended endogenous 
target protein.  My concern about using the monovalent Fab alone is that between the 
larger volume of distribution, and the less efficient uptake due to the lack of an Fc, that it 
may not achieve sufficient presentation to ablate a productive CD4+ T cell response.  
Assuming that there is not a vast amount of aggregation, an Fc-Fab fusion would allow 
for the efficient presentation mediated by the Fc, have the Fab component containing the 
variable region that is likely to be immunogenic, and be unable to make immune 
complexes due to its monovalency.  This is definitely a speculative idea, but one that I 
find intriguing for its potential to alleviate rejection of mAbs, which I believe may be a 
function of the natural action of the antibody, making complexes. 
VI.3.3 The tendency of immune complexes to generate Th2 responses 
 
I am intrigued by the idea that immune complexes may be activating DCs, and 
perhaps rapidly “exhausting” them, and that this activation may be stimulating the DCs to 
present to T cells in such a way that they are more likely to adopt a Th2 cytokine profile.  
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With the current CA30 cell CFSE assay, I think that we we could enrich for CD4+ and 
then use FACS sorting to acquire these cells from different CFSE divisions, with an 
emphasis on an early (3rd division) and late (7th division) from each population.  We 
could restimulate these cells in culture with the Vκ36-71 peptide and assess for their 
production of IFN-γ (Th1) or IL-4 or IL-5 (Th2).  Assessing cytokine transcript 
production in these cells using real time PCR might be an alternative way to assess for 
polarization.  If we can establish that the immune complexes are more likely to induce 
cells to divide more and take on a Th2 phenotype, then we can attempt to replicate this 
effect in a different model.  The most obvious candidate in the short term would be to 
acquire or produce B1-8 Ig and use it to complex NP-OVA or NP-OVA-3K.  These 
immune complexes could be used to replicate the results of the CA30 cell proliferation in 
a different cell population, either the OT-II TCR Tg cell or the F508 TCR Tg cell.  It has 
been shown previously that immune complexes increase the presentation of T cell 
epitopes in the antigen, and that they also increase the production of anti-antigen IgG, but 
addressing this question from the perspective of cell division and Th2 versus Th1 
polarization has not been shown explicitly to my knowledge.  This type of result would 
have implications for our understanding of how Ig-regulates CD4+ activation during the 
progression of an immune response.  There are papers that have sought to model Ig-
regulation of Ig-production in the germinal center via high affinity masking of epitopes, 
but my proposed approach would attempt to understand the progression of Ig-regulated 
CD4+ activation, presumably by dendritic cells, during the progression from antigen 
excess, and the presence of high numbers of immune complexes, to Ig excess, in which 
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case there would be more available monomeric Ig, which could disrupt the further 
polarization of CD4+ cells towards a Th2 phenotype.  
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PERCENTAGES OF CD45.1+ CELLS IN EACH CFSE DIVISION FOR 
PROLIFERATION EXPERIMENTS 
Every table in this appendix contains mean values for every FlowJo designated CFSE 
division in the CD4+, CD8α-, CD19-, MHC II-, F4/80-, CD45.1+ gate. In each case, n=4 
for each group and was generated in the same experiment, except for Table A3, which is 
composite data from 2 independent experiments 
 
Table A1 Mean number of divisions: monomeric and heat aggregated Ig 
Treatment 
Number of Divisions 



















































Table A2 Mean number of divisions: monomeric and immune complex 
Treatment 
Number of Divisions 

















































Table A3 Mean number of divisions: large head aggregated Ig and large immune 
complex 
Treatment 
Number of Divisions 



















































Table A4 Mean number of divisions: F(ab')2, Fab, and F(ab')2 complex 
Treatment 
Number of Divisions 







































































Table A5 Mean number of divisions: Isotype control and α-CD20 mIg2A5D2 
Treatment 
Pretreatment  Isotype 










































































 Pretreatment  a-CD20 
Monomeric 
Ig 0.28 
(SD 
0.27) 
0.30 
(SD 0.25) 
1.34 
(SD 0.93) 
4.45 
(SD 
2.15) 
10.24 
(SD 
2.42) 
17.00 
(SD 
1.21) 
18.85 
(SD 
1.45) 
17.9 
(SD 
3.40) 
Heat 
Aggregated 
Ig 
25.4 
(SD 
11.66) 
7.86 
(SD 4.22) 
4.53 
(SD 1.49) 
5.5 
(SD 
0.45) 
6.56 
(SD 
0.50) 
8.76 
(SD 
4.44) 
8.98 
(SD 
3.51) 
7.72 
(SD 
3.03) 
Immune 
Complex 
3.40 
(SD 
0.67) 
3.63 
(SD 1.29) 
4.12 
(SD 1.28) 
6.88 
(SD 2.3) 
10.55 
(SD 
2.46) 
12.88 
(SD 
1.57) 
14.13 
(SD 
1.52) 
13.2 
(SD 
2.24) 
 
 
 
